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SUMMARY
The presence of interferon-alpha (IFN-alpha) in 
human tissues has been described extensively in viral 
infections. In the last decade many workers have also 
shown the presence of low levels of IFN-alpha in 
conditions other than viral infections. While the 
precise origin of the synthesis of low levels of IFN- 
alpha in these physiological conditions has not been 
clearly defined, some evidence has suggested that 
macrophages may be involved.
In an attempt to find the likely source of IFN- 
alpha in physiological conditions, an initial study was 
carried out in which the cellular distribution of 
immunoreactive IFN-alpha was studied in formalin fixed 
paraffin embedded normal adult human tissues from 38 
different organs using various immunocytochemical 
techniques. These samples were drawn from over 300 
individuals none of whom had evidence of viral 
infection. Tissue histiocytes from all organs in the 
body, with the exception of cerebral and cerebellar 
cortex in brain and renal cortex and medulla, stained 
positively for IFN-alpha. Kupffer cells, pulmonary 
alveolar macrophages and lymph node macrophages were 
also positive for IFN-alpha. Parenchymal cells in some 
other organs also contained immunoreactive IFN-alpha. 
These included syncytiotrophoblast in first, second and
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third trimester placentas, cuboidal lining cells of the 
choroid plexus in the brain, thyroid follicullar cells, 
pituitary endocrine cells, adrenocortical cells and 
parathyroid endocrine cells. These findings are 
compatible with previous suggestions that IFN-alpha may 
be synthesized and released in the absence of viral 
infection and may have a role in normal physiology. The 
presence of IFN-alpha in most cells of the mononuclear 
phagocyte system suggests that these cells play a major 
role in the defence against viral infection. This 
speculation, however does not preclude other possible 
roles for IFN-alpha, such as modulation of cell growth, 
major histocompitability antigen expression etc.
The demonstration of immunoreactive IFN-alpha in 
formalin fixed paraffin embedded normal adult human 
tissues prompted other studies. In the first of these 
studies the cellular distribution of immunoreactive 
IFN-alpha was studied in formalin fixed paraffin 
embedded normal human autopsy tissues from 32 fetuses 
(7-42 weeks gestation) and 20 infants (aged from a few 
hours to 24 months). This study was performed to test 
the hypothesis that microbes have a role in switching 
on IFN-alpha synthesis. Fetal tissues are "germ free" 
while the infants had been exposed to a normal 
microbial flora. Immunoreactive IFN-alpha was first 
seen at 9 weeks gestation in macrophages in the fetal 
liver and thereafter was seen in macrophages in most
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other organs except in kidneys and cerebral and 
cerebellar cortex. When infant lungs were compared with 
fetal lungs a statistically significant increase in the 
number of macrophages (PcO.OOOl, Mann-Whitney test) and 
the percentage of these cells expressing IFN-alpha 
(P<0.0005, Mann-Whitney test) was noted in infant 
lungs. No such changes were observed in spleen, liver 
and thymus following birth. These findings suggested 
that there is a basal level of IFN-alpha production by 
macrophages, which is not dependent on microbial 
products, but that such microbial products can enhance 
synthesis of this cytokine. Immunoreactive IFN-alpha 
was also demonstrated in parenchymal cells of thyroid 
gland, choroid plexus in brain, anterior pituitary 
gland and adrenal gland in the fetal and infant 
tissues. These findings were almost identical to those 
seen in adult tissues.
In a separate study an attempt was made to 
extract, detect and quantify IFN-alpha in human tissues 
using protein extraction and an immunoradiometric assay 
kit for the detection of IFN-alpha. 20 placentas (14-42 
weeks gestation) obtained fresh within 1-2 hours of 
vaginal delivery, 4 specimens of amniotic fluid 
obtained at the time of caesarean section from 37-39 
weeks gestation pregnancies, 10 samples of choroid 
plexus and cerebral cortex, 11 thyroid glands and 9 
fetal adrenal glands from adult and fetal autopsies
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performed within 10-24 hours of death were studied. 
IFN-alpha was detected in 9 placentas, 1 adult thyroid 
gland and all 4 amniotic fluids. However, this study 
failed to detect IFN-alpha in the remaining placentas 
and adult thyroid glands and in all choroid plexuses, 
cerebral cortex and fetal adrenal glands. Formalin 
fixed paraffin embedded tissues from these organs did 
show immunoreactive IFN-alpha in cells using the 
immunocytochemical techniques.
Finally an attempt was made to detect IFN-alpha 
messenger RNA (mRNA) in normal human tissues using an 
in situ hybridization method. Formalin fixed paraffin 
embedded normal human placenta (n=3), adult tonsil (5) 
and fetal spleen (3) were tested for the presence of 
IFN-alpha mRNA using two separate oligonucleotide 
probes to IFN-alpha mRNA. A poly-d-T probe 
(complementary to the poly-A-tail of mRNA molecules and 
which had been used previously by workers to 
demonstrate total mRNA in formalin fixed tissues) was 
used as a positive control in the in situ hybridization 
techniques. Although the study demonstrated mRNA in 
formalin fixed paraffin embedded normal human tissues 
using the poly-d-T probe, it failed to detect IFN-alpha 
mRNA with the two IFN-alpha oligonucleotide probes in 
the tissues studied. Some staining was observed with 
probe 1 in cells in the three fetal spleens and one 
tonsil. High power microscopy and various
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immunocytochemical and immunofluorescence techniques 
helped to identify these cells as neutrophil 
polymorphs. This staining in neutrophil polymorphs was, 
however, inconsistent and ribonuclease enzyme treatment 
of tissue sections failed to abolish it and/was 
therefore regarded as non-specific staining.
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CHAPTER ONE
INTRODUCTION
1) GENERAL INTRODUCTION ON INTERFERON (IFN).
In 1957 Isaacs and Lindenmann identified a non- 
viral protein produced by cells in response to viral 
infection that could protect other cells of the same 
species from subsequent viral infection. They named 
this interfering protein Interferon (Isaacs & 
Lindenmann,1957).
Today interferon is identified as a group of 
proteins rather than a single protein. "To qualify as 
an interferon a factor must be a protein which exerts 
virus-nonspecific, antiviral activity at least in 
homologous cells through cellular metabolic processes 
involving synthesis of both RNA and protein"
(Anonymous,1980).
In the current nomenclature interferons are 
classified into three distinct groups on the basis of 
antigenic specificities. They are interferon-alpha 
(IFN-alpha), interferon-beta (IFN-beta) and interferon- 
gamma (IFN-gamma) .
In the old nomenclature interferons were also 
divided into three types, leucocyte interferon (IFN- 
alpha) , fibroblast interferon (IFN-beta) and immune 
interferon (IFN-gamma). They were misnomers because 
both leucocytes and fibroblasts can produce IFN-alpha
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and IFN-beta (Havell et al.,1978; & Hayes et al.,1979), 
while immune interferon is also induced by mitogens in 
addition to antigen induction. Another previous 
nomenclature divided interferons into only two types.
a) Type 1, virus induced interferon (corresponding to 
IFN-alpha and IFN-beta). b) Type 2, antigen or mitogen 
induced interferon (IFN-gamma).
IFN-alpha.
A large number of genes coding for structurally 
different human IFN-alpha proteins have been 
identified. They are grouped into two subfamilies, IFN- 
alphaj and IFN-alphaI3:. The IFN-alphaj subfamily has at 
least 14 potentially functional genes and one 
pseudogene, while the IFN-alphajj subfamily has only one 
functional gene, IFN-alphaIX 1 and at least 7 
pseudogenes. Two other pseudogenes IFN-alpha 11 and 
IFN-alpha 12 have also been described (Weissmann & 
Weber., 1986) . The IFN-alphaI3: 1 gene is also called IFN- 
alpha omega 1 (Adolf,1990). The human IFN-alpha gene 
family is located on chromosome 9 (Slate et al.,1982). 
The IFN-alpha genes lack introns (non-coding 
sequences), they also lack N-glycosylation sites. IFN- 
alpha proteins are secreted as pre-IFNs containing a 
23-amino acid residue leader sequence which is cleaved 
off during maturation. The mature IFN-alpha sequence of 
all subtypes contains 166 amino acids with the
exception of IFN-alpha 2, which contains only 165 
aminoacids and IFN-alpha 1, which has 172 amino acids 
(Weissman & Weber.,1986). IFN-alpha molecules occur as 
pure proteins due to lack of N-glycosylation sites in 
the IFN-alpha genes as described above. It has a 
molecular weight of 19,000-24,000 daltons (Stanton et 
al.,1987). It is pH-2 (acid) stable except for one 
subtype which is pH-2 labile (Preble et al.,1982).
IFN-beta
Only a single gene coding for human IFN-beta(1) 
protein has been fully characterized. This is in sharp 
contrast to the many genes coding for IFN-alpha, but, 
like the IFN-alpha genes, this human IFN-beta gene is 
also located on the short arm of chromosome 9 and lacks 
introns (Trent, Olson & Lawn,1982). It codes for a 166 
amino acid long peptide that is preceded by a 21 amino 
acid leader sequence. It has a molecular weight of
20,000 daltons. It is hydrophobic and occurs as a 
glycoprotein because the human IFN-beta gene contains 
an N-glycosylation site at position 180 (Derynck et 
al.,1980; & Houghton et al.,1980). The IFN-beta(l) has 
a 29% homology with IFN-alpha at the amino acid level 
and a 45% homology at the nucleotide level (Taniguchi 
et al.,1980).
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A protein called IFN-beta (2) has also been 
described. The gene coding for this protein is not 
found on chromosome 9. It has a molecular weight of 
23,700 daltons with 212 amino acids. It is neutralized 
by an antibody raised against IFN-beta(1) and shows 
antiviral activity that is considerably lower than IFN- 
beta (1) (Zilberstein et al.,1986; & Van-Damme et 
al.,1987). A gene coding for IFN-beta(2) has been 
located on chromosome 7 (Seghal et al., 1986). Its 
designation as an interferon is controversial (De- 
Maeyer & De-Maeyer Guignard, 1988a) .
IFN-gamma
IFN-gamma has also one gene, located on the long 
arm of chromosome 12 (Trent et al.,1982; Naylor et 
al.,1983). Unlike the IFN-alpha and IFN-beta genes, the 
IFN-gamma gene has 3 introns (Gray & Goeddel, 1982) . The 
molecular weight of IFN-gamma protein measured by 
molecular sieve chromatography ranges between 25,000-
70,000 daltons (Falcoff,1972). However using sodium 
dodocyl sulphate polyacrylamide gel electrophoresis,
Yip et al (1982) showed the presence of IFN-gamma 
molecules of two different molecular weights, 20,000 
daltons & 25,000 daltons, respectively, and suggested 
that in native form the IFN-gamma protein may occur as 
a dimmer composed of 20,000 and 25,000 dalton subunits.
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Caput et al (1986) identified a nucleotide base 
sequence TTATTTAT at the 3 'non-coding region in the 
genes of various cytokines e.g tumour necrosis factor, 
interleukin 1, granulo-monocyte colony stimulating 
factor (GM-CSF), and most of the IFNs (including IFN- 
alpha, IFN-beta & IFN-gamma). It was also shown that 
introduction of a 51 nucleotide AT sequence (identical 
to that found in the human GM-CSF) into the 
3'untranslated region of the rabbit beta-globulin gene, 
made the otherwise stable beta-globulin messenger RNA 
(mRNA) highly unstable. It was therefore suggested that 
this 3 'non-coding TTATTTAT region of these genes 
contributes to the short half-life of cytokine mRNAs 
and serves as a logical point for post transcription 
regulation (Shaw & Kamen,1986).
Sources of IFNs.
IFN-alpha and IFN-beta.
Every cell in the vertebrate organism is said to 
be capable of producing IFN-alpha and IFN-beta. This 
has never actually been fully investigated for all 
different cell types that make up the vertebrate 
organism, but whenever differentiated cells like 
fibroblasts, macrophages, leucocytes and human and 
animal continuous cell lines have been examined, it has
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been possible to induce IFN-alpha and IFN-beta 
production (De-Maeyer & De-Maeyer Guignard,1988b).
IFN-gamma.
IFN-gamma is produced by T lymphocytes activated 
by either antigens or mitogens. IFN-gamma is also 
probably produced by natural killer cells (Green, 
Cooperband & Kibrick,1969; Yip et al.,1982; Trinchieri 
& Perussia,1985).
Inducers of IFN synthesis. 
IFN-alpha and IFN-beta.
1) Viruses. They were the first known inducers of IFN 
synthesis (Issacs & Lindenman,1967) and irrespective of 
their structure and mode of replication all viruses are 
capable of inducing IFN-alpha and IFN-beta synthesis.
2) Double stranded RNA (ds RNA). Both natural and 
synthetic dsRNAs induce IFN-alpha and IFN-beta with 
high efficiency (Field et al.,1967).
3) Micro-organisms. Bacteria; Corynebacterium parvum, 
Brucella abortus and Listeria monocytogenes can induce 
IFN-alpha and IFN-beta (Kirchner, Weyland &
Storch,1986; Youngner & Stinebring,1964; Havell,1986). 
Lipopolysaccharides (endotoxins) derived from the walls 
of gram-ve bacteria can also induce IFN-alpha and beta 
(Gessani et al., 1987) . Intracellular parasites like
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rickettsiae induce acid stable type 1 interferons 
(Kohno et al.,1970). Mycoplasma under certain 
conditions can induce IFN-alpha (Birke et al.,1981). 
Detectable levels of IFN-alpha have been reported in 
the serum of children with acute Plasmodium falciparum 
infection (Ojo-Amaizi et al.,1981). Toxoplasma gondii, 
Plasmodium berghei and some strains of Trypansoma cruzi 
induce IFN-alpha and IFN-beta in mice (Freshman et 
al.,1966; Sonnenfeld and Kierszenbaum,1981).
4) Low molecular weight substances, such as 
cylcoheximides, kanamycin, toluidine blue and organic 
polymers such as pyran copolymers or polyvinylsulphate 
can also induce IFN-alpha and IFN-beta synthesis 
(Friedman & Vogal,1983; Stanton et al.,1987).
5) Cytokines. Interleukin 1 can stimulate the 
production of IFN-beta by fibroblasts (Billiau et 
al.,1986). It can also increase the production of 
interleukin 2 which in turn stimulates T lymphocytes1 
growth and IFN-gamma production (Vilcek et al.,1985). 
Interleukin 2 mainly regulates the synthesis of IFN- 
gamma (Kasahara et al.,1983), but can also induce IFN- 
alpha/beta in bone marrow cells (Reyes et al.,1986). 
IFN-gamma can also induce IFN-alpha synthesis (Hughes & 
Baron,1987). Other cytokines such as colony stimulating 
factor type 1, platlet derived growth factor and tumour 
necrosis factor can induce IFNs (Zullo et al.,1985; & 
Moore et al.,1984).
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IFN-gamma.
The IFN-gamma inducers can be divided into two groups.
1) Mitogens.
2) Antigens.
1) Mitogens. Phytohemagglutinin and 12-0- 
tetradecanoylphorbol-13-acetate, potently induce T 
lymphocytes to produce IFN-gamma in vitro (Yip et 
al.,1982; Nathan et al.,1981; Falcoff,1972). 
Staphylococcal enterotoxin B also induces IFN-gamma 
synthesis in peripheral blood mononuclear cells in 
vitro (Lee et al.,1990).
Lipopolysaccharides (endotoxins) can stimulate IFN- 
gamma in murine T lymphocytes, if the T lymphocytes are 
first exposed to endogenously produced or exogenously 
applied interleukin 2 (Blanchard et al.,1986).
2) Antigens. IFN-gamma has been detected in the sera 
of immunized mice, after the administration of the 
immunizing antigen (Salvin, Youngner & Lederer,1973).
It has also been detected in lymphoid cell cultures 
from immunized animals after exposure to the immunizing 
antigen (Gifford, Tibor & Peavy,1971). IFN-gamma 
synthesis by T lymphocytes in response to specific 
antigen stimulation is a clonally restricted process 
and only T lymphocytes previously sensitized to that 
antigen would produce IFN-gamma (Kiener &
Spitalny,1987). The antigen specific IFN-gamma 
synthesis by T lymphocytes is mainly dependent on 
antigen presenting or assessory cells, but can also 
take place even in the absence of these antigen 
presenting cells (De-Maeyer & De-Maeyer 
Guignard,1988c).
Actions of IFNs
1) The best known action of IFNs is their anti-viral 
activity (Isaacs & Lindenmann,1957). IFNs can inhibit 
attachment and uncoating of various viruses. They can 
also inhibit early viral transcription, viral 
translation, protein synthesis and budding from the 
cell surface (Balkwill, 1989) .
2) IFNs influence both cell growth and division 
(Paucker et al.,1962). The usual effect of IFNs is the 
inhibition of cellular replication and they act as 
mutual antagonists to growth factors (De-Maeyer & De- 
Maeyer Guignard,1988d). Tumour cell lines are more 
sensitive to the anti-proliferative effect of IFNs than 
normal fibroblasts (Paraf et al.,1983).
3) IFNs can reverse the phenotype of malignant 
fibroblast cells to a more normal phenotype (Sergiescu 
et al.,1986). They can also redirect other tumour cells 
to a more differentiated state (Exley et al.,1987) but 
occasionally high amounts of IFNs have the opposite
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effect and block commitment to differentiation 
(Rossi,1985).
4) All three types of IFNs enhance the expression of 
class I major histocompatibility complex (MHC) antigens 
(Trinchieri & Perussia,1985). IFN-gamma induces or 
increases the expression of class II major 
histocompatibility complex antigens in a large number 
of cell types (Wong et al.,1983). IFN-alpha and IFN- 
beta mainly increase the expression of class I MHC 
antigens but can also stimulate the expression of class 
II MHC antigens on some lymphoid cells of B and T 
lineage (Capobianchi et al.,1985).
5) All interferons and especially IFN-gamma can cause 
stimulation of macrophages (Dean & Virelizier,1983; 
Nathan et al., 1983).
6) IFN-alpha and IFN-beta can also cause stimulation 
of natural killer cells (Gidlund et al.,1978).
Basis of action of IFNs.
IFNs interact with cells by binding to specific 
receptors present on the cell surface. Evidence for the 
existence of IFN receptors was first presented by 
Aguet(1980). IFN-alpha and beta share a common receptor 
(Branca & Baglioni,1981) while IFN-gamma uses a 
different receptor. Most studies so far have shown that 
IFN is internalized and degraded in much the same way 
as other polypeptide hormones. However internalization
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is not an essential part of IFN's mechanism of action 
(Rubinstein & Orchansky,1986).
At least two enzymes have been discovered in 
humans whose levels are elevated by IFN treatment of 
cells: 1) (2,-5f)A synthetase, which catalyses the
synthesis of 2'-5' linked oligoadenylates and 2) A 
double-stranded, RNA dependent protein kinase.
Detection of these enzymes has been used in the past to 
infer the presence of IFNs (Galabru et al.,1985). (2'-
5')A synthetase can interact with double stranded RNA 
(dsRNA) to convert adenosine triose phosphate (ATP) 
into 2'-5'linked oligoadenylates. 2'-5'linked 
oligoadenylates can then activate an endonuclease that 
can cleave single stranded RNAs. This leads to 
degradation of messenger RNAs and ribosomal RNAs and 
causes irreversible translation inhibition. Activation 
of the dsRNA dependent protein kinase phosporylates the 
smallest subunit of the peptide chain initiation factor 
eIF-2 making it inactive. This results in inhibition of 
protein synthesis at the level of peptide chain 
initiation (Stanton et al.,1987).
Therapeutic uses of IFNs.
The high activity of several IFN preparations in 
treatment of hairy cell leukaemia has been confirmed in 
studies world-wide, with a response rate of 70-90%. 
IFN-alpha show some activity in multiple myeloma and
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produces objective responses in patients with malignant 
endocrine pancreatic tumours, AIDS-related Kaposi's 
sarcoma, and in a small minority with renal cell 
carcinoma and melanoma (Balkwill,1989; Mandelli, 
Awisati & Petrucci, 1990) . High activity of IFNs has 
also been reported in chronic myeloid leukaemia (Talpaz 
et al.,1987). IFN-alpha causes a rapid and selective 
lowering of platelet count in over 80% of patients with 
essential thrombocythaemia (Giles et al.,1988).
Due to their well known antiviral activity, IFNs 
have been tried clinically for treatment of the common 
cold. It has been shown that short term prophylaxis of 
family contacts of an infected individual reduced the 
risk of a rhinovirus cold by 78% but was not active 
against colds caused by other viruses (Douglas,1986) 
and that intranasal administration of IFN may control 
the spread of rhinovirus cold in some healthy contacts 
of ill family members (Hayden et al.,1986). However 
IFNs are ineffective in the treatment of symptomatic 
common cold patients (Balkwill,1989). It has been shown 
that administration of recombinant IFN-gamma prior to 
or at the time of lymphocytic choriomeningitis virus 
inoculation into mice, reduced significantly the virus 
titres in the spleens of the infected mice (Klavinskis, 
Geckeler & Oldstone,1989). Therapeutic injection of 
recombinant human IFN-alpha 2 directly into genital 
warts is an effective form of therapy for condyloma
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acuminata (Eron et al., 1986) . IFN-alpha has been shown 
to slow tumour growth rate in patients with laryngeal 
papillomatosis (Healy, Gelber & Trowbridge,1988). 
Clinical trials with IFNs in patients with chronic 
viral hepatitis B and C are currently been tried 
throughout the world (Ruiz-Moreno et al.,1990; Di- 
Bisceglie et al.,1989).
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2) PHYSIOLOGICAL INTERFERON.
Since the discovery of IFN (Isaacs &
Lindenmann,1957) much emphasis has been laid on the 
presence and role of IFN in viral infections. However 
in the last decade many workers have demonstrated the 
presence of IFNs in conditions other than viral 
infections and have used various words, such as 
physiological, preformed, spontaneous, endogenous, or 
constitutive IFN production to describe their findings.
The expression, "physiological IFN response" was 
first used by Bocci (1980). He put forward the idea 
that IFN was produced continuously in health in low 
physiological amounts which increased with an acute 
viral infection (Bocci,1981).
The most likely contenders for the production of 
low levels of physiological IFNs are cells of the 
mononuclear phagocyte system and lymphocytes. These 
cells may produce and release small amounts of IFNs 
into their surroundings (Bocci,1988). Evidence for this 
comes from some in vitro studies. It has been shown 
that normal rabbit and mouse peritoneal and alveolar 
macrophages (obtained from animals reared in 
conventional conditions but which were apparently 
pathogen free) immediately after isolation released low 
levels of IFNs in vitro (Smith & Wagner,1967; De- 
Maeyer, Fauve & De-Maeyer-Guignard,1971; Belardelli et 
al.,1987). De-Maeyer et al (1971) also showed that this
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spontaneous release of IFN by macrophages in culture 
stops after 72 hours without further induction. The 
addition of lipopolysaccharides (endotoxin) or gram-ve 
bacteria to these macrophage cultures reinduced IFN 
production. Also, peritoneal macrophages obtained from 
mice reared in a germ free environment did not release 
detectable levels of IFN in vitro. Many animal viruses 
failed to multiply in fresh cultures of normal mouse 
peritoneal macrophages but the cells were rendered 
permissive by injection of mice with an antiserum 
directed against IFN-alpha and IFN-beta prior to 
harvesting, suggesting that peritoneal macrophages are 
maintained in an antiviral state by endogenous IFN in 
vitro (Belardelli et al., 1984). These findings raise 
the possibility that this spontaneous IFN production by 
macrophages is due to low levels of IFN inducers 
(bacteria and endotoxin) present under physiological 
conditions. Also, spontaneous production of IFN-gamma 
by T cells, newly isolated from the blood of adult and 
newborn humans, has been demonstrated without any 
antigen or mitogen stimulation in vitro (Martinez-Maza 
et al.,1984). This spontaneous release of IFN-gamma may 
be due to the T cells having been stimulated in vivo.
Human beings and animals are exposed to a variety 
of exogenous and endogenous microbial stimuli. A large 
number of bacteria colonize various parts of the human 
body such as the intestines, skin, genital tracts etc
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to form the normal bacterial flora of the human body. 
Lipopolysaccharide (endotoxin), which is derived from 
the walls of gram-ve bacteria, is a good inducer of 
IFN-alpha and gamma (Kirchner et al.,1986; Blanchard et 
al.,1986). Man is also exposed to a large number of 
viruses and other substances in every day life. The 
human body exposed to these exogenous and endogenous 
stimuli may try to counteract them by producing various 
cytokines which help to maintain the animal in a state 
of health. Thus absorption of small amounts of 
endotoxin from the bacterial flora of the human body 
and exposure to low levels of viruses and other IFN 
inducers in the environment might be sufficient to 
provide a stimulus for low levels of IFN production by 
various cells like macrophages or lymphocytes. This IFN 
production would keep the cells in a primed state to 
combat any acute viral or bacterial infection and form 
the first line of defence. Certain sites of the human 
body have a high exposure to various exogenous and 
endogenous stimuli and are the most likely sites for 
physiological IFN production. These include the gut 
associated lymphoid tissue, duct associated lymphoid 
tissue, skin associated lymphoid tissue, immune 
associated lymphoid tissue (thymus, spleen & bone 
marrow), and the bronchoalveolar surface. Bocci et al 
(1984), showed the presence of IFN (IFN-gamma or an 
acid labile IFN-alpha or a mixture) in the lymph
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draining the gastrointestinal tract of normal healthy 
rabbits. Some workers have reported low levels of IFN- 
alpha in normal human bone marrow (Zoumbas et 
al.,1985). An IFN-alpha like substance has been 
identified in the plasma of healthy individuals 
(Shiozawa et al.,1986) and IFN-alpha and IFN-gamma have 
been demonstrated in bronchoalveolar lavage fluid of 
healthy human volunteers (Prior & Haslam,1989).
In addition, recently, some conclusive evidence 
for the presence of immunoreactive-IFN-alpha in 
macrophages in conditions other than viral infections 
has emerged. Using an immunocytochemical technique in 
formalin fixed paraffin embedded normal human pancreas 
it was shown that cells with a similar morphology to 
macrophages contained immunoreactive-IFN-alpha (Foulis, 
Farquharson & Meager,1987). Using the above 
immunocytochemical method Howatson et al (1988) 
demonstrated immunoreactive-IFN-alpha in macrophages in 
human placenta and immunoreactive-IFN-alpha was shown 
in the Kupffer cells in normal human liver (Sutherland 
et al.,1989). These findings helped further to localize 
the likely source of physiological IFN synthesis.
Another important site where IFN-alpha has been 
demonstrated in physiological conditions is the 
placenta. Evidence for the presence of IFN in the 
placenta first emerged with the demonstration of IFN in 
mouse placenta (Fowler, Reed & Giron,1980). Later IFN
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was demonstrated in the amniotic fluid in normal human 
pregnancy (Lebon et al.,1982), in human placenta, 
membranes and fetal blood (Duc-Goiran et al.,1985) and 
in perfused human term placentas (Bocci, Paulesu & 
Ricci,1985). Recently, IFN-alpha has been identified in 
normal fetal blood, fetal organs, placenta, membranes, 
amniotic fluid and decidua, using a specific two-site 
immunoradiometric assay (Chard et al.,1986). The ovine 
trophoblast antiluteolytic protein responsible for 
inhibiting corpus luteum regression in early pregnancy 
in sheep, shows a 30% sequence homology with human IFN- 
alpha protein (Stewart et al.,1987) and IFN-alpha 2 
mimics some of the effects of ovine trophoblast 
antiluteolytic protein (Salamonsen et al.,1988).
Finally immunoreactive-IFN-alpha has been localized to 
the syncytiotrophoblast of chorionic villi and to 
macrophages in human placentas (Howatson et al.,1988).
These studies, by showing the presence of 
immunoreactive-IFN-alpha in macrophages and other cells 
under physiological conditions, helped to pin-point the 
likely source of physiological IFN synthesis. However 
it is well known that cells, and especially 
macrophages, take up (phagocytoze) various proteins, 
foreign bodies, etc and thus the mere presence of IFN- 
alpha in cells does not provide conclusive evidence 
that these cells are actually producing IFN-alpha. It 
has been shown that IFN-alpha messenger RNA is present
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constitutively in extracts of spleen, liver, kidney and 
peripheral blood leucocytes of normal human individuals 
(Tovey et al.,1987) proving that transcription of IFN- 
alpha genes is taking place under normal physiological 
conditions but this technique fails to define which 
cells are producing IFN-alpha at the time of the test.
Aims of the study
1) The first aim of the present study was to 
demonstrate cells containing immunoreactive-IFN- 
alpha in various normal human tissues. To achieve 
this aim an immunocytochemical technique using a 
sheep anti-human IFN-alpha antiserum (H51) was 
used to study the presence of immunoreactive IFN- 
alpha in a large number of formalin fixed paraffin 
embedded normal adult human tissues (Chapter 
Three). Alternative immunocytochemical techniques 
using a monoclonal anti-human IFN-alpha antibody 
and another polyclonal sheep anti-human IFN-alpha 
were also tried.
2) The second aim was to study the ontogeny of IFN- 
alpha in humans. This aim was achieved by studying 
the presence of IFN-alpha in formalin fixed normal 
human fetal tissues (Chapter four).
3) Also, as has been suggested above physiological 
IFN-alpha synthesis may be induced by the presence 
of low levels of various IFN inducers like
bacteria and viruses, present in the environment. 
Therefore the third aim of the study was to 
observe the effect of these physiological stimuli 
on IFN-alpha synthesis. To achieve this, the 
distributions of immunoreactive IFN-alpha 
containing cells in fetuses and infants was 
compared. It was expected that fetuses, which are 
essentially germ free, should have low levels of 
physiological IFN-alpha in their tissues compared 
to infants who are exposed to various exogenous 
stimuli. (Chapter four).
The fourth aim of the study was to show the 
presence of IFN-alpha in normal human tissues by a 
technique completely different from the 
immunocytochemical technique used by Foulis et al 
(1987). Chard et al (1986) had already 
demonstrated the presence of IFN-alpha in various 
fresh normal human fetal tissues, amniotic fluids 
and placentas, using a "Sucrosep" IFN-alpha two- 
site immunoradiometric assay. Therefore using the 
same "Sucrosep" IFN-alpha immunoradiometric assay 
an attempt was made to detect and quantitate IFN- 
alpha in some fresh normal human tissues (Chapter 
five). The detection of IFN-alpha in various fresh 
human tissues would provide additional support for 
previous findings of immunoreactive IFN-alpha in 
various formalin fixed normal human tissues and
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strengthen the initial hypothesis of a low level 
synthesis of IFN-alpha under physiological 
conditions.
5) The final objective of the study was to
demonstrate the presence of IFN-alpha messenger 
RNA (mRNA) in cells shown to contain 
immunoreactive IFN-alpha. This aim could be 
achieved by developing an in situ hybridization 
technique for the demonstration of IFN-alpha mRNA 
in formalin fixed normal human tissues. In situ 
hybridization is a technique used to demonstrate 
specific DNA or mRNA sequences in tissue sections 
or cytological preparations (Pardue,1985). It 
utilizes labelled nucleic acid probes which are 
complementary to the target DNA or mRNA sequences. 
These labelled probes can hybridize i.e form 
sequence specific, base paired duplexes with 
complementary DNA or mRNA sequence in tissue 
sections. The label is subsequently demonstrated, 
resulting in the precise cytological localization 
of the target sequence (Chapter six).
These studies would help define which cells 
normally produce IFN-alpha and give further insight 
into its physiological role in the human body.
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CHAPTER TWO
MATERIALS AND METHODS. 
MATERIALS.
They can be divided into 2 groups.
1) Human tissues.
2) Antibodies, immunoradiometric assay kit and probes 
used in the in situ hybridization study.
1) The human tissues studied can be further divided 
into three parts; a, b & c.
a) Normal human tissues from routine surgical 
specimens and autopsies collected over a period of 20 
years were studied for the presence of immunoreactive 
IFN-alpha. As the study for the immunocytochemical 
localization of IFN-alpha in formalin fixed paraffin 
embedded normal human tissues was divided in 2 parts, 
described in chapter 3 and chapter 4, respectively, the 
tissues studied can also be divided into 2 groups.
i) Tissues used in chapter 3.
Normal adult human tissues studied for the 
immunocytochemical localization of IFN-alpha, described 
in chapter 3. These include tongue (n=3), salivary 
gland (6), oesophagus (11), stomach (11), duodenum 
(11), jejunum (10), appendix (10), large intestine
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(10), liver (10), gallbladder (10), pancreas (8), 
adrenals (7), testes (10), ovaries of premenupausal 
non-pregnant women (10), ovaries of pregnant women (5), 
uterus (9), fallopian tubes (8), breast (10), cervix 
(10), skeletal muscle (10), myocardium (8), skin (8), 
bone marrow (10), spleen (9), lymph nodes (9), tonsil 
(8) kidney (6), ureters (8), renal pelvis (8), urinary 
bladder (3), prostate (9), bronchial tree (9), lungs & 
pleura (6), thyroid (8), pituitary (20), placenta (2 
first timester, 5 second trimester and 5 third 
trimester), peripheral blood leucocytes (4), brain (5) 
and parathyroid (11). The peripheral blood leucocytes 
were studied in a clot formed from the buffy coats of 
20 mis of blood from 4 human subjects, fixed in formol 
saline for 1 hour and embedded in paraffin wax. Normal 
human tissues collected from the routine surgical or 
autopsy specimens during this study period were fixed 
in formol saline for not more then 24-48 hours and 
embedded in paraffin wax. Cases from whom the specimens 
were collected did not have clinical evidence of any 
viral or bacterial infection.
ii) Tissues used in chapter 4.
Formalin fixed paraffin embedded normal human 
fetal tissues from 32 fetal autopsies performed within 
24 hours of death were studied. These included 4 
fetuses of 7-11 weeks gestation (removed accidently at 
curettage from women previously not known to be
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pregnant), 20 fetuses of 12-25 weeks gestation (12 
terminations of normal pregnancy, 5 hydrocephalics, 1 
anencephalic and 2 fetuses with maternal placental 
complications) and 8 fetuses of 26-42 weeks gestation 
(stillbirths) with no evidence of viral or bacterial 
infection. Formalin fixed paraffin embedded normal 
tissues from autopsies on 20 infants aged from a few 
hours to 24 months were also studied for the 
immunocytochemical localization of IFN-alpha (chapter
4). These included 6 accidental deaths, 7 infants with 
congenital heart disease and 7 fatalities from sudden 
infant death syndrome. All showed no clinical or 
laboratory evidence of bacterial or viral infection.
b) Tissues used in chapter 5.
Various fresh human tissues and fluids were 
collected for the detection of IFN-alpha by the 
immunoradiometric assay. These included 15 placentas 
from selective terminations of pregnancy (14-18 weeks 
gestation), 5 placentas from normal vaginal deliveries 
(38-42 weeks gestation) and 4 specimens of amniotic 
fluid obtained at the time of caesarean section from 
37-39 weeks gestation pregnancies. Also, 10 samples of 
choroid plexus and cerebral cortex, 11 thyroid glands 
and 9 fetal adrenal glands were obtained from adult and 
fetal autopsies performed within 10-24 hours of death. 
All 20 placentas were obtained fresh within 1-2 hours
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of vaginal delivery. They were washed with running cold 
tap water to remove excess blood. The membranes were 
dissected off and small pieces of placental tissues 
were weighed and stored at -70°C. The choroid plexus 
and cerebral cortex samples, thyroid glands and fetal 
adrenal glands were snap frozen in liquid nitrogen and 
kept at -70°C. Small pieces of each such tissue from 
all cases were also fixed in formol saline for 24 hours 
and embedded in paraffin wax.
c) Tissues used in chapter 6.
Human tissues studied for the detection of IFN- 
alpha messenger RNA, using the in situ hybridization 
technique, included normal adult human tonsil (n=5), 
human placentas at 30-40 weeks gestation (3) and fetal 
spleen (3). The normal adult human tonsils were 
obtained fresh within half hour of surgical removal and 
the placentas were also obtained fresh within 1-2 hours 
of vaginal delivery. The fetal spleens were obtained 
from fetal autopsies performed within 24 hours of 
death. 2 spleens, 3 tonsils and 2 of the placentas 
studied, were fixed in buffered formalin for 
approximately 24 hours while 1 tonsil was fixed in 
buffered formalin for only 5 hours and embedded in 
paraffin wax. Finally 1 spleen, placenta and tonsil 
each, were fixed in formol saline instead of buffered 
formalin for 24 hours and embedded in paraffin wax.
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2) Antibodies, immunoradiometric assay kit and probes 
used in the In situ hybridization study.
i) Antibodies.
Primary antibodies.
The polyclonal sheep anti-human IFN-alpha antiserum 
(H51). This antiserum was raised in sheep by Anthony 
Meager (National Institute for Biological Standards and 
Control, Potters Bar, Hertfordshire,UK) using human 
lymphoblastoid IFN-alpha Namalwa, "Wellferon" (Wellcome 
Research Laboratories, Beckenham,UK) as antigen. 
Wellferon was greater than 80% pure with respect to IFN 
protein. The sheep anti-human IFN-alpha antiserum (H51) 
neutralized all IFN-alpha preparations in a viral 
inhibition assay but also showed weak neutralization of 
purified human IFN-beta (Exley et al.,1984). The H51 
antiserum did not neutralize IFN-gamma (Meager,1987). 
Monoclonal anti-human IFN-alpha antibody (Code 
NO.0050). The Green Cross Corporation, Osaka 541,
Japan.
Another polyclonal sheep anti-human IFN-alpha 
antiserum. Gift from Dr. Cantell, Helsinki.
KP1. This monoclonal antibody, raised against a 
lysosomal fraction of human lung macrophages, detected 
the monocyte/macrophages associated antigen CD68 in
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routinely processed human tissue sections (tissues 
fixed in various fixatives, and embedded in paraffin 
wax). Gift from K.A.F Pulford, Oxford University, UK. 
Mac 387. A monoclonal macrophage antibody (Dako, 
Roskilde, Denmark).
LN-2 6. A monoclonal B lymphocyte marker (Dako).
EMA. A monoclonal epithelial membrane antigen marker 
(Dako) .
LeuM 1. A monoclonal antibody that detects Reed 
Sternberg cells and neutrophils (Dako).
Anti-muramidase. A rabbit polyclonal antiserum raised 
against the lysosomal fraction of human macrophages 
(Dako) .
Anti-prekeratin. A rabbit polyclonal antiserum, 
directed against the cellular cytokeratin, called 
prekeratin (Dako).
The following secondary antisera were used in the 
study.
Peroxidase-conjugated swine anti-sheep immunoglobulin 
antiserum (Serotec, Oxford), peroxidase-conjugated 
swine anti-rabbit immunoglobulin antiserum (Dako), 
peroxidase-conjugated rabbit anti-mouse immunoglobulin 
antiserum (Dako) , rhodamine-conjugated swine anti­
rabbit immunoglobulin antiserum (Dako) , rhodamine- 
conjugated rabbit anti-mouse immunoglobulin antiserum 
(Dako).
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ii) The immunoradiometric assay kit.
A "Sucrosep" IFN-alpha immunoradiometric assay 
(Boots Celltech Diagnostics Ltd, Slough,UK) was used 
for the demonstration of IFN-alpha in human tissue 
homogenates and fluids. "Sucrosep” IFN-alpha assay is a 
two-site immunoradiometric assay which utilizes a 125I 
labelled monoclonal antibody (designated Yok 5/19). The 
Yok 5/19 antibody recognizes at least 7 subtypes of 
IFN-alpha protein, namely IFN-alpha A(2), IFN-alpha C, 
IFN-alpha D (1), IFN-alpha G(5), IFN-alpha L, IFN-alpha 
J(7) and IFN-alpha K(6) (Data sheet, Celltech, culture 
product division,UK). The secondary antiserum in the 
"Sucrosep" IFN-alpha immunoradiometric assay kit was a 
sheep anti-human IFN-alpha antiserum attached to solid 
phase.
iii) Probes used in the in situ hybridization 
technique.
Probe 1.
Probe 1 was a 17 base oligonucleotide anti-sense 
IFN-alpha messenger RNA (mRNA) probe (Glasgow 
University, department of Biochemistry, Glasgow,UK).
The nucleotide sequence of probe 1 was, 5 f-C-C-T-C-C- 
C-A-G-G-C-A-C-A-A-G-G-G-3'. It was supplied as solution 
in ammonium hydroxide. The nucleotide sequence of probe
44
1 was based on selected conserved cDNA sequences of 
IFN-alpha genes A-H, position 481 to 497 (Goeddel et 
al.,1981). This probe had been used previously for the 
demonstration of the IFN-alpha WA gene (Torczynski,
Fuke & Bollon,1984).
Probe 2.
Probe 2 was a 24 base oligonucleotide anti-sense 
IFN-alpha messenger RNA (mRNA) probe (Glasgow 
University, department of Biochemistry, Glasgow,UK).
The nucleotide sequence of probe 2 was, 5'-G-A-T-C-T- 
C-A-T-G-A-T-T-T-C-T-G-C-T-C-T-G-A-C-A-3'. The 
nucleotide sequence of probe 2 was also based on 
selected conserved cDNA sequences of IFN-alpha genes A- 
H, position 499 to 502 (Goeddel et al.,1981). Probe 2 
was supplied in pure solid form, with an optical 
density of 3.6.
Poly-d-T probe.
Poly-d-T (poly-deoxythymidylic acid) 
oligonucleotide probe (Pharmacia LKB Biotechnology, 
Central Milton Keynes,UK) was 20 deoxythymidylic acid 
bases (T-T-T etc) long. It is complementary to the 
poly-A tail (A-A-A etc) of mRNA molecules. It was 
supplied in pure form ready to use. The poly-d-T probe 
had been used by previous workers to demonstrate total 
mRNA in formalin fixed human tissues by in situ
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hybridization (Pringle et al., 1989). In this study it 
was used as a control to demonstrate total mRNA in 
tissue sections from organs that were also used for the 
detection of IFN-alpha mRNA with probe 1 and probe 2 in 
the in situ hybridization technique.
METHODS
The methodology is divided into six main groups 
comprising various techniques used throughout the 
study. They are as follow.
A) Immunocytochemical techniques used for the
detection of immunoreactive-IFN-alpha in formalin 
fixed paraffin embedded normal human tissues. They 
are again subgrouped into two.
i) Indirect immunoperoxidase technique used for the 
demonstration of immunoreactive-IFN-alpha using 
the polyclonal sheep anti-human IFN-alpha 
antiserum (H51).
ii) Immunocytochemical techniques used for the 
detection of IFN-alpha using a monoclonal antibody 
(Code NO.0050) and another polyclonal anti-human 
IFN-alpha antiserum beside H51 (gift from Dr. 
Cantell, Helsinki).
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B) Indirect immunoperoxidase immunocytochemical 
techniques using various antibodies against 
macrophages, neutrophils and epithelial antigens.
C) Serial section technique. This method was used to 
study co-localization of different antigens in the 
same cell and thus helped to identify which cells 
contained immunoreactive-IFN-alpha.
D) Double staining technique. This technique was 
initially developed to identify which cells 
contained immunoreactive-IFN-alpha in formalin 
fixed normal human tissues. It was also used later 
to identify cells in the in situ hybridization 
technique. It utilized an indirect 
immunoperoxidase or an in situ hybridization 
technique in step one and an indirect 
immunofluorescence method in step two.
E) Immunoradiometric assay "Sucrosep" IFN-alpha 
(Boots Celltech,UK) for the detection of IFN-alpha 
in tissue homogenates and fluids.
F) In situ hybridization for the detection of IFN- 
alpha mRNA in formalin fixed paraffin embedded 
normal human tissues.
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A) PRINCIPLE OF INDIRECT IMMUNOPEROXIDASE TECHNIQUE.
In this technique an unlabelled primary antibody 
binds to the antigen. The primary antibody is then 
identified by a horseradish peroxidase conjugated 
secondary antibody raised to the immunoglobulins of the 
species providing the primary antibody. The horseradish 
peroxidase enzyme is isolated from the root of the 
horseradish plant and is easily attached covalently or 
noncovalently to other proteins. It oxidizes several 
substances and can form coloured enzyme-substrate 
complexes. In this study 3'diaminobenzidine 
tetrahydrochloride (DAB) was used as a substrate 
(Appendix). It is converted by horseradish peroxidase 
into a brown product that is highly insoluble in 
alcohol and other organic solvents.
A(i) INDIRECT IMMUNOPEROXIDASE TECHNIQUE USED FOR THE 
DEMONSTRATION OF IMMUNOREACTIVE-IFN-ALPHA IN 
FORMALIN FIXED PARAFFIN EMBEDDED NORMAL HUMAN 
TISSUE USING THE POLYCLONAL SHEEP ANTI-HUMAN IFN- 
ALPHA ANTISERUM (H51).
The sheep anti-human IFN-alpha antiserum (H51) was 
supplied as neat serum. Normal sheep serum shows 
unacceptable nonspecific staining in immunocytochemical 
techniques on human tissues. Therefore prior to its use 
in the indirect immunoperoxidase technique the H51
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antiserum had to be absorbed to avoid background or
unwanted staining.
Protocol for the absorption of sheep anti-human IFN- 
alpha antiserum (H51).
1) A mixture of guinea pig and porcine liver powders 
(both from Sigma,UK) was used. Half an ml of each 
liver powder was put into a small test tube.
2) The powders were then washed with tris buffered 
saline (0.01M Tris HCL, pH 7.6, 0.15M sodium 
chloride). 3 mis of tris buffered saline was added 
to the tubes containing the powder and mixed well.
3) The tubes were then centrifuged at 1500g at room 
temperature for 5 minutes.
4) The supernatant fluid was discarded and the liver 
powder pellets resuspended in 3 mis of tris 
buffered saline and mixed well. The above 
procedure was repeated at least 3 times.
5) Then 1 ml of the sheep anti-human IFN-alpha 
antiserum (H51) (in 1/50 dilution, in tris 
buffered saline) was added to the washed liver 
powders and mixed well. It was left at 4°C for 5 
hours (occasionally mixed).
6) After 5 hours the tubes containing the mixture 
were centrifuged again at 1500g for 5 minutes and 
the supernatant antiserum was collected. It was
49
again added to freshly washed liver powders, mixed 
and left overnight at 4°C.
7) Next morning the tubes were spun at 1500g for 5 
minutes, the supernatant antiserum was carefully 
collected and the liver powder pellets discarded. 
The H51 antiserum supernatant was again 
centrifuged for 5 minutes at 1500g to get rid of 
any traces of liver powder and finally the 
absorbed supernatant H51 antiserum obtained was 
ready for use in the indirect immunoperoxidase 
technique.
Coating of glass slides.
This was done to prevent cut sections floating off
the slides during the immunocytochemical techniques.
Two methods were used
a) Poly-L-lysine (Sigma, Poole, Dorset,UK) coating.
b) 3-aminopropyltriethoxysilane (Sigma) coating.
a) Poly-L-lysine coating. A drop of poly-L-lyine was 
applied on the marked side of the prewashed glass 
slides and spread over the slide to from a thin 
film. It was left to dry for half an hour before 
use.
b) 3-aminopropyltriethoxysilane coating. Prewashed 
glass slides were put in 2% Decon 75 (Decon Lab;
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Hove,UK) and left overnight. Next morning they 
were washed in running tap water for 1 hour. The 
slides were put first into acetone (BDH, Poole,UK) 
for 5 minutes and then into 2% 3- 
aminopropyltriethoxysilane in acetone for 5 
minutes. This was followed by washing the slides 
in tap water for 1 hour and leaving them to dry. 
Once dried the slides could be stored for months 
before use.
Standard protocol for the indirect immunoperoxidase 
technique used for the demonstration of immunoreactive- 
IFN-alpha in formalin fixed paraffin embedded normal 
human tissue using the polyclonal sheep anti-human IFN- 
alpha antiserum (H51).
Steps.
1) 4 micron thick sections were cut from formol
saline or buffered formalin fixed, paraffin wax 
embedded human tissues. The sections, mounted on 
poly-l-lysine or 3-aminopropyltriethoxysilane 
coated glass slides, were placed in two changes of 
xylene for 5 minutes each, to remove the paraffin 
wax. They were then placed in two changes of 
absolute alcohol and one change of methyl alcohol 
for 5 minutes each and rinsed in tap water.
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2) The slides were washed in tris buffered saline for 
10 minutes.
3) To remove the endogenous peroxidase activity in 
the tissue sections the slides were placed in 3% 
hydrogen peroxide (Evans Medical ltd, Langhurst, 
Horsham, UK) for 10 minutes.
4) Normal swine serum (Gibco,Paisley,UK) diluted 1/5 
in tris buffered saline was applied to the tissue 
sections for 15 minutes.
5) Excess of normal swine serum was removed from the 
sections. The primary sheep anti-human IFN-alpha 
antiserum (H51), diluted 1/100 (in 50% normal 
human serum [Biogenesis, Bournemouth,UK] in tris 
buffered saline) was then applied on the tissue 
sections and left overnight at 4°C.
6) Next morning the slides were washed twice in tris 
buffered saline for 10 minutes.
7) Normal swine serum diluted 1/5 in tris buffered 
saline was then placed on the slides and left for 
15 minutes (the secondary antiserum was a swine 
anti-sheep immunoglobulin antiserum and adding 
normal swine serum at this stage avoided non­
specific sticking of the secondary antiserum to 
the tissue sections) .
8) Excess of normal swine serum was removed and 
horseradish peroxidase conjugated swine anti-sheep 
immunoglobulin antiserum diluted 1/200 (in 20%
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normal human serum in tris buffered saline), was 
added to the sections for 30 minutes.
9) The sections were washed twice in tris buffered 
saline for 10 minutes each time.
10) The slides were placed in DAB substrate solution 
(Appendix) for 10 minutes.
11) The sections were then washed in running tap water 
and counterstained with haematoxylin for 30 
seconds. They were then rinsed in tap water and 
placed in acid alcohol (1% HC1 in methyl alcohol) 
for a few seconds, rinsed again in tap water and 
placed in Scotts water (alkaline pH water) until 
blue. They were checked under a microscope at this 
stage for the degree of counterstaining and rinsed 
in water.
12) The slides were then placed in methyl alcohol for 
five minutes, in absolute alcohol (two changes) 
five minutes each and in xylene (two changes) for 
five minutes each. Finally they were mounted in a 
fixed mounting medium (Harleco synthetic resin, 
Kodak,UK) and visualized under a Leitz Laborlux 
light microscope.
Different batches of the secondary peroxidase 
conjugated swine anti-sheep immunoglobulin antiserum 
were used in the study. They showed a slight variation 
in staining and each time a new batch of the secondary
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antiserum was used, the optimum dilution had to be
worked out for that antiserum.
Evaluation of the specificity of the sheep anti-human
IFN-alpha antiserum (H51).
a) Neutralization/blocking of the H51 antiserum with 
Wellferon (human lymphoblastoid Namalwa, IFN- 
alpha) .
Protocol
1) The same procedure was used for the absorption of 
the H51 antiserum by the liver powders as that 
described earlier in section A (i), except that it 
was absorbed in a 1/20 dilution instead of a 1/50 
dilution in tris buffered saline.
2) Two tubes were labelled A and B. To tube A was 
added 40 microlitres of the absorbed H51 antiserum 
in a 1/20 dilution + 30 microlitres of normal 
human serum + 130 microlitres (1300 mega units) of 
Wellferon.
3) To tube B was added 40 microlitres of the absorbed 
H51 antiserum in 1/20 dilution + 30 microlitres of 
normal human serum + 130 microlitres of tris 
buffered saline.
4) Both the tubes were left overnight at 4°C.
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5) Next morning two sets of tissue sections on glass 
slides were set up for the indirect 
immunoperoxidase staining for IFN-alpha. On one
set the neutralized H51 antiserum from tube A was
used. The contents of tube B were used as a 
positive control on the other set.
6) The standard protocol for the indirect
immunoperoxidase staining for IFN-alpha was then
used.
The neutralization/blocking experiment was carried 
out on at least one section of all human tissues 
studied.
b) Negative Control.
Normal sheep serum (Scottish antibody production 
unit, Law hospital, Lanarkshire,Scotland), absorbed in 
the same way by liver powders as that described for H51 
antiserum, was substituted for H51 antiserum in the 
neutralization/ blocking experiment with Wellferon as 
described above. The remaining procedure was the same 
as that for the H51 antiserum.
c) Positive Control.
Two tissues were used as positive controls.
1) Tissue sections from two human pancreases from 
patients with chronic pancreatitis, previously 
shown to have spindle shaped cells consistently
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staining positively for immunoreactive IFN-alpha, 
were used as positive controls (Foulis efc 
al.,1987).
2) Tissue sections from human placentas, previously 
shown to contain immunoreactive IFN-alpha in the 
syncytiotrophoblast and macrophages, were also 
used as positive controls (Howatson et al.,1988).
d) Assessment of cross reactivity of the H51 
antiserum.
As stated before, in a viral inhibition assay the 
sheep anti-human IFN-alpha (H51) antiserum showed a 
weak neutralization of purified human IFN-beta (Exley 
et al.,1987). Therefore it was important to assess any 
cross reactivity of sheep anti-human IFN-alpha 
antiserum (H51) with IFN-beta before use in the 
indirect immunoperoxidase technique.
Two methods were adopted.
i) Neutralization/ blocking of the H51 antiserum with 
recombinant IFN-beta (Triton, Biosciences,
CA,USA).
ii) Immunoblots.
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i) Neutralization/ blocking of the H51 antiserum with 
recombinant IFN-beta.
The same procedure was used as that described 
earlier for the neutralization/ blocking experiment of 
the H51 antiserum with Wellferon except that the tris 
buffered saline in tube B in step 2 was replaced by 130 
microlitres of recombinant IFN-beta (approximately 
12,400 units).
ii) Immunoblots.
This technique was adopted as a quick means of 
excluding cross reactions of the H51 antiserum with 
IFN-beta and some other proteins and sera.
Protocol
1) A strip of nitrocellulose paper (Gelmen Sciences 
Inc, Ann Arbor, MI,USA) was marked into small 
sections and one edge cut as an identification 
mark.
2) The strip was washed in tris buffered saline and 
left to dry for a few minutes.
3) 2 microlitres of each of the following were
spotted on the nitrocellulose paper strip in the 
centre of each section: normal sheep serum (Law 
hospital,Scotland), normal human serum 
(Biogenisis,UK), tumour necrosis factor 
(Genentech, San Francisco,USA), Wellferon (IFN-
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alpha), IFN-beta (Triton, Biosciences, CA,USA) and 
interleukin 1-1 alpha and interleukin 1-1 beta 
(both from National Institute for Biological 
Standards and Control, Potters Bar,UK), tris HCL 
buffer,pH 7.6. The exact location of various 
substances on the nitrocellulose paper (the cut 
edge is used as a marker) was noted on a separate 
piece of paper.
4) The nitrocelluse paper was left to dry at room 
temperature for one hour.
5) The strip was treated with 3% bovine serum albumin 
in tris buffered saline for 2 hours. This helped 
to decrease the background staining.
6) The strip was washed twice in tris buffered saline 
for 10 minutes.
7) The nitrocellulose paper was then sealed in a 
plastic bag with 2 mis of absorbed H51 antiserum 
diluted 1/100 (in 50% normal human serum in tris 
buffered saline), and left overnight at 4°C.
8) Next morning the nitrocellulose paper was washed 
in 3 changes of tris buffered saline for 15 
minutes.
9) It was then sealed in a fresh plastic bag 
containing 2 mis of the horseradish peroxidase 
conjugated swine anti-sheep immunoglobulin 
antiserum diluted 1/200 (in 20% normal human serum
in tris buffered saline). It was left at room 
temperature for 30 minutes.
10) It was then washed in tris buffered saline for 15 
minutes, changing the fluid three times.
11) The nitrocelluse paper was then placed in the DAB 
substrate solution (Appendix) for 10 minutes.
12) It was finally washed well in tap water and left 
to dry at room temperature before being sealed in 
a plastic bag.
Aii) IMMUNOCYTOCHEMICAL TECHNIQUES USING OTHER PRIMARY
ANTISERA TO IFN-ALPHA.
Two immunocytochemical technique were used.
1) Avidin-biotin immunocytochemical technique.
2) Indirect immunoperoxidase technique.
1) Protocol for the avidin-biotin immunocytochemical
technique used for the demonstration of 
immunoreactive-IFN-alpha in formalin fixed 
paraffin embedded normal human tissues using a 
monoclonal anti-human IFN-alpha antibody (Code 
No.0050).
Steps.
1) The first 4 steps of the protocol were the same as 
in the protocol of the indirect immunoperoxidase
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technique used for the demonstration of 
immunoreactive-IFN-alpha using the polyclonal 
sheep H51 antiserum.
2) Normal horse serum (Vector lab; Bretton, 
Peterborough,UK) [diluted 1 drop in 3 mis of tris 
buffered saline] was added to the tissue sections 
for 15 minutes, blocking non-specific sites on the 
tissue sections.
3) Excess of the normal horse serum was removed from 
the sections. The primary monoclonal anti-human 
IFN-alpha antibody (Code No.0050) diluted 1/100 in 
tris buffered saline, was left on the sections for 
2 hours at room temperature.
4) The slides were washed in tris buffered saline for 
10 minutes, changing twice.
5) The secondary antiserum, biotinylated horse anti­
mouse immunoglobulins (Vector lab; UK), diluted 
1/100 in 20% normal human serum in tris buffered 
saline, was placed on the sections for 30 minutes.
6) The sections were than washed in tris buffered 
saline for 10 minutes, changing twice.
7) A horseradish peroxidase conjugated Vectastain ABC 
reagent (Vector Lab. U.K) [Appendix] was applied 
to the sections for 1 hour at room temperature.
8) The sections were washed in tris buffered saline 
for 10 minutes, changing twice.
60
9) The slides were placed in a freshly prepared DAB 
substrate solution for 10 minutes.
10) The slides were washed, counterstained and mounted
in a fixed mounting medium as described in the
protocol of the indirect immunoperoxidase 
technique used for the demonstration of 
immunoreactive-IFN-alpha with the H51 antiserum.
Amendments to the above protocol.
i) Effect of trypsinization.
After step 4 the tissue sections were trypsinized 
(Appendix) for 10 minutes. The procedure was identical 
thereafter.
11) Varying the primary antibody (Step 2).
Variation(a). The primary antibody diluted 1/100 was 
left overnight on the sections at 4°C instead of 2 
hours incubation at room temperature.
Variation(b). The primary antibody was used in 1/5,
1/10, 1/20, 1/50, 1/200 dilutions on consecutive serial 
sections of the same normal human tissue.
iii) Varying the secondary antiserum (Step 5).
Variation (a) . The secondary antiserum, biotinylated 
horse anti-mouse immunoglobulins antiserum was left on 
for 1 hour and 2 hours on consecutive serial sections 
of the same normal human tissue at room temperature .
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Variation(b). The secondary antiserum was used in 1/50 
dilution.
iv) Varying the biotin detection system (Step 7).
Instead of the Vectastain ABC reagent, an alkaline 
phosphatase conjugated Streptavidin-biotin complex 
(Appendix) was applied to the sections for 1 hour. The 
sections were treated with an alkaline phosphatase 
substrate solution, Fast Red (Appendix) , for 10 
minutes. The sections were then counterstained in 
haematoxylin for 10 seconds, washed in tap water and 
mounted in Glycergel (water mounting medium) (Dako).
2) Indirect immunoperoxidase technique using the 
above monoclonal antibody.
Protocol
1) The first 4 steps of the protocol were the same as 
the protocol for the indirect immunoperoxidase 
technique used for the demonstration of 
immunoreactive-IFN-alpha using the H51 antiserum, 
described in section A(i).
2) The primary monoclonal anti-human IFN-alpha 
antibody (Code No.0050) diluted 1/100 in tris 
buffered saline was then applied to the sections 
and left for 2 hours at room temperature.
3) The slides were washed in tris buffered saline for 
10 minutes.
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4) A horseradish peroxidase conjugated rabbit anti­
mouse immunoglobulin antiserum diluted 1/50 (in 
20% normal human serum in tris buffer saline) was 
applied to the sections and left for 30 minutes.
5) Sections were washed in tris buffered saline for 
10 minutes, changing twice.
6) The slides were placed in DAB substrate solution 
for 10 minutes.
7) Sections were counterstained and mounted in a 
fixed mounting medium as described in the protocol 
of the indirect immunoperoxidase technique using 
H51 antiserum.
Negative Control.
Throughout the above avidin-biotin and indirect 
immunocytochemical techniques, a monolonal antibody, 
Clonab-LNC raised against an irrelevant antigen, 
(BIOTEST Serum Institute, West Germany) was applied on 
at least one section of each tissue as a negative 
control to exclude any non-specific staining of the 
monoclonal antibody.
Positive Control.
Two monoclonal antibodies, LN26 and EMA were used 
as positive controls. LN26 stains B lymphocytes and EMA 
antibody stains epithelial membrane antigens in 
formalin fixed human tissues. Sections from a human
63
lymph node (having abundant B lymphocytes) and breast 
tissue were used as control slides for LN26 and EMA 
antibody respectively. The protocol used for LN26 and 
EMA antibodies was the same in every respect to the 
protocols of the avidin-biotin immunocytochemical 
technique and the indirect immunoperoxidase technique 
using the monoclonal anti-human IFN-alpha antibody(Code 
No.0050) .
The protocol used for the detection of 
immunoreactive IFN-alpha, using the polyclonal sheep 
anti-human IFN-alpha antiserum (Dr Cantell) was the 
same as the protocol for the polyclonal sheep anti­
human IFN-alpha antiserum (H51).
B) INDIRECT IMMUNOPEROXIDASE IMMUNOCYTOCHEMICAL 
TECHNIQUES USING VARIOUS ANTIBODIES DIRECTED 
AGAINST MACROPHAGES, NEUTROPHILS AND EPITHELIAL 
ANTIGENS.
Two monoclonal antibodies, KP1 and Mac 387, and a 
polyclonal anti-muramidase antiserum were used 
throughout the study for the demonstration of 
macrophages. A neutrophil marker, LeuM 1 monoclonal 
antibody was used to identify cells in tissue sections 
during the in situ hybridization technique. A 
polyclonal anti-prekeratin antiserum (epithelial cell 
marker) was used to identify cells staining positively 
for immunoreactive IFN-alpha in human fetal thymus.
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Protocol for the monoclonal antibodies/ KP1, Mac 387 
and LeuM 1 using an indirect immunoperoxidase 
technique.
The same protocol was used as that described for 
the monoclonal anti-human IFN-alpha antibody in section 
A(ii)2 with the following variations.
Trypsinization.
The tissue sections were trypsinized for 10 
minutes prior to application of all three monoclonal 
antibodies.
Variation in primary antibodies.
The KP1 antibody was used at a 1/10 dilution and 
left on the sections overnight at 4°C.
The Mac 387 antibody was used at a 1/20 dilution
and left on the sections for 2 hours at room
temperature.
The LeuM 1 antibody was used at a 1/50 dilution
and left on the sections for 2 hours at room
temperature.
All the monoclonal antibodies were diluted in tris 
buffered saline.
Amendment to the staining protocol for KP1 antibody.
The tissue sections were trypsinized for 20 
minutes instead of 10 minutes. The remaining procedure 
was the same.
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Absorption of the KP1 antibody with Wellferon.
This procedure was performed to exclude the 
possibility of cross-reaction between KP1 and IFN- 
alpha .
Two tubes were taken marked A and B. 20
microlitres of KP1 antibody was put in tube A and 200
microlitres of Wellferon (2000 mega units) was added to 
the KP1 in tube A. In tube B, 20 microlitres of KP1 
antibody was placed and 200 microlitres of tris
buffered saline was added. The content of tube B were
used as positive control. Both tubes A & B were left 
overnight at 4°C. Next morning the absorbed and the 
positive control unabsorbed KP1 antibody were used to 
stain slides as described above in the protocol for the 
KP1 antibody.
Protocol for the indirect immunoperoxidase technique 
using the polyclonal anti-muramidase and anti­
prekeratin antisera.
The same protocol was used as that of the indirect 
immunoperoxidase technique using the H51 antiserum 
described in section A(i), with the following 
variations.
Trypsinization.
After step 3 the sections were trypsinized for 20 
minutes.
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Variation in primary antiserum.
The rabbit anti-muramidase antiserum was applied 
to the sections at a 1/200 dilution and left on at room 
temperature for 1 hour.
The rabbit anti-prekeratin antiserum was applied 
to the sections at a 1/200 dilution for 30 minutes at 
room temperature.
Both the antisera were diluted in tris buffered 
saline.
Variation in secondary antiserum.
Horseradish peroxidase conjugated swine anti­
rabbit immunoglobulin antiserum was used at 1/50 
dilution in 20% normal human serum in tris buffered 
saline, for 30 minutes.
C) SERIAL SECTION TECHNIQUE.
Two serial section techniques were used.
1) Mirror image technique (Noordan,1986). A 3 microns 
thick section of formalin fixed paraffin embedded 
human tissue was cut and picked up on a poly-L- 
lysine or 3-aminopropyltriethoxysilane coated 
glass slide. The second serial section was turned 
upside down and picked up on another slide. Thus 
the superficial aspects of the two sections were 
those cut surfaces which had been separated by the 
knife (figure,2.1). One section was stained for
Figure 2,1
Mirror image serial section technique
KNIFE
< —  Tissue section
Slide 1. Slide 2.
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IFN-alpha with the sheep anti-human IFN-alpha 
antiserum (H51) and the second section for KP1 
(macrophage marker). For comparison the two 
sections were visualized together with two 
different microscopes but one diffuser(head). 
Specific fields were identified in each section 
and photographed. The photograph from one slide 
was printed in reverse so that the mirror image 
could be cancelled.
2) Two 3 micron thick sections were cut from formalin 
fixed paraffin embedded normal human tissues and 
both picked up on poly-L-lysine or 3- 
aminopropyltriethoxysilane coated glass slides in 
the usual way. The first serial section was 
stained for IFN-alpha with the sheep H51 antiserum
and the second serial section for KP1. A similar
field was identified in the two serial sections 
and photographed for comparison.
D) DOUBLE STAINING TECHNIQUE.
The technique can be divided into two parts.
a) Indirect immunoperoxidase technique used for the
demonstration of immunoreactive-IFN-alpha using 
the polyclonal sheep H51 antiserum or in situ 
hybridization for the detection of IFN-alpha 
messenger RNA (mRNA).
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b) Indirect immunofluorescence technique.
a) After the indirect immunoperoxidase technique used 
for the demonstration of immunoreactive-IFN-alpha or 
the in situ hybridization technique the slides were 
examined under the microscope to confirm positive 
staining of cells. The coverslips were then removed by 
placing the slides in xylene in the case of the 
indirect immunoperoxidase technique or in water in the 
case of the in situ hybridization technique. The same 
slides were then used in the indirect 
immunofluorescence technique. Slides stained days or 
months before for IFN-alpha by the above indirect 
immunoperoxidase technique could be used in this double 
staining technique.
b) The indirect immunofluorescence technique. 
Principle.
The tissue sections are treated with an unlabelled 
primary antibody that binds to the antigen. The bound 
primary antibody is identified by a rhodamine labelled 
secondary antiserum raised to the immunoglobulins of 
the species providing the primary antibody. The slides 
are then veiwed by a fluorescence microscope.
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Testing various antibodies suitability for 
immunofluorescence before use in the double staining.
Two monoclonal antibodies KP1 and Mac 387 and the 
rabbit polyclonal anti-muramidase and anti-prekeratin 
antisera were tested.
Protocol for the monoclonals KP1 and Mac 387.
The same protocol was used as that described for 
monoclonal anti-human IFN-alpha antibody in section 
B(2) with the following variations.
Trypsinization.
The tissue sections were trypsinized for 10 
minutes prior to application of KP1 and MAC 387 
monoclonal antibodies.
Variation in primary antibodies.
The KP1 antibody was used at a 1/10 dilution and 
left on the sections overnight at 4°C.
The Mac 387 antibody was used at a 1/20 dilution. 
It was left on two consecutive sections from the same 
tissue, for 2 hours at room temperature, and overnight 
at 4°C, respectively.
Both the monoclonal antibodies were diluted in 
tris buffered saline.
Variation in secondary antiserum.
A rhodamine conjugated rabbit anti-mouse 
immunoglobulin antiserum was used at a 1/20 dilution 
(in 20% normal human serum in tris buffered saline) for
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45 minutes instead of the horseradish peroxidase 
conjugated rabbit anti-mouse immunoglobulin antiserum. 
The slides were then washed in tris buffered saline for 
10 minutes, counterstained in haematoxylin for 5 
seconds, washed thoroughly in tap water and mounted in 
Glycergel (water mounting medium).
Control.
A section was treated with tris buffered saline 
instead of the primary antibody to avoid 
misinterpreting non-specific immunofluorescence due to 
the secondary antiserum.
Anti-muramidase and anti-prekeratin antisera.
The protocol was the same as the protocol of the 
indirect immunoperoxidase technique using the 
polyclonal sheep H51 antiserum described in section 
A(i) with the following Amendments.
Trypsinization.
After step 3 the sections were trypsinized for 20 
minutes.
Variation in primary antiserum.
The rabbit anti-muramidase antiserum was applied 
to the sections at a 1/50 dilution and left on at room 
temperature for 2 hour.
The anti-prekeratin antiserum was applied to the 
sections at a 1/100 dilution for 2 hours at room 
temperature.
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Both the antisera were diluted in tris buffered 
saline.
Variation in secondary antiserum.
A secondary rhodamine conjugated swine anti-rabbit 
immunoglobulin antiserum was used at a 1/20 dilution 
(in 20% normal human serum in tris buffered saline) for 
45 minutes. The slides were then washed in tris 
buffered saline for 10 minutes, counterstained in 
haematoxylin for 5 seconds, washed thoroughly in tap 
water and mounted in Glycergel.
Control.
A section was treated with tris buffered saline 
instead of the primary antibody to avoid 
misinterpreting non-specific immunofluorescence due to 
the secondary antiserum.
Once the antibody tested was shown to detect 
antigen with strong immunofluorescence and little
background it was then used in part (b) of the double
>
staining technique, as described below.
The slides were taken to water after part (a) of 
the double staining technique and one of the above 
indirect immunoflourscence methods was applied to the 
same section. Double stained sections were viewed with 
a Leitz "Orthomat" fluorescence microscope.
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Control for the double staining.
Tissue sections shown previously to have cells 
fluorescing strongly with the antibodies described in 
section (b) were used in the double staining technique 
as positive controls. These tissue sections were 
treated with tris buffered saline instead of the H51 
antiserum in part (a) of the double staining technique. 
The remaining protocol was the same.
E) IMMUNORADIOMETRIC ASSAY "SUCROSEP" IFN-ALPHA
(BOOTS CELLTECH,UK) FOR THE DETECTION OF IFN-ALPHA 
IN HUMAN TISSUE HOMOGENATES AND FLUIDS.
All human tissues had to be homogenized and the 
fluids cleared before use in the immunoradiometric 
assay.
Protocol for homogenization of human tissues.
1) All human tissues stored at -70°C were defrosted 
and suspended in viral transport medium (Gibco,UK) 
at 4°C. Approximately 1 gram of tissue was added 
per 2 mis of viral transport medium for all 
tissues except choroid plexus. As the choroid 
plexus tissue samples were very small in size, 1 
gram of tissue was suspended in 4 mis of viral 
transport medium to obtain a reasonable volume for 
homogenization.
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2) All the suspensions were homogenized for 60 
seconds in an Ultra Turrax homogenizer (Janke & 
Kunkel).
3) The suspensions were then immediately centrifuged 
at 3500g for 30 minutes, at 4°C.
4) The clear supernatant was collected and stored in 
aliquots at -70°C.
During the entire process of homogenization the 
temperature of the suspensions was kept down by placing 
the suspension containers in ice. The homogenization 
bur was also cooled before use and during the 
homogenization procedures. This was done in order to 
avoid denaturation of proteins by a rise in temperature 
during processing.
The 4 amniotic fluids collected from caesarean 
section operations were also centrifuged at 3500g for 5 
minutes at 4°C and the clear supernatants thus obtained 
were stored in aliquots at -70°C.
Amendment to the above protocol.
Pepstatin A (pepsin inhibitor) and Aprotinin A 
(trypsin inhibitor, 13.8 trypsin inhibitor 
units/milligram) (both were from Sigma, ST Louis,USA) 
were added to the homogenizing buffer just before the 
start of the homogenization procedure. They were used 
in a concentration of 1 microgram of Pepstatin A + 1
74
microgram of Aprotinin A/ ml of the homogenizing 
buffer.
The f,Sucrosep,f IFN-alpha immunoradiometric assay. 
Principle.
The principle of the "Sucrosep" IFN-alpha 
immunoradiometric assay is briefly outlined in 
figure,2.2. It shows that there are two sites of IFN- 
alpha capture, utilizing a 125I monoclonal Yok 5/19 
anti-IFN-alpha antibody in the first step and a 
polyclonal sheep anti-IFN-alpha antiserum (solid phase) 
in the second step.
Procedure for the "Sucrosep" IFN-alpha
immunoradiometric assay, for the detection of IFN-alpha 
in human tissue homogenates and fluids.
Steps.
1) The freeze dried IFN-alpha standard provided with 
the ’’Sucrosep" IFN-alpha immunoradiometric assay 
kit (calibrated against the MRC 69/19 
International reference preparation for human 
leucocyte IFN, obtained from the National 
Institute for Biological Standards and Control, 
Potters Bar, UK) was reconstituted with 3 mis of 
viral transport medium. The resulting stock 
solution contained 1024 international units/ml
1st Incubation
iiii
IFN-alpha
+
125l Monoclonal Antibody
-
\  ^
MAb/IFN-alpha Complex
2nd Incubation
+
n / )  Solid phase
^ ---- v \  sheep
N anti-IFN-alpha - MAb/Antigen/ 
Antibody complex
Figure 2 .2. Principle of the "Sucrosep" IFN-alpha immunoradiometric 
assays (IRMA)
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(IU/ml) of IFN-alpha. A series of IFN-alpha 
standards; 0, 1, 4, 16, 64 and 256 IU/ml were 
prepared from the stock solution (1024 IU/ml of 
IFN-alpha) with viral transport medium as a 
diluent.
2) 200 microlitres of each standard and 200 
microlitres of specimen were added in the test 
proper to each of 2 test tubes in a rack of 20 
tubes.
3) 50 microlitres of radiolabelled monoclonal 
antibody was than added to each tube and the tube 
contents vortex mixed for a few seconds. 50 
microlitres of radiolabelled monoclonal antibody 
was added to 2 tubes without specimens and left to 
the final counting procedure. These tubes were 
later referred to as "total count" tubes.
4) After an incubation period of 2 hours at room 
temperature, 50 microlitres of the polyclonal IFN- 
alpha antiserum (solid phase) suspension was added 
to the mixture and thoroughly mixed by repeated 
inversion of the capped bottle immediately before 
and during pipetting.
5) The tubes were then left for 2 hours on an orbital 
shaker. This helped to keep the polyclonal anti­
human IFN-alpha antiserum (solid phase) in 
suspension while it reacted with IFN-alpha present 
in samples.
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6) At the end of this period the tubes were removed 
from the shaker and any empty tube spaces in the 
racks were filled with spare tubes before 
commencing the separation procedure.
7) Labelled monoclonal antibody bound to IFN-alpha in 
the solid phase was washed and separated in a 
gravity dependent sucrose separation system 
"Sucrosep".
8) One ml of pre-wash buffer was added to each tube 
to wash the walls of the test tubes. The tubes 
were allowed to stand for 5 minutes.
9) Using a sucropette (reagent delivery device), 2 ml 
of "Sucrosep" reagent was delivered to the lower 
part of each tube. The dense "Sucrosep" solution 
displaces residual monoclonal antibody and the 
specimen to the upper part of the test tube. The 
sucropette was carefully removed when the sucrose 
solution had been layered below the incubate.
10) The tubes were then left for 15 minutes to allow 
the solid phase polyclonal antiserum to gravitate 
to the base of the tube, carrying with it any 
radiolabelled immune complex present.
11) Using an aspirator provided with the kit, the tube 
contents were aspirated, leaving approximately 0.3 
ml in the bottom of each tube.
12) A second "Sucrosep" separation step was then 
carried out after which the tubes were sealed.
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13) The radioactivity was counted in all the tubes 
with a gamma scintillation counter (Packard Auto 
Gamma 5650, United technologies, Packard), for a 
time sufficient to accumulate at least 50,000 
counts in the "total count" tubes. These tubes 
with 50 microlitres of the radiolabelled 
monoclonal antibody were always added as a part of 
the assay in order to determine the relative 
radioactivity of the label.
14) Empty tubes were also used to check the background 
radiation.
15) Using a log/log plot, 125I counts versus IFN-alpha 
standard concentrations were plotted. A standard 
curve was drawn from this data and used to 
interpolate IFN-alpha concentrations in the 
specimens studied.
In this study the "Sucrosep" IFN-alpha 
immunoradiometric assay was used to measure IFN-alpha 
in tissue homogenates diluted in viral transport medium 
(VTM). The "Sucrosep" IFN-alpha immunoradiometric assay 
was developed by Boots-Celltech Diagnostics,UK for the 
measurement of human IFN-alpha in serum or tissue 
culture fluids. As the assay was to be used on the 
extraction buffer (VTM) rather than serum buffer, it 
was considered important to determine the assay 
performance when VTM was used as a diluent. The 
following experiments were performed to test the
reproducibility and specificity of the assay with VTM 
as a diluent.
a) Intra-assay analysis.
To test the intra-assay precision of the 
"Sucrosep" IFN-alpha immunoradiometric assay, 8 sample 
of VTM with no IFN-alpha activity were analyzed on the 
same day by the "Sucrosep" IFN-alpha immunoradiometric 
assay, as described above. The mean of the total numbe 
of counts, standard deviation and coefficient of 
variation were determined for these 8 samples of VTM.
b) Inter-assay analysis.
The reproducibility of the assay was analysed by 
calculating the mean value for each standard 
concentration derived from 10 different "Sucrosep" IFN 
alpha immunoradiometric assays (with VTM used as the 
diluent) performed over a period of several months. 
These mean values were used to plot a standard curve. 
Standard deviation, standard error and coefficient of 
variation were also calculated for each standard 
concentration.
c) Neutralization/ blocking experiment.
This experiment evaluated the specificity of the 
"Sucrosep" IFN-alpha immunoradiometric assay by 
removing IFN-alpha from the specimens before testing,
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when performed in parallel to samples tested with no
treatment.
Procedure of the neutralization/ blocking experiment.
1) IFN-alpha standards of 0, 1, 4, 16, 64, and 246 
IU/ml were prepared from the standard IFN-alpha 
preparation of 1024 IU/ml.
2) 200 microlitres of each standard was added to a 
set of 4 tubes. Two tubes of each set were 
selected as the samples for the neutralization/ 
blocking and the remaining two were used as IFN- 
alpha standard controls.
3) 50 microlitres of the sheep anti-human IFN-alpha 
antiserum attached to solid phase was added to 
each of the tubes with the specimens to be 
neutralized.
4) The samples were placed in an orbital shaker and 
incubated at room temperature for two hours.
5) After this period, the samples were centrifuged at 
3000g and 200 microlitres of the supernatant was 
collected.
6) The neutralized supernatants and the control IFN- 
alpha standards were assayed in duplicate for IFN- 
alpha activity following the standard procedure of 
the "Sucrosep" IFN-alpha immunoradiometric assay 
for the detection of IFN-alpha.
80
The solid phase in the third step of the above 
experiment was a sepharose micro-bead system to which 
the polyclonal sheep anti-human IFN-alpha antiserum was 
covalently attached. It was possible to capture IFN- 
alpha in the specimens onto the solid phase with 
incubation and remove it from the specimen by 
centrifugation. The supernatants could then be tested 
for residual unblocked IFN-alpha.
F) IN SITU HYBRIDIZATION TECHNIQUE FOR THE DETECTION
OF IFN-ALPHA MESSENGER RNA (mRNA) IN FORMALIN
FIXED PARAFFIN EMBEDDED NORMAL HUMAN TISSUES.
It is well known that messenger RNA (mRNA) can be 
easily destroyed by various ribonuclease enzymes found 
abundantly in the environment. Therefore certain 
precautions were always carried out during various in 
situ hybridization procedures.
Glassware.
All the glassware was placed in 2% RBS solution 
(Chemical Concentrates, Kent,UK) in water for 4-5 
hours. The glassware was then washed thoroughly with 
tap water and dried before use in the in situ 
hybridization procedure.
Gloves.
Gloves were worn all the time while handling 
glassware and other reagents used in the in situ
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hybridization technique to avoid contamination with the 
high concentrations of ribonuclease (RNase) enzymes 
found on the fingers.
Distilled water and buffers.
Distilled water and most buffers used in the in 
situ hybridization technique were treated with 
diethylpyrocarbonate (DEPC) (Sigma,UK). One ml of DEPC 
was added to 1000 mis of distilled water or buffer, 
mixed well by shaking and left overnight in capped 
bottles (DEPC is a potential carcinogen, therefore the 
above procedure was always performed in a fume 
chamber). Next morning the bottles containing the 
buffers and water were autoclaved at 140°C. DEPC 
destroys ribonuclease enzymes in the solutions and 
autoclaving converts excess DEPC into ethanol and 
carbon dioxide (Arrand, 1985) . After autoclaving the 
water and buffers were cooled before use in the in situ 
hybridization techniques. The word DEPC has been used 
throughout the text before buffers and water treated 
with DEPC, as described above.
Two oligonucleotide probes, probe 1 and probe 2, 
were selected for the demonstration of IFN-alpha mRNA 
in formalin fixed normal human tissue, as described 
earlier in the materials section. A poly-d-T probe 
demonstrating total mRNA in formalin fixed normal human 
tissues was also used as positive control for the in 
situ hybridization technique.
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Probe 1 (17 base oligonucleotide probe) was
supplied in ammonium hydroxide solution. To isolate the
probe from the ammonium hydroxide solution a procedure
called ethanol precipitation, was used.
Ethanol precipitation procedure.
1) 360 microlitres of oligonucleotide probe 1, 
supplied in ammonium hydroxide solution, was put 
in a microcentrifuge tube. 40 microlitres of 3 
molar(M) sodium acetate (BDH,UK) in water was 
added to the probe and mixed to give 400 
microlitres of 0.3M sodium acetate solution 
containing the oligonucleotide probe.
2) 1.2 mis of absolute ethanol (kept at -20°C) was 
added to the 0.3M sodium acetate solution 
containing the oligonucleotide probe, mixed and 
left overnight at -70°C.
3) Next morning the solution was centrifuged at 
15,000g for 10 minutes at room temperature. A 
pellet was observed at the base of the tube.
4) The supernatant was removed with a glass pasteur 
pipette.
5) The pellet was rinsed with absolute ethanol, kept 
at -20°C, by carefully pipetting down the side of 
the tube, opposite the pellet.
6) Next the above solution was centrifuged for 10 
minutes at 15,000g.
7) Most of the ethanol was carefully removed with a 
glass pasteur pipette and the rest left to 
evaporate till the pellet was dry.
8) The pellet was dissolved in 20 microlitres of T.E 
buffer (Appendix).
9) 1 microlitre of the above solution was added to 
500 microlitres of T.E buffer.
10) The optical density of this solution was measured 
with a spectrophotometer (PU 8620 series, 
Scientific & Analytical Equipment, Philips,UK).
For oligonucleotide probes one optical density 
reading is equal to 20 micrograms of the probe per 
ml. With the help of the optical density reading 
from the spectrophotometer, it was shown that 
there was 94.4 micrograms of probe in the 20 
microlitres of solution analysed. To obtain a 
probe concentration of 1 microgram/ microlitre, 
74.4 microlitres of T.E buffer was added to this 
probe solution. The probe solution of 1 microgram/ 
microlitre in T.E buffer finally obtained was 
stored at -20°C.
Probe 2 (24 base oligonucleotide) on the other 
hand was supplied in a pure solid form, ready to use 
(with an optical density reading of 3.6). T.E buffer 
was added to make a probe solution with a final
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concentration of 1 microgram of the probe/ 1 microlitre 
of T.E buffer.
Poly-d-T probe was also obtained in a ready to use 
form and was diluted in T.E buffer to get a probe 
concentration of 1 microgram of the probe/ 1 microlitre 
of T.E buffer.
All three stock probes (1 microgram of the probe/
1 microlitre of T.E buffer) were kept at -20°C.
Labelling of the oligonucleotide probes.
The oligonucleotide probes were labelled with a 
nonradioactive labelling substance called 
digoxigenin.11.dUTP (Boehringer Mannheim Ltd, East 
Sussex, England).
Standard protocol for labelling of the IFN-alpha mRNA 
oligonucleotide probes with digoxigenin.11.dUTP.
It can be divided into two parts.
a) Labelling reaction.
b) Separation of the labelled probe.
a) Labelling reaction [end-labelling with terminal
deoxynucleotidyl transferase(TdT) enzyme]
30 microlitres of diethylpyrocarbonate (DEPC) 
treated water and 10 microlitres of 5 x tailing buffer 
[Bethesda Research Lab; (BRL) Life Technologies 
Inc,USA] (100 mM potassium cacodylate, pH 7.2, 2mM
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Cocl-2/ 0.2 mM DTT) were put in a microcentrifuge tube 
and mixed well. 5 nanomoles of digoxigenin.11.dUTP and 
1 nanomole of deoxy-cytidine-triphosphate (Pharmacia, 
UK) were then added to the above mixture. 1 microgram
of the oligonucleotide probe was then added and mixed
well. Finally approximately 44 units of the terminal 
deoxynucleotidyl transferase enzyme (BRL,USA) was added 
and mixed well. The mixture was spun in the 
microcentrifuge tube for a few seconds and incubated 
overnight at 37°C.
b) Separation of the labelled probe.
1) Next morning a vertical stand was taken and a 
ruler was placed in the horizontal position on the 
stand. A sephadex G-25 separation column (NAP-5,
Pharmacia,UK) was attached to the ruler in upright
position.
2) Equilibration of the sephadex G-25 separation 
column.
A 0.1% standard saline citrate(SSC), 0.1 % sodium 
dodecyl sulphate (SDS) solution in water was placed 
on the top of the column till the column was full. 
The solution was allowed to drip down the lower 
end of the column till the column was empty. The 
process was repeated 3 times.
3) 10 microcentrifuge tubes were marked from 1-10 and 
placed in order in a rack.
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4) A nitrocellulose paper strip (Gelmen Sciences, USA) 
was taken and divided into 10 small parts. A small 
edge was cut as an identification mark. The strip 
was first placed in DEPC water and then in DEPC 
20xSSC solution (lxSSC= 0.15M sodium chloride, 
0.015 M sodium citrate) for a few minutes. The 
nitrocellulose paper strip was taken out and dried 
between two filter papers (Whatman International, 
Maidstone,England).
5) The microcentrifuge tube (containing the probe + 
labelling reagents' solution incubated overnight 
at 37°C) was centrifuged for a few seconds and 
placed on ice. 5 microlitres of lOOmM 
ethylenediamine tetraacetic acid (Sigma) was added 
to the tube and mixed well to stop the labelling 
reaction. The solution was then placed on top of 
the sephadex separation column.
6) The microcentrifuge tube marked 1 was placed under 
the sephadex column. 200 microlitres of 0.1% SSC, 
0.1% SDS solution was then placed on top of the 
sephadex column. Approximately 200 microlitres of 
fluid drips down the column which was collected in 
the microcentrifuge tube. The same procedure was 
repeated for all the 10 marked microcentrifuge 
tubes in an orderly way from 1 to 10.
7) One microlitre of the solution from each 
microcentrifuge tube was spotted on a separate
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part of the nitrocellulose paper strip and dried 
in air. The nitrocellulose paper strip was then 
placed between two ordinary filter papers held by 
paper clips and baked at 80°C for two hours.
8) After baking at 80°C for two hours the 
nitrocellulose paper strip was washed briefly in 
buffer one (lOOmM tris HCL, 150mM sodium 
chloride).
9) The nitrocellulose paper strip was then sealed in 
a plastic bag with buffer 2 (3% bovine serum 
albumin [Sigma] in buffer one) , for 30 minutes at 
42°C.
10) The strip was washed briefly in buffer one.
11) The nitrocellulose paper strip was then sealed in
a plastic bag containing alkaline phosphatase 
conjugated anti-digoxigenin antibody (Boehringer, 
Mannheim,UK) at 1/1000 dilution in buffer one and 
left for 30 minutes at room temperature, on a 
shaker.
12) The nitrocellulose paper strip was washed twice in 
buffer one for 15 minutes each, on a shaker, to 
remove the unbound anti-digoxigenin antibody.
13) The nitrocellulose paper strip was then washed
with buffer three (lOOmM tris HCL, lOOmM NaCl,
50mM magnesium chloride, pH 9.5) for 5 minutes on
a shaker.
14) The nitrocellulose paper strip was incubated in a 
sealed plastic bag with an alkaline substrate 
solution, Nitroblue tetrazolium (NBT) and 5-bromo- 
4-chloro-3-indolylphosphate (BCIP) (both from 
Sigma) [Appendix] for 30 minutes. Light was 
excluded from the reaction by wrapping the plastic 
bag in aluminium foil.
15) The above reaction was stopped by placing the 
nitrocellulose paper strip in buffer four (lOmM 
tris HCL, ImM EDTA, pH 8) for 5 minutes. The 
nitrocellulose paper strip was then dried between 
two filter papers and sealed in a plastic bag.
16) The fractions of the separated solution which 
contained the labelled probe appeared as a blue 
dot on the nitrocellulose strip.
17) Those fractions containing labelled probe were 
pooled and placed in a freeze dryer for 16-18 
hours. The freeze dried (lyophilized) labelled 
probe was stored at -20°C. The labelled probe was 
reconstituted in 100 microlitres of TE buffer 
before use in in situ hybridization techniques.
Amendment to the protocol of the labelling reaction.
2 micrograms of probe was added to the labelling 
reaction reagents instead of 1 microgram. The remaining 
procedure was the same as above.
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Labelling of the poly-d-T probe with digoxigen.11.dUTP.
The same labelling procedure was used as that 
described for the IFN-alpha mRNA oligonucleotide probes 
with the following amendments.
The labelling reaction.
4 microlitres of 5 x tailing buffer was added to 
10 microlitres of DEPC water and mixed in a 
microcentrifuge tube. 2 nanomoles of 
digoxigenin.11.dUTP was then added to the above 
mixture, followed by the addition of 2 micrograms of 
the poly-d-T probe, and was mixed well. Finally, 
approximately 30 units of the terminal deoxynucleotidyl 
transferase enzyme was added to the mixture and 
incubated overnight at 37°C. The separation procedure 
was the same as that described for IFN-alpha mRNA 
probes.
Protocol of in situ hybridization technique for the 
detection of IFN-alpha mRNA in formalin fixed paraffin 
embedded normal human tissues using the 
digoxigenin.11.dUTP labelled probe.
Procedure
1) 4 microns thick sections were cut from buffered
formalin or formol saline fixed paraffin wax 
embedded normal human tissues and mounted on 3- 
aminopropyltriethoxysilane coated glass slides. A
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set of 8 tissue sections from the same human 
tissues (cut and mounted as above) was taken and 
placed in two changes of xylene for 5 minutes 
each, to remove the paraffin wax. This was 
followed by placing the slides in two changes of
absolute alcohol for 5 minutes and one change of
methyl alcohol for 5 minutes and rinsed in DEPC 
water.
2) The slides were then washed in DEPC phosphate
buffered saline, pH 7.3 (Oxoid Ltd,UK) for 5
minutes and placed in DEPC 0.2N HCL for 20 minutes 
at room temperature.
3) After rinsing the slides in DEPC phosphate 
buffered saline they were then placed in 0.3% 
Triton-X 100 (Sigma) in DEPC phosphate buffered 
saline for 15 minutes and again rinsed in DEPC 
phosphate buffered saline.
4) Proteinase-k treatment.
4 different concentrations of proteinase-k enzyme 
(Sigma) were prepared in proteinase-k buffer (0.1M 
tris HCL, 50mM ethylenediamine tetraacetic acid, 
pH 8) at 37°C. These concentrations were 2, 5, 10 
and 20 micrograms of the proteinase-k enzyme/ ml 
of proteinase-k buffer. 2 sections each, from the 
set of 8, were incubated at 37°C, for 30 minutes, 
with 2, 5, 10 and 20 micrograms of proteinase-k 
enzyme/ ml of proteinase-k buffer, respectively.
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5) The slides were washed for 1 minute in DEPC 0.2% 
glycine solution in water, to stop the proteinase- 
k reaction. They were then rinsed in DEPC 
phosphate buffered saline.
6) They were next placed in 4% paraformaldehyde 
solution in DEPC phosphate buffered saline for 5 
minutes.
7) The slides were then washed in DEPC phosphate 
buffered saline for 5 minutes on a shaker and 
incubated with pre-hybridization buffer (50% 
formamide, DEPC 20xSSC) for 2 hours, at 37°C.
8) Hybridization.
The digoxigenin labelled probe was added to the 
hybridization buffer, 50% formamide (Appendix), in 
a concentration of 5 microlitres of labelled 
probe/ 15 microlitres of hybridization buffer. One 
set of 4 tissue sections treated with 2, 5, 10 and 
20 micrograms of proteinase-k enzyme/ ml of 
proteinase-k buffer in step 4, were treated with 
the above probe + hybridization buffer solution. 
The second set of tissue sections (treated with 2, 
5, 10 and 20 micrograms of proteinase-k enzyme/ ml 
of proteinase-k buffer in step (4) was used as a 
negative control and treated with hybridization 
buffer only. All the sections were covered with 
dimethyldichlorosilane coated glass coverslips 
(Appendix). Next the sections were placed in a
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humid box sealed in a plastic bag and incubated 
overnight at room temperature (approximately 
20°C).
9) After 16-18 hours the coverslips were removed from 
the tissue sections by placing the slides in 4xSSC 
solution (lxSSC= 0.15M sodium chloride, 0.015 M 
sodium citrate) for 5 minutes.
10) Post-hybridization washes.
The slides were washed twice in 2xSSC solution at 
room temperature for 15 minutes and then in 
O.lxSSC solution at room temperature for 20 
minutes, followed by one wash in buffer one for 5 
minutes. All these washes were performed on a 
shaker.
11) The alkaline phosphatase conjugated anti- 
digoxigenin antibody (1/500 dilution in buffer 
one) was applied on the sections for 2 hours at 
room temperature.
12) The slides were washed twice in buffer one for 15 
minutes.
13) The slides were then washed once in buffer three 
for 5 minutes.
14) The slides were next placed in freshly prepared 
alkaline phosphatase substrate solution, NBT/BCIP 
(Appendix) in a coplin jar and light was excluded 
from the reaction. They were left overnight at 
room temperature.
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15) After 16-18 hours the slides were removed from the 
substrate solution and washed in distilled water. 
They were then counterstained in haematoxylin for 
5 seconds, washed thoroughly in distilled water, 
mounted in Glycergel (Dako), and veiwed under a 
Leitz Laborlux light microscope.
Working out the temperature of incubation of the 
oligonucleotide probes in the in situ hybridization 
technique.
The incubation temperature was calculated using a 
formula described for the oligonucleotide probes 
(Davis, Dibner & Battey,1986). The formula was as 
follows,
Tm - 16.6 log (M) + 0.41(Pgc) + 81.5 - Pm - B/L - 
0.65(Pf)
Tm (melting point). It is the temperature at which the 
strands of a DNA duplex or an RNA-DNA hybrid are half 
dissociated or denatured (Britten & Davidson,1987).
M is the molar concentration of sodium ions, to a 
maximum of 0.5M.
Pgc is the percentage of guanine or cytosine nucleotide 
bases in the oligonucleotide probe (between 30 and 70). 
Pm is the percentage of mismatched nucleotide bases, if 
known.
Pf is the percentage of formamide in the hybridization 
buffer.
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B is equal to 675 (synthetic oligonucleotide probes up 
to 100 nucleotide bases long).
L is the oligonucleotide probe length in nucleotide 
bases.
Once the Tm (melting point) for the 
oligonucleotide probe was calculated, the temperature 
of incubation (Ti) was then determined by using the 
following formula.
Ti = Tm - 15°C
With 50% formamide (BDH,UK) in the hybridization 
buffer, the Tm (melting point) for probe one was 
30.2°C. The incubation temperature (Ti) therefore 
worked out to be 15.2°C.
With 50% formamide in the hybridization buffer, 
the Tm (melting point) for probe two was 29.96°C. 
Therefore the incubation temperature (Ti) worked out to 
be 14.96°C.
Amendments to the protocol of the in situ hybridization 
technique for the demonstration of IFN-alpha mRNA using 
probe 1 and probe 2. 
Varying the proteinase-k treatment.
a) The proteinase-k enzyme in the 4 different 
concentrations described in the standard protocol for 
in situ hybridization, was left on the sections for 20, 
45 and 60 minutes at 37°C respectively instead of the
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standard 30 minutes. The remaining procedure was the 
same as above.
b) The proteinase-k enzyme was also used in a 
concentration of 40 micrograms of proteinase-k 
enzyme/ml of proteinase-k buffer, in addition to the 
above 4 different concentrations. The remaining 
procedure was the same as the standard hybridization 
protocol.
Varying the incubation temperature of hybridization and 
post-hybridization washes.
a) The tissue sections were hybridized overnight with 
the probe + hybridization buffer solution (step 12 of 
the standard hybridization protocol) at 37°C. This was 
followed by the following post-hybridization washes.
The slides were washed twice in 2xSSC (lxSSC= 0.15M 
sodium chloride, 0.015 M sodium citrate) at room 
temperature, for 15 minutes. They were then washed 
twice in 0.1XSSC solution at 37°C for 20 minutes (the
0.lxSSC solution was made one day before the post­
hybridization washes and incubated overnight at 37°C). 
This was followed by one wash in buffer one for 5 
minutes. All these washes were performed on a shaker.
b) The tissue sections were hybridized overnight with 
the probe + hybridization buffer solution (step 12 of 
the standard hybridization protocol) at 42°C. This was 
followed by the following post-hybridization washes.
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The slides were washed twice in 2xSSC solution at room 
temperature for 15 minutes. They were then washed once 
in 0.lxSSC solution at 42°C for 20 minutes (the O.lxSSC 
solution was made one day before the washes and 
incubated overnight at 42°C), followed by one wash in 
O.lxSSC solution for 20 minutes at room temperature.
The slides were then washed once in buffer one for 5 
minutes.
Negative control tissue sections (incubated with 
the hybridization buffer only) were also treated in 
exactly the same way as the sections incubated with the 
probe.
Varying the concentration of formamide in the 
hybridization buffer.
The concentration of formamide was reduced from 
50% in the hybridization buffer to 20% (Appendix). The 
sections were then incubated overnight with the probe + 
hybridization buffer solution (step 12 of the standard 
hybridization protocol) at 37°C. The negative control 
sections incubated with the hybridization buffer only 
were treated in the same way. After 16-18 hours, the 
post hybridization washes done were as follow. The 
slides were washed twice in 2xSSC solution at room 
temperature for 20 minutes. They were then washed once 
in 2xSSC solution at room temperature for 15 minutes 
and in O.lxSSC solution at 37°C for 15 minutes (the 
O.lxSSC solution was made one day before the washes and
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incubated at 37°C). This was followed by one wash in 
buffer one for 5 minutes. The remaining procedure was 
the same as the standard protocol.
Demonstration of total messenger RNA (mRNA) in formalin 
fixed normal human tissues using the poly-d-T probe.
All messenger RNA molecules have a poly A tail (a 
varying number of adenosine nucleotide bases) attached 
at the 3 ’end. It has been demonstrated that a probe 
directed against this part of the mRNA molecule, called 
a poly-d-T probe, can show the presence of mRNA in 
formalin fixed human tissues by in situ hybridization 
(Pringle et al,1989). This study provided an 
opportunity to demonstrate mRNA in formalin fixed human 
tissues and was used as a control for the in situ 
hybridization technique, developed to demonstrate IFN- 
alpha mRNA.
Protocol of the in situ hybridization technique adopted 
for the demonstration of total mRNA in formalin fixed 
normal human tissues using a digoxigenin.11.dUTP 
labelled poly-d-T probe.
The protocol adopted for the demonstration of 
total mRNA in formalin fixed normal human tissues using 
a digoxigenin.11.dUTP labelled poly-d-T probe was the 
same as the protocol used for the in situ demonstration
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of IFN-alpha mRNA described earlier, with the following 
amendments.
Variation in proteinase-k treatment.
The proteinase-k enzyme in 4 different 
concentrations was left on the sections for 60 minutes 
instead of 30 minutes at 37°C.
Variation in step 7 .
The slides were incubated in the pre-hybridization 
buffer for 1 hour at 37°C.
Variation in hybridization.
The labelled poly-d-T probe was used in a 
concentration of 3 microlitres/17 microlitres of the 
hybridization buffer and the sections were incubated 
overnight with the (probe + hybridization buffer) 
solution, at 37°C.
Variation in post-hybridization washes.
After the coverslips were removed, the sections 
were washed twice in 2xSSC buffer for 20 minutes at 
room temperature on a shaker. They were then washed 
twice in 2xSSC buffer, at 37°C for 20 minutes, followed 
by one wash in 2xSSC buffer, at room temperature for 5 
minutes. They were finally washed in buffer one, at 
room temperature for 5 minutes.
Variation in step 14.
The slides were incubated in the alkaline 
phosphatase substrate solution (NBT/BCIP) for one hour, 
instead of using an overnight incubation.
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Specificity of the in situ hybridization staining.
To demonstrate that positive staining obtained 
during the in situ hybridization procedures was 
specific, the tissue sections that showed positive 
staining in cells with the oligoprobes were treated 
with ribonuclease enzymes (RNase).
The RNase enzyme used in this study was 
Ribonuclease-A (Sigma). A stock solution of 10 
milligrams of Ribonuclease-A/ml of water was made. The 
solution was then boiled for 10 minutes to get rid of 
deoxyribonuclease enzymes, aliquoted and stored at - 
20°C until needed.
Protocol for RNase enzyme treatment of the sections.
The same hybridization protocol described earlier 
for the in situ localization of IFN-alpha mRNA or total 
mRNA was used, with the following addition.
After step 5 in the standard protocol for in situ 
hybridization, the sections were treated with 
Ribonuclease-A. The Ribonuclease-A stock solution 
prepared above was used in a concentration of 1 
milligram of Ribonuclease-A/ml of 50mM tris HCL buffer, 
pH 7.5. It was left on the sections for 2 hours at 
37°C.
The sections were washed 4 times in DEPC phosphate 
buffered saline for 10 minutes. Both sets of tissue
sections described in the hybridization protocol (i.e 
the one incubated with the probe and the other 
"negative control", incubated only with the 
hybridization buffer) were treated with the 
Ribonuclease-A enzyme. The remaining procedure was the 
same as the hybridization protocol for the oligoprobes. 
Positive control.
Sections incubated with 50mM of tris HCL buffer 
instead of the RNase enzyme in step 5 of the 
hybridization protocol were used as positive controls 
for the RNase procedure. These control sections were 
hybridized in exactly the same way as RNase treated 
sections with the probe and with the negative control 
(hybridization buffer alone) .
Varying the Ribonuclease-A concentration.
The Ribonuclease-A enzyme was used in 
concentrations of 2, 4 and 8 milligrams/ml of 50mM tris 
HCL buffer, respectively.
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CHAPTER THREE
THE DISTRIBUTION OF INTERFERON-ALPHA IN FORMALIN FIXED 
PARAFFIN EMBEDDED NORMAL ADULT HUMAN TISSUES.
INTRODUCTION
Since the discovery of IFN (Isaacs &
Lindenmann,1957) much emphasis has been laid on the 
presence and role of IFN in viral infections. Recently, 
many workers have demonstrated the presence of IFN- 
alpha in conditions other than viral infections. IFN- 
alpha has been demonstrated in placenta by many workers 
(Chard et al.,1986; Duc-Goiran et al.,1985; Bocci et 
al.,1985). Some workers have reported low levels of 
IFN-alpha in normal human bone marrow (Zoumbas et 
al.,1985). Bocci et al (1984), showed the presence of 
IFN (IFN-gamma or an acid labile IFN-alpha or a 
mixture) in the lymph draining the gastrointestinal 
tract of normal healthy rabbits. An IFN-alpha like 
substance has been identified in the plasma of healthy 
individuals (Shiozawa et al.,1986) and IFN-alpha and 
IFN-gamma have been demonstrated in bronchoalveolar 
lavage fluid of healthy human volunteers (Prior & 
Haslam,1989). Traces of IFN-alpha have been 
demonstrated in the cerebrospinal fluid of normal 
individuals (Ho-Yen & Carrington,1987).
1The expression, "physiological IFN response" was 
first used by Bocci (1980). He put forward the idea 
that IFN was produced continuously in health in low 
physiological amounts which increased with an acute 
viral infection (Bocci,1981).
The ability to demonstrate immunoreactive IFN- 
alpha in formalin fixed paraffin embedded human tissues 
using a polyclonal sheep anti-human IFN-alpha antiserum 
(H51) (Foulis et al.,1987) permitted an examination of 
the cellular distribution of IFN-alpha in a wide 
variety of formalin fixed paraffin embedded normal 
human tissues. Such a study was designed to help define 
which cells normally produce IFN-alpha and to hopefully 
give further insight into its physiological role.
In this study the polyclonal sheep anti-human IFN- 
alpha antiserum (H51), monoclonal anti-human IFN-alpha 
antibody (Code NO.0050) and another polyclonal sheep 
anti-human IFN-alpha antiserum (gift from Dr. Cantell, 
Helsinki) were used for the demonstration of 
immunoreactive-IFN-alpha in various formalin fixed 
paraffin embedded normal human tissues, as described in 
chapter 2, section A.
A new macrophage/ histiocytic marker, KP1 
monoclonal antibody (developed by K.A.F. Pulford,
Oxford), was used in this study in addition to the 
macrophage/ histiocytic marker, anti-muramidase 
antiserum.
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OBSERVATIONS 
Observations from assessment of the specificity of the 
H51 antiserum. 
Non-specific and specific positive staining with the 
H51 antiserum.
Using the H51 antiserum in the indirect 
immunoperoxidase technique, positive staining for 
immunoreactive-IFN-alpha was observed in spindle shaped 
cells scattered variably in almost all formalin fixed 
paraffin embedded normal human tissues studied except 
cerebral and cerebellar cortex in brain, renal cortex 
and medulla. Positive staining was also observed in 
some other parenchymal cells in the human body. However 
a problem of non-specific staining with the H51 
antiserum was encountered when studying the 
distribution of IFN-alpha in various formalin fixed 
paraffin embedded human tissues. This non-specific 
staining was mimicked by substituting normal sheep 
serum for the H51 antiserum in the indirect 
immunoperoxidase technique. (The normal sheep serum was 
used as a negative control for the sheep anti-human 
IFN-alpha antiserum [H51] in the indirect 
immunoperoxidase technique, described in chapter 2). 
Incubation of the H51 antiserum with Wellferon (IFN-
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alpha) prior to its use in the indirect 
immunoperoxidase technique, as described in the 
neutralization/ blocking experiment in chapter two 
section A(a), failed to abolish this non-specific 
staining. Non-specific staining, as described above, 
was observed in the mucosal epithelial lining cells, 
oxyphil and chief cells of all stomach cases studied, 
in the mucosal epithelial lining cells of the 5 jejunal 
and 2 duodenal cases and in the epithelial lining cells 
of the bronchial tree in all cases studied. Non­
specific staining was also seen in the tubular 
epithelial lining cells in kidney and in Leydig cells 
in the testis in all the cases studied and in the 
endocrine cells in 1 anterior pituitary gland and in 5 
parathyroid glands.
The term "specific positive staining1 was used in 
this study to describe a situation where cells stained 
positively when H51 antiserum was used as primary 
antiserum, but did not stain when the H51 antiserum was 
replaced by normal sheep serum in the indirect 
immunoperoxidase technique (figure 3.1). Figure 3.1(a), 
shows that spindle shaped or round cells scattered 
variably in the lamina propria of the jejunal mucosa 
are positive for IFN-alpha using the H51 antiserum. 
These cells stained negatively with the normal sheep 
serum shown in figure 3.1(b). However, mucosal 
epithelial lining cells staining positive in figure
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3.1(a), with the H51 antiserum, also show similar 
staining with the normal sheep serum in figure 3.1(b), 
demonstrating that the epithelial staining was non- 
specfic. Specific positive staining was further defined 
by showing that positive staining of cells was 
abolished if the H51 antiserum was preincubated with 
Wellferon (IFN-alpha) prior to its use, as described in 
the neutralization/ blocking experiment in chapter two 
section A(a) [figure 3.1(c); & figure 3.6]. Figure 
3.1(c), shows that staining in spindle shaped or round 
cells in lamina propria in the jejunum completely 
disappeared, while non-specific staining observed in 
epithelial cells was not abolished by preincubation of 
the H51 antiserum with Wellferon in the neutralization/ 
blocking experiment. The neutralization/ blocking 
experiment with Wellferon was carried out on at least 
one section of all human tissues studied.
The neutralization/ blocking experiment performed with 
recombinant IFN-beta.
In no instance did absorption of the H51 antiserum 
with IFN-beta alter the specific positive staining with 
the H51 antiserum [described in chapter two,section 
A(d,i) ] .
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Immunoblots.
Immunoblot analysis [described in chapter two, 
section A(d,ii)] showed that the H51 antiserum reacted 
only with Wellferon (IFN-alpha) on the nitrocellulose 
paper strip (figure 3.2). The H51 antiserum did not 
recognize IFN-beta, tumour necrosis factor, interleukin 
1-alpha and interleukin 1-beta, normal sheep serum, 
normal human serum and tris HCL buffer with the 
immunoblot technique.
Observations of specific positive staining in various 
formalin fixed normal human tissues.
Observations of specific positive staining for 
IFN-alpha with the H51 antiserum in various formalin 
fixed paraffin embedded normal human tissues are 
summarized in table 3.1.
It can be divided into 2 parts.
i) Specific positive staining observed in spindle 
shaped cells and other cells of the mononuclear 
phagocyte system.
ii) Specific positive staining observed in parenchymal 
cells.
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i) Specific positive staining in spindle shaped cells 
and other cells of the mononuclear phagocyte 
system.
Table 3.1 shows that specific positive staining 
for IFN-alpha was observed in spindle shaped cells 
scattered variably in all human tissues studied except 
cerebral and cerebellar cortex in brain, renal cortex 
and medulla. A comparison between results with the H51 
and anti-muramidase antisera and KP1 monoclonal 
antibody was made by counting positive cells in at 
least 10 high power fields (one high power field=
62,500 square microns) on consecutive serial sections, 
stained with the respective antisera. Most of the 
spindle shaped cells staining positively for IFN-alpha 
with the H51 antiserum also stained positively with the 
two macrophage/ histiocytic markers, anti-muramidase 
antiserum and the monoclonal antibody KP1 (figure 3.3). 
In bone marrow many spindle shaped cells showed 
positive staining with the H51 antiserum. The KP1 
antibody and the anti-muramidase antiserum did not 
perform satisfactorily on these decalcified bone marrow 
sections, so comparisons were not possible here.
Other cells known to be components of the 
mononuclear phagocyte system also showed specific 
positive staining with H51 antiserum. These included 
Kupffer cells in the liver (figure 3.4), pulmonary 
alveolar macrophages in the lungs (figure 3.5),
tingible body macrophages and macrophage-like cells 
outside germinal centres in lymphoid tissue (figure 
3.6). However osteoclasts in the bone marrow sections 
and monocytes in the buffy coats of the blood (both of 
which are components of the mononuclear phagocyte 
system) were negative for IFN-alpha. The alveolar 
macrophages, monocytes in the buffy coats of the blood, 
tingible body macrophages and macrophage-like cells 
outside the germinal centres in lymphoid tissues were 
also positive with KP1 and the anti-muramidase 
antiserum. Kupffer cells in the liver, however, were 
negative with anti-muramidase antiserum but strongly 
positive with KP1.
Double staining technique observations.
The monoclonal antibodies KP1 and Mac 387 (another 
macrophage marker) did not show sufficient 
immunofluorescence in the indirect immunofluorescene 
technique to be used in the double staining technique 
described in chapter two section (D) . Only the anti- 
muramidase antiserum used in the indirect 
immunofluorescence technique showed strong 
immunofluorescence in macrophages, with little 
background, and it was therefore used in part(b) of the 
double staining technique. It was shown by using the 
double staining technique that some tingible body 
macrophages in human tonsil staining positively with
the H51 antiserum i.e containing immunoreactive IFN- 
alpha, also showed immunofluorescence with the anti- 
muramidase antiserum (macrophage marker) on the same 
tissue section (figure, 3.7) .
When this study was carried out the antigen 
recognized by the KP1 monoclonal antibody was not 
known. Therefore it was important to assess the 
possibility of cross reaction between the KP1 antibody 
and the H51 antiserum. The experiment of absorption of 
KP1 antibody with Wellferon prior to its use in the 
indirect immunoperoxidase technique, as described in 
chapter 2, was thus performed to assess if the KP1 
antibody recognized IFN-alpha in tissue sections.
Observations from experiment of absorption of the KP1 
antibody with Wellferon.
Absorption of KP1 with Wellferon had no effect on 
staining using this antibody, demonstrating that KP1 
antibody did not recognize IFN-alpha in tissue 
sections.
The KP1 antibody, as shown in table 3.1, stained 
all cells of the mononuclear phagocyte system except 
osteoclasts in the bone marrow. Comparison of KP1 
antibody and the anti-muramidase antiserum showed that 
KP1 was a better macrophage/ histiocytic marker. The 
KP1 antibody showed positive staining in Kupffer cells 
in the liver and spindle shaped cells in the ovaries,
which stained negatively with the anti-muramidase 
antiserum. The KP1 monoclonal antibody also showed less 
background staining, as compared to the polyclonal 
anti-muramidase antiserum in tissue sections. 
Trypsinization of tissue sections for 20 minutes 
instead of the usual 10 minutes trypsinization 
described in the standard protocol for KP1 antibody 
staining procedure, resulted in a background staining 
in neutrophils which was not observed with 10 minutes 
trypsinization.
ii) Observations of specific positive staining with
the H51 antiserum in parenchymal cells in various
formalin fixed normal human tissues.
Specific positive staining for IFN-alpha with the 
H51 antiserum was seen in adrenocortical cells in the 
adrenal gland (figure, 3.8), cuboidal epithelium of the 
choroid plexus in brain (figure, 3.9), follicular 
epithelium in thyroid gland (figure, 3.10) and 
endocrine cells in the parathyroid and anterior 
pituitary gland (figure, 3.11 & 3.12). Specific 
positive staining for IFN-alpha was also seen in the 
syncytiotrophoblast in human placenta (figure, 3.13).
In the adrenal glands specific positive staining 
for IFN-alpha was observed in the adrenocortical cells 
of the zona fasciculata and zona glomerulosa. In the 
zona reticularis interpretation of the staining was
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difficult because of the presence of brown staining 
lipofuscin, but some positive staining was probably 
present there also. In the 20 pituitary glands stained 
for IFN-alpha in this study, 19 showed specific 
staining in some of the endocrine cells of the anterior 
pituitary. Only one of the 20 pituitary glands showed 
non-specific staining. No attempt was made to define 
which pituitary endocrine cells contained IFN-alpha. In 
the 11 cases of parathyroid studied, 5 showed specific 
positive staining for IFN-alpha in endocrine cells. 6 
showed only non-specific staining. The cuboidal cells 
of the choroid plexus in brain showed specific positive 
staining in all cases studied. The staining observed in 
the cuboidal epithelial cells of the choroid plexuses 
was uniformly distributed throughout the entire 
epithelial lining. Thyroid follicular cells also showed 
specific positive staining in all cases studied, 
however the intensity of the staining in the follicular 
cells varied from case to case. Specific positive 
staining was observed in the syncytiotrophoblast and in 
macrophages in all first, second and third trimester 
placentas studied. In no instance did the KP1 antibody 
or the anti-muramidase antiserum stain the parenchymal 
cells in these tissues.
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Observations with the monoclonal anti-human IFN-alpha 
antibody (Code NO.0050).
The monoclonal antibody (Code No.0050) showed weak 
positive staining for IFN-alpha in the
syncytiotrophoblast of formalin fixed paraffin embedded 
normal human placentas (n=5), when applied to the 
sections at a 1/100 dilution, with an overnight 
incubation at 4°C and when using the avidin-biotin 
immunocytochemical technique [section A(ii),l] (figure,
3.14). Trysinization of tissue sections or using the 
monoclonal antibody (Code.No.0050) in lower dilutions 
did not increase the positive staining in 
syncytiotrophoblast of the placenta [section 
A(ii),l,i]. However the positive staining in 
syncytiotrophoblast of the placenta improved slightly, 
when the biotinylated horse anti-mouse immunoglobulin 
antiserum was left on the sections for 2 hours with a 
1/50 dilution [section A (ii),1,iii]. The staining was 
also slightly improved when the Vectastain ABC reagent 
was replaced by streptavidin-biotin complex in the 
biotin detection system [section A(ii),l,iv] (figure,
3.15). However, no staining for IFN-alpha was observed 
with the monoclonal antibody (Code No:0050) in cuboidal 
epithelial cells of choroid plexus, endocrine cells or 
macrophages in other formalin fixed paraffin embedded 
normal human tissues.
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In no instance did the negative control monoclonal 
antibody Clonab-LNC showed positive staining in the 
syncytiotrophoblast of placenta. When using the same 
staining protocol as the monoclonal anti-human IFN- 
alpha antibody, the positive control monoclonal 
antibodies, LN26 and EMA, showed positive staining in B 
lymphocytes and epithelial cells respectively (figure,
3.16) .
The second polyclonal sheep anti-human IFN-alpha 
antiserum (Dr.Cantell) also showed no positive staining 
for IFN-alpha in various formalin fixed human tissues 
studied.
Figure 3.1
Specific positive staining
In a) the section is stained by an indirect immunoperoxidase 
(IIP) technique using H51 as the primary antiserum. Many 
cells in the lamina propria of the jejunum stain 
positively. These cells do not stain when normal sheep 
serum is substituted for H51 in the technique (b), or when 
H51 is preincubated with Wellferon prior to use in the 
technique (c) (x 180)
Non-specific staining
The mucosal lining cells, by contrast, are stained in all 
three preparations.

Figure 3,2
Immunoblot
This figure shows that the H51 antiserum recognised only 
Wellferon in the immunoblot technique. The materials spotted 
on the nitrocellulose paper strip from left to right (cut 
edge) are as follows: Normal human serum, normal sheep
serum, tumour necrosis factor, Wellferon (IFN-alpha), 
IFN-beta, interleukin 1-alpha, interleukin 1-beta and tris 
HCL buffer.

Figure 3.3
Involuting corpus luteum in ovary.
L represents the lumen of the corpus luteum and S the 
ovarian stroma. In between lies the wall of the corpus 
luteum which is heavily infiltrated by cells which express 
both IFN-alpha (a) and KP1 (b) (arrowed). This shows that 
cells expressing IFN-alpha in this corpus luteum are 
macrophages.
IIP for IFN-alpha in (a) and KP1 (b) (x 75).
w Y m» cl*? .
Figure 3.4
IFN-alpha in liver
Kupffer cells in the liver show positive staining for 
IFN-alpha.
IIP for IFN-alpha (x 300).
Figure 3,5
IFN-alpha in lung
Pulmonary alveolar macrophages in the lungs show positive 
staining for IFN-alpha.
IIP for IFN-alpha (x 190)

Figure 3.6
Absorption with Wellferon
Tingible body macrophages within germinal centres (arrows) 
in a lymph node are strongly positive for IFN-alpha as are 
some cells outwith the germinal centres (arrow heads) IIP 
for IFN-aLpha (x 150) (a). (b) shows that all positive
staining in these cells is completely abolished by 
preincubation of the H51 antiserum with Wellferon.

Figure 3.7
Adult tonsil.
Some tingible body macrophages staining positively for 
IFN-alpha (arrow heads), in (a), also fluoresce with ant 
muramidase (macrophage marker) in (b). This shows that 
cells of the macrophage lineage contain IFN-alpha.
IIP for IFN-alpha (a) and immunofluorescence using 
anti-muramidase (b) on the same section (x 780).

Figure 3.8
IFN-alpha in adrenal cortex
Adrenocortical cells in the adrenal gland show positive 
staining for IFN-alpha (arrows).
IIP for IFN-alpha (x 380).
Fiqiire 3.9
IFN-alpha in choroid plexus
The cuboidal lining epithelium of choroid plexus (arrow) in 
the brain is strongly positive for IFN-alpha.
IIP for IFN-alpha (x 150).
Figure 3.10
IFN-alpha in thyroid gland
Thyroid follicular cells (arrows) show positive staining for 
IFN-alpha.
IIP for IFN-alpha (x 270).
.<vVl
Figure 3.11
IFN-alpha in parathyroid gland
Endocrine cells in the parathyroid gland show positive 
staining for IFN-alpha.
IIP for IFN-alpha (x 300).
Figure 3,12
IFN-alpha in anterior pituitary
Some endocrine cells in the anterior pituitary gland show 
positive staining for IFN-alpha.
IIP for IFN-alpha (x 300).

Figure 3,13
IFN-alpha in placenta (H51)
i
Syncytiotrophoblast in the placenta show positive staining 
for IFN-alpha.
IIP for IFN-alpha with the polyclonal sheep anti-human 
IFN-alpha antiserum (H51) (x 380).
Figure 3.14
IFN-alpha in placenta (monoclonal antibody)
Syncytiotrophoblast in the placenta show weak positive 
staining for IFN-alpha.
Avid in-biotin for IFN-alpha with the monoclonal anti-human 
IFN-alpha antibody (Code No. 0050) (x 210).
Figure 3.15
IFN-alpha in placenta (monoclonal antibody)
Syncytiotrophoblast in the placenta show slightly strong 
positive staining for IFN-alpha than in figure 3.14.
Streptavidin-biotin for IFN-alpha with the monoclonal 
anti-human IFN-alpha antibody (Code No. 0050) (x 390).

Figure 3,16
Female breast (EMA)
Epithelial cells in the breast are staining positively for 
epithelial membrane antigen (EMA)
Avidin-biotin for EMA (x 200)
Lymph node (LN26)
Two germinal centres are marked 0 ^  in this section. B 
lymphocytes mainly present in these germinal centres are 
positive for LN26 (B cellMmarker) as are some B lymphocytes 
outwith the germinal centres.
Streptavidin-biotin for LN26 (x 80)
':.' ,^#rV ‘
DISCUSSION
This study demonstrated that spindle-shaped cells, 
positive for immunoreactive IFN-alpha with the H51 
antiserum, were present in nearly all human tissues 
except cerebral and cerebellar cortex in brain and 
renal cortex and medulla. These cells also showed a 
similar staining with the two macrophage/histiocytic 
markers, KP1 antibody and anti-muramidase antiserum, 
suggesting that the cells are a part of the mononuclear 
phagocyte system and probably are tissue histiocytes, 
normally present in human tissues. Other cells known to 
be part of the mononuclear phagocyte system, such as 
tingible body macrophages, Kupffer cells and pulmonary 
alveolar macrophages were also positive for IFN-alpha 
with the H51 antiserum. The finding that monocytes in 
the peripheral blood were negative for IFN-alpha is 
confirmation of previous work (Saksela et al.,1984).
While it is conceded that the demonstration of 
immunoreactive IFN-alpha in tissue histiocytes does not 
provide direct evidence that they are actually 
producing IFN-alpha, its presence in these and other 
cells known to be part of the mononuclear phagocyte 
system, such as tingible body macrophages, Kupffer 
cells and pulmonary alveolar macrophages in over 300 
hundred individuals with no clinical evidence of viral 
infection, leads to the conclusion that most cells of
the mononuclear phagocyte system probably produce IFN- 
alpha under normal circumstances.
One cause of the synthesis of IFN-alpha by such 
cells may be the presence of low levels of inducers of 
IFN-alpha synthesis in normal human tissues 
(Bocci,1981). Endotoxin released from gut bacteria may 
be one such inducer (Bocci, 1988) . The human body is 
also exposed to a variety of microbes (viruses, 
bacteria, etc) under physiological conditions. These 
microbes do not produce any evident clinical infection 
because they are efficiently counteracted by the host 
defences. This stimulus may, however, be sufficient to 
activate cells of the mononuclear phagocyte system 
(which are usually the first line of defence against 
infections and other exogenous stimuli) to produce IFN- 
alpha and other cytokines. Many workers have suggested 
that there may be production of low levels of 
endogenous IFN-alpha under physiological conditions 
(Gresser et al.,1985; Belardelli et al.,1984; Galabru 
et al.,1985; Zoumbos et al.,1985; Gessani et al.,1987; 
Bocci et al.,1984; Bocci,1988). While the precise 
origin of this IFN-alpha production has not been 
clearly defined, some evidence has suggested that 
macrophages may be involved. It has been shown that 
normal rabbit and mouse peritoneal macrophages release 
low levels of IFN in vitro (Smith & Wagner,1967; De- 
Maeyer et al.,1971). Gresser et al (1985) showed that
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injection of mice with antibody to mouse interferon- 
alpha/beta decreased the level of 2'-5' oligoadenylate 
synthetase (marker of IFN action) in vitro in 
peritoneal macrophages, and rendered them permissive 
for vesicular stomatitis virus infection. Similarly, in 
another study, many animal viruses failed to multiply 
in fresh cultures of normal mouse peritoneal 
macrophages but they were rendered permissive by 
injecting mice with an antiserum directed against IFN- 
alpha and beta prior to harvesting, suggesting that 
peritoneal macrophages are maintained in an anti-viral 
state by endogenous IFN-alpha in vivo (Belardelli et 
al.,1987).
It is therefore tempting to suggest that the cells 
of the mononuclear phagocyte system, shown positive for 
immunoreactive IFN-alpha in our study, might be the 
main source of the low levels of endogenous IFN-alpha 
found in physiological conditions. It could also be 
inferred that these cells play a front line role in the 
defence against viral infection.
It is of course possible that mononuclear 
phagocyte cells may produce IFN-alpha in the absence of 
known inducers of its synthesis, and speculation that 
IFN-alpha produced by these cells may have a role in 
defence against viral infection does not preclude other 
possible roles for this substance, such as modulation 
of cell growth and the immune response.
The finding of immunoreactive IFN-alpha in the 
cuboidal epithelium of choroid plexus is in keeping 
with the demonstration of detectable levels of IFN- 
alpha in the cerebrospinal fluid of normal individuals 
(Ho-Yen & Carrington,1987). The brain contains neurons 
which are permanent cells (permanent cells once 
destroyed cannot be replaced). Viral infection of brain 
thus has disastrous effects but these viral infections 
are remarkably infrequent. The choroid plexus produces 
cerebrospinal fluid which bathes the whole brain. It is 
therefore suggested here that IFN-alpha may be 
synthesized by cuboidal epithelial cells of choroid 
plexus and released into the cerebrospinal fluid, where 
it may have a role in preventing viral infections in 
the central nervous system.
Using the H51 antiserum immunoreactive IFN-alpha 
was demonstrated in the syncytiotrophoblast and 
macrophages in normal human placenta. When this study 
was conducted the findings of Howatson et al (1988) of 
the presence of immunoreactive IFN-alpha in the 
syncytiotrophoblast and macrophages in normal human 
placenta were not yet published. Immunoreactive IFN- 
alpha was also demonstrated in the syncytiotrophoblast 
in human placentas using the monoclonal anti-human IFN- 
alpha antibody (Code No.0050). This was confirmation of 
the findings by other workers that IFN-alpha was 
present in the human placenta (Chard et al.,1986; Bocci
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et al.,1985; Duc-Goiran et al., 1985) . However these 
authors did not establish the site of IFN-alpha 
synthesis. It is of interest that sheep corpus luteal 
regression is prevented by release of the hormone ovine 
trophoblastic anti-luteolytic protein (oTP-1) from 
sheep trophoblast. This hormone has been shown to have 
significant nucleotide and amino acid sequence homology 
with IFN-alpha (Imakawa et al.,1987; Stewart et 
al.,1987). Furthermore human IFN-alpha and oTP-1 have 
similar effects on cultured sheep endometrial cells 
(Salamonsen et al.,1988). It has been demonstrated 
recently that IFN-alpha enhances the ectopic production 
of the beta-subunit of human chorionic gonadotrophin by 
bladder tumour cells (lies & Chard,1989). Whether or 
not IFN-alpha has a hormonal effect in human pregnancy 
awaits investigation.
The stimulus for the production of IFN-alpha in 
human pregnancy is not known. Inducers of IFN-alpha 
synthesis such as viruses, bacteria, endotoxins, etc 
can be excluded as a possible source of stimulus for 
induction of IFN-alpha synthesis in the placenta, since 
IFN-alpha production seems to be a common phenomenon, 
demonstrated by many workers, in normal human pregnancy 
with no evidence of microbial infections. Viral 
infections in fetuses are relatively rare in spite of a 
poorly developed fetal immune system. It is possible 
that IFN-alpha synthesis by the placenta and fetal
tissues may be partly responsible for this low 
incidence of viral infections in fetuses. IFN can also 
affect cell growth and differentiation (Paucker et 
al.,1962). The fetal tissues are being constantly 
remodelled and therefore it is equally possible that 
IFN-alpha is produced as a normal cytokine in human 
pregnancy along with other factors that control or 
influence cell growth and differentiation of fetal 
tissues.
The demonstration of immunoreactive IFN-alpha in 
endocrine cells of thyroid follicles, parathyroid, 
anterior pituitary and adrenal cortex with the H51 
antiserum was completely unexpected. However the 
possibility of various hormonal effects of IFN-alpha in 
man awaits further investigation.
The monoclonal anti-human IFN-alpha antibody (Code 
No.0050) also demonstrated immunoreactive IFN-alpha in 
the syncytiotrophoblast in formalin fixed paraffin 
embedded normal human placentas. However, it failed to 
stain any macrophage type cells or other endocrine 
cells in the human body. It is possible that the 
monoclonal anti-human IFN-alpha antibody (Code No.0050) 
antibody recognises a specific IFN-alpha protein 
antigen that is found only in the placenta. Also, in 
contrast to the polyclonal antiserum, the monoclonal 
antibody recognises only one specific epitope. If that 
particular epitope is not exposed in fixed tissues or
is denatured or is not present in adequate amounts for 
the antibody to react with, no positive reaction would 
be obtained.
The fact that the second sheep polyclonal anti­
human IFN-alpha antiserum did not detect IFN-alpha in 
formalin fixed paraffin embedded human tissues, but the 
H51 did, suggests that relatively few epitopes of the 
interferon molecule are unchanged by formalin fixation.
KP1 was a new macrophage/ histiocytic monoclonal 
antibody developed by K.A.F. Pulford,Oxford. When the 
present study was carried out the antigen recognised by 
KP1 monoclonal antibody was not known. The KP1 antibody 
was shown to recognize macrophages in nearly all human 
tissues studied with little background problems and 
proved better as a macrophage marker than the anti- 
muramidase antiserum. This study (published in Khan et 
al.,1989) was the first to show the specificity of the 
KP1 antibody as a macrophage/ histiocytic marker. 
Results similar to these with the KP1 antibody were 
confirmed in a subsequent study (Pulford et al., 1989) .
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CHAPTER FOUR
THE DISTRIBUTION OF INTERFERON-ALPHA IN FORMALIN FIXED 
PARAFFIN EMBEDDED NORMAL FETAL AND INFANT HUMAN 
TISSUES.
INTRODUCTION
In the previous chapter the cellular distribution 
of immunoreactive IFN-alpha was studied in formalin 
fixed paraffin embedded normal adult human tissues. The 
indirect immunoperoxidase technique using the H51 
antiserum showed that tissue histiocytes, Kupffer 
cells, pulmonary alveolar macrophages and lymph node 
macrophages contained immunoreactive IFN-alpha. 
Parenchymal cells in some other organs also contained 
immunoreactive IFN-alpha. It was suggested that the 
presence of IFN-alpha in most cells of the mononuclear 
phagocyte system may play a major part in defence 
against viral infection.
Bocci (1988) has proposed that since bacteria and 
endotoxin are known inducers of IFN-alpha synthesis 
(Havell et al.,1986; Gessani et al.,1987) much of the 
physiological IFN-alpha response may be due to the 
presence of the normal bacterial flora in the gut, 
skin, mouth and genital tract. This hypothesis is 
supported by in vitro studies which have shown 
spontaneous release of IFN-alpha by peritoneal
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macrophages from mice kept in a normal environment (De- 
Maeyer et al.,1971). It has also been observed that 
mice kept in a germ free environment, or those treated 
with broad spectrum antibiotics, which destroy the 
normal microbial flora, have lower levels of the IFN 
mediated enzymes, 2-5A synthetase and protein kinase, 
than mice kept under normal environmental conditions 
(Galabru et al.,1985). Maximal production of IFN-alpha 
in mice occurs at 8 weeks of age, shortly after 
weaning, when the animal would be expected to 
experience maximal novel microbial challenge (Black- 
Olszewska, Cambzynska-Nowak and Kwasniewska, 1984) .
In this study an attempt was made to test Bocci's 
hypothesis (1988) of physiological IFN synthesis in man 
by comparing the frequency of IFN-alpha containing 
tissue cells in fetuses with that found in infants. A 
normal fetus is germ free but after birth it is exposed 
to a large variety of microbes. Therefore, if Bocci's 
hypothesis were true, low numbers of IFN-alpha positive 
cells might be expected up until birth, after which a 
dramatic rise might be predicted.
The other objectives of the present study were 1) 
to establish whether the cellular distribution of IFN- 
alpha containing cells in human fetal tissues was the 
same as that found in adults and 2) to find out at 
what stage of fetal life IFN-alpha containing cells 
appeared.
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Determination of proportion of macrophages expressing 
IFN-alpha.
To assess the proportion of macrophages expressing 
IFN-alpha in various tissues in infants and fetuses, 
cells positive with the monoclonal antibody KP1 and 
those containing immunoreactive IFN-alpha were counted 
in the same 10 high power fields on consecutive serial 
sections (one high power field = 62,500 square 
microns).
Assessment of quantitation of positive cells using the 
serial section technique.
Two successive serial sections from 9 blocks of 
tissue (4 thymus, 4 liver, 1 spleen) were stained for 
IFN-alpha. Similarly two further successive serial 
sections from the same blocks of tissue were stained 
with the KP1 antibody. The number of positive cells 
counted in the same 10 high power fields on the first 
and second serial section was counted for each antibody 
technique. A linear regression analysis was then 
performed to assess how closely the results on the 
second serial section correlated with those on the 
first serial section.
OBSERVATIONS
Like the study described in chapter 3, a similar 
problem of non-specific staining was seen using the H51 
antiserum in formalin fixed paraffin embedded normal
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fetal and infant tissues. This non-specific staining 
was mimicked by substituting normal sheep serum for the 
H51 antiserum in the indirect immunoperoxidase 
technique. Non-specific staining was observed in the 
epithelial lining cells of the bronchial tree and in 
the tubular epithelial lining cells in kidneys in all 
cases studied. Non-specific staining was also seen in 
Hassall's corpuscles in the fetal and infant thymus.
The term "specific positive staining" as defined 
in chapter 3 was used in this study to describe a 
situation where cells stained positively when H51 
antiserum was used as primary antiserum, but did not 
stain when the H51 antiserum was replaced by normal 
sheep serum in the indirect immunoperoxidase technique. 
Specific positive staining was further defined by 
showing that positive staining of cells was abolished 
if the H51 antiserum was preincubated with Wellferon 
(IFN-alpha) prior to its use, as described in the 
neutralization/ blocking experiment with Wellferon, 
chapter 2, section A(a). This neutralization/ blocking 
experiment was carried out on at least one section of 
all fetal and infant tissues studied (figure 4.10) .
i) Ontogeny.
Specific positive staining for IFN-alpha was first 
observed at 9 weeks gestation in spindle shaped or 
somewhat rounded cells scattered variably in the fetal
liver (figure 4.1). Thereafter, specific positive 
staining for IFN-alpha was seen in similar cells 
scattered in all fetal and infant organs except kidney 
and cerebral and cerebellar cortex in brain. As 
described in chapter 2 section C, a special serial 
section "mirror image" technique was used to study co­
localization of different antigens in the same cell. 
This helped to identify which cells contained 
immunoreactive-IFN-alpha. In this study the first 
serial section was stained with the H51 antiserum for 
IFN-alpha and the second mirror image serial section 
was stained for KP1 (macrophage marker), as described 
in chapter 2. Most of the spindle shaped or somewhat 
rounded cells containing immunoreactive IFN-alpha 
appeared to show a similar positive staining with the 
macrophage/ histiocytic marker, KP1 monoclonal antibody 
(figure 4.2). Thymus, in both fetuses and infants, 
proved to be an exception in this regard (figure 4.3).
ii) Observations from assessment of quantitation of
positive cells using the serial section technique.
Quantitation of positively staining cells on 
successive serial sections appeared to be reliable.
When cells were counted on 2 adjacent serial sections 
stained for IFN-alpha, as described earlier, and 
results subjected to regression analysis the r value
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was 0.997. The equivalent figure for KP1 staining was 
0.999.
iii) Determination of proportion of macrophages
expressing IFN-alpha.
Figure 4.4 illustrates the number of cells 
positive with KP1 antibody in 10 high power fields (as 
previously defined) in the thymus, spleen, liver and 
lungs of infants and fetuses (12 weeks gestation and 
above). It demonstrates a statistically significant 
increase in the number of KP1 positive cells in infant 
lungs when compared to fetal lungs (P<0.0001, Mann- 
Whitney test) . The number of KP1 positive cells in 
fetal and infant thymus, spleen and liver did not show 
any statistically significant difference between the 2 
groups.
The number of spindle shaped or rounded cells 
positive for IFN-alpha in 10 high power fields in the 
thymus, spleen, liver and lungs in infants and fetuses 
is illustrated in figure 4.5. It also shows a 
statistically significant increase in the number of 
immunoreactive IFN-alpha positive cells in the infant 
lungs when compared to fetal lungs (P<0.0001, Mann- 
Whitney test) . There was no statistical difference 
between the numbers of IFN-alpha positive cells in 
spleen, thymus and liver found in fetuses compared to 
the numbers found in infants.
Figure 4.6 illustrates the percentage of KP1 
positive cells containing immunoreactive IFN-alpha in 
10 high power fields in the spleen, liver and lungs of 
infants and fetuses. The percentage of macrophages 
expressing IFN-alpha was significantly greater in the 
infant lungs compared to fetal lungs (P<0.0005, Mann- 
Whitney test). Such a difference was not observed in 
the other organs examined. Alveolar macrophages shown 
positive for IFN-alpha in the lungs of an infant (aged 
5 months) are shown in figure 4.7.
In the thymus, as shown in figure 4.3(a) many 
cells containing immunoreactive IFN-alpha failed to 
stain positively with the KP1 monoclonal antibody 
(macrophage/ histiocytic marker) figure 4.3(b). Tissue 
sections from these thymus cases were also stained with 
two other macrophage markers, the monoclonal antibody 
MAC 387 and the polyclonal anti-muramidase antiserum, 
using an indirect immunoperoxidase technique described 
in chapter 2. This showed that most IFN-alpha 
containing cells in the thymus stained negatively with 
the monoclonal antibody MAC 387 and the polyclonal 
anti-muramidase antiserum, demonstrating that these 
cells were probably not macrophages. A double staining 
technique was used to establish whether cells in the 
thymus containing immunoreactive IFN-alpha were thymic 
epithelial cells. The double staining technique 
utilized the H51 antiserum in part(a) and a polyclonal
anti-prekeratin antibody (epithelial cytokeratin 
marker) in part(b), as described in chapter 2, 
section(D). It showed that cells positive for 
immunoreactive IFN-alpha failed to fluoresce for 
prekeratin and were therefore probably not epithelial 
cells (figure 4.8). The control sections (adult human 
thyroid), used in the double staining technique, double 
stained for IFN-alpha and prekeratin, showing that 
there was no problem in identifying both these markers 
within the one cell (figure 4.9).
Unfortunately the number of spindle shaped cells 
positive for IFN-alpha in the gastrointestinal mucosa 
of fetuses could not be counted and compared with that 
in infants because of post mortem autolysis in the 
fetal gastrointestinal mucosa.
iv) IFN-alpha in parenchymal cells of various human
tissues.
The findings of IFN-alpha in parenchymal cells of 
various human fetal tissues are summarized in table 
4.1.
It shows that specific positive staining for 
immunoreactive IFN-alpha was first observed in the 
fetal zone of the adrenal cortex at 10 weeks gestation 
(figure 4.10). This zone is a major part of the fetal 
adrenal gland and produces a steroid,
dehydroepiandrosterone sulphate which is transported to
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the placenta and used as a precursor for the production 
of estrogens, necessary for the maintenance of 
pregnancy. This fetal zone disappears rapidly after 
birth. All fetal adrenal glands above 10 weeks 
gestation showed a similar specific positive staining 
for IFN-alpha. Staining observed in cells in the fetal 
zone of adrenal glands was very strong compared to 
staining seen in the adrenocortical cells in adult 
adrenal glands, described in chapter 3. Cuboidal 
epithelium of choroid plexuses in the brain showed 
specific positive staining for IFN-alpha at 11 weeks 
gestation (figure 4.11) . The cuboidal epithelium of all 
choroid plexuses from fetuses above 11 weeks gestation 
and from infants were positive for immunoreactive IFN- 
alpha. The specific positive staining observed in the 
cuboidal epithelium of choroid plexus in some cases was 
patchy and not as uniform as that observed in the adult 
choroid plexus described in chapter 3. Specific 
positive staining for IFN-alpha was demonstrated in 
thyroid follicular cells at 13 weeks gestation (figure 
4.12). All thyroid glands of fetuses above 13 weeks 
gestation and of infants showed specific positive 
staining for IFN-alpha in the thyroid follicular cells. 
Some endocrine cells in the anterior pituitary glands 
showed specific positive staining for IFN-alpha at 13 
weeks gestation and onwards.
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Figure 4.1
IFN-alpha in fetal liver
An intrasinusoidal cell (arrow) staining positively for 
IFN-alpha in the liver of a 9 week old fetus.
Indirect immunoperoxidase (IIP) for IFN-alpha (x 780).
Figure 4.2
Macrophages in fetal liver contain IFN-alpha
Liver of a 38 week gestation fetus. Figure (a) and (b) are 
serial sections (mirror image technique) stained for 
IFN-alpha and KPl respectively. The distribution of 
staining of intrasinusoidal cells (arrows) is similar in 
both sections showing that cells of the macrophage lineage 
contain IFN-alpha.
IIP for IFN-alpha (a) and KPl (b) (x 450).
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Figure 4.3
IFN-alpha in fetal thymus
Cells staining positively for IFN-alpha (arrow heads) (a), 
often failed to stain positively for KPl (b) in the fetal 
thymus (mirror image serial section technique).
IIP for IFN-alpha (a) and KPl (b) (x 230)
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Figure 4,4
Distribution of macrophages in thymus, spleen, liver and 
lungs.
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Figure 4.5
Distribution of immunoreactive IFN-alpha (IR-IFN-alpha) 
positive cells in thymus, spleen, liver and lungs.
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Figure 4.7
IFN-alpha in infantile lung
Pulmonary alveolar macrophages in the lungs of an infant 
(aged 5 months) show positive staining for IFN-alpha.
IIP for IFN-alpha (x 350).

/Figure 4.8
IFN-alpha in fetal thymus.
Cells positive for IFN-alpha (arrows) (a) failed to 
fluoresce for prekeratin.(epithelial cytokeratin) in (b) 
(arrows). This shows that they are probably not epithelial 
cells.
Double staining technique; IIP for IFN-alpha (a) and 
iinmunofluorescence for prekeratin (b) on the same section (x 
780 ).

Figure 4.9
Double staining technique for IFN-alpha and prekeratin.
Thyroid follicular cells positive for IFN-alpha (arrow 
heads) (a), fluoresce strongly for prekeratin (b). This 
demonstrates that there is no problem in identifying both 
these markers within one cell.
Double staining technique: IIP for IFN-alpha (a) and immuno 
fluorescence for prekeratin (b) on the same section (x 780)

Figure 4.10
Specificity of staining for IFN-alpha in fetal adrenal*
Most cells in the fetal zone of fetal adrenal gland show 
specific positive staining for IFN-alpha (arrows) (a). The 
positive staining is completely abolished by absorption of 
the H51 antiserum with Wellferon prior to its use in the IIP 
technique (neutralization/blocking experiment) (b).
IIP for IFN-alpha with unabsorbed H51 antiserum (a) and 
absorbed with Wellferon (b) (x 200)
•“
-■
v
Figure 4.11
I
IFN-alpha in fetal choroid plexus
The cuboidal lining epithelium of choroid plexus in brain 
(arrow) is positive for IFN-alpha.
IIP for IFN-alpha (x 200).
Figure 4.12
IFN-alpha in fetal thyroid
Thyroid follicular cells (arrows) show positive staining for 
IFN-alpha.
IIP for IFN-alpha (x 350).
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DISCUSSION
This study shows that immunoreactive IFN-alpha is 
present in very early fetal life in spindle shaped 
cells that are scattered variably in nearly all fetal 
tissues except in kidneys and cerebral and cerebellar 
cortex in brain. Most of these cells showed similar 
positive staining with the macrophage/ histiocytic 
marker, KP1 monoclonal antibody, and were therefore 
probably tissue histiocytes (macrophages) .
The demonstration of immunoreactive IFN-alpha in 
macrophages in germ free fetuses suggests that 
bacteria, endotoxin or viruses are not necessary for 
the initial synthesis of this product in man.
There does remain the possibility that endotoxin 
from the mother could cross the placenta into the 
fetus. When administered in large quantities to 
experimental animals endotoxin can cross the placental 
barrier (Dzvonyar et al.,1970). Traces of endotoxin can 
be found in the portal blood under physiological 
conditions but this is taken up by the 
reticuloendothelial system in the liver so that the 
peripheral blood is practically endotoxin free (Jacob 
et al.,1977) . Thus exposure of the fetus to endotoxin 
from the mother in a normal pregnancy is likely to be 
negligible.
After birth, with exposure to a normal microbial 
flora, there was a significant increase in the number
of macrophages in the infant lungs, and the percentage 
of these cells containing IFN-alpha also increased.
This finding provides some support for Bocci's 
hypothesis. While the finding that IFN-alpha positive 
macrophages were present in germ free fetuses suggests 
that there is a basal level of IFN-alpha production, 
not dependent on microbial products, the increased 
expression of IFN-alpha in infant lungs suggests that 
such products do have a local role in enhancing IFN- 
alpha synthesis. This enhancing effect was not seen in 
organs not directly exposed to a microbial flora.
Unfortunately the effect of a normal microbial 
flora on macrophages in the gastrointestinal tract, 
proposed by Bocci (1988) as an important site for 
physiological IFN-alpha synthesis, could not be 
assessed because of post mortem autolysis in the 
gastrointestinal mucosa of fetuses.
In fetal and infant thymuses many cells present in 
the cortical regions of the thymus which contained 
immunoreactive IFN-alpha did not stain positively with 
any of the macrophage/ histiocytic markers used in this 
study. Double staining for IFN-alpha and prekeratin 
showed that IFN containing cells were not thymic 
epithelial cells either. At present the exact nature of 
these cells cannot be determined. They could be a 
population of macrophages not recognised by any of the 
macrophage markers used in this study. Alternatively,
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they may represent a completely different cell type 
which could only be marked using fresh frozen tissue 
sections and appropriate monoclonal antibodies.
The findings of immunoreactive IFN-alpha in 
parenchymal cells of various organs were almost 
identical to those seen in the adult human tissues 
(chapter three). It was proposed in the previous 
chapter that secretion of IFN-alpha by cells in the 
choroid plexus could be a defence mechanism against 
viral infection in the central nervous system but the 
function of IFN-alpha in the other organs remains 
unknown.
Previous work had suggested that IFN-alpha may be 
present in fetal tissues. The presence of IFN-alpha had 
been reported in a variety of fetal tissues using a 
specific two-site immunoradiometric assay (Chard et 
al.,1986). In the study by Chard et al (1986) 
approximately 60% of the fetal blood samples and fetal 
organ homogenates showed positive IFN-alpha levels. 
However the study did not localize the source of IFN- 
alpha in these tissues and also failed to mention which 
fetal tissues had positive levels of IFN-alpha. Equally 
the gestation age at which IFN-alpha was first found 
was not studied.
The demonstration of immunoreactive IFN-alpha in 
various normal human fetal tissues has potentially 
opened up a new area for future research. It provides
an opportunity to apply the same techniques as used 
here to study the tissue distribution and role of other 
cytokines, such as IFN-gamma, tumour necrosis factor 
and the interleukins in fetal development. Tumour 
necrosis factor and interleukin 2 like material have 
already been demonstrated in human placenta and 
amniotic fluid (Jaatela, Kiuusela & Saksela,1988; 
Soubiran, Zapitelli & Schaffer,1987) and IFN-gamma has 
been demonstrated in the umbilical cord blood of 
newborns (Martinez-Maza et al.,1984).
139
CHAPTER FIVE
EXTRACTION, DETECTION AND QUANTITATION OF INTERFERON- 
ALPHA IN HUMAN TISSUES AND FLUIDS. 
INTRODUCTION
In the previous two chapters the presence and 
distribution of immunoreactive IFN-alpha in various 
formalin fixed paraffin embedded adult, infant and 
fetal human tissues was assessed using 
immunocytochemical techniques. In this chapter an 
attempt is described to detect and quantify IFN-alpha 
in fresh human tissues. The detection of IFN-alpha 
protein in various fresh human tissues would provide 
additional support for findings of immunoreactive IFN- 
alpha in formalin fixed normal human tissues and 
strengthen the hypothesis that low levels of IFN-alpha 
are synthesized under physiological conditions.
In order to achieve these objectives, homogenates 
from various human tissues were made, as described in 
chapter two section(E), and tested for the presence of 
IFN-alpha using a "Sucrosep" IFN-alpha 
immunoradiometric assay. The "Sucrosep" IFN-alpha 
immunoradiometric assay utilizes a non-cenrifugation 
system-the sucrose layering separation system, 
described by Wright & Hunter(1983). The "Sucrosep" IFN- 
alpha assay is a two—site immunoradiometric assay which
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utilizes a 125I labelled monoclonal antibody (designated 
Yok 5/19). The Yok 5/19 antibody recognizes at least 7 
subtypes of IFN-alpha protein, namely IFN-alpha A(2), 
IFN-alpha C, IFN-alpha D(l), IFN-alpha G(5), IFN-alpha 
L, IFN-alpha J(7) and IFN-alpha K(6). The secondary 
antiserum in the "Sucrosep" IFN-alpha immunoradiometric 
assay kit was a sheep anti-human IFN-alpha antiserum 
attached to sepharose as the solid phase.
The "Sucrosep" IFN-alpha immunoradiometric assay 
has been used previously to detect IFN-alpha in human 
serum (Abbott et al.,1984), cerebrospinal fluid (Ho-Yen 
& Carrington,1987), nasopharyngeal secretions 
(Salas,1987) and tissue homogenates and amniotic fluids 
(Chard et al., 1986) . The assay can detect as little as
0.5 IU/ml of IFN-alpha and showed negligible cross 
reactivity with IFN-beta and IFN-gamma (Abbott et 
al., 1984) . In another study Salas (1987) showed that 
the "Sucrosep" IFN-alpha immunoradiometric assay can 
detect as little as 0.2 IU/ml of IFN-alpha in 
nasopharyngeal secretions, diluted in viral transport 
medium.
Various biological assays have also been used in 
the past to detect IFN-alpha. The biological assays are 
laborious, involving cell culture and challenge viruses 
which require special handling. They are time consuming 
and less sensitive when compared to solid phase 
radioimmunoassays. Several radioimmunoassays have been
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described and all perform favourably compared to 
biological assays. Therefore in the present study no 
attempt was made to use biological assays for detecting 
IFN-alpha.
OBSERVATIONS 
Observations from experiments on the performance 
characteristics of the "Sucrosep" IFN-alpha 
immunoradiometric assay. 
i) The intra-assay analysis.
8 viral transport medium samples with no IFN- 
alpha activity were analysed by the "Sucrosep" IFN- 
alpha immunoradiometric assay on the same day. The mean 
of the total number of counts was 117, with a standard 
deviation of 7.33 and a coefficient of variation of 
6.26% (table 5.1) .
ii) The inter-assay analysis.
The mean value for each standard concentration 
derived from 10 different standard curves (with viral 
transport medium as a diluent) performed over several 
months, was used to plot a standard curve for 
"Sucrosep" IFN-alpha immunoradiometric assay (figure 
5.1) . The standard deviation, standard error and 
coefficient of variation for each point of the standard 
curve is given in table 5.2. In these inter-assay tests
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the coefficient of variation varied from 11% to 18% 
which was considered to be acceptable.
iii) Neutralization/ blocking experiment (chapter 2,
section E(c).
It was possible to neutralize 100% of the IFN- 
alpha activity in the 1-16 IU/ml of IFN-alpha 
standards. 1.5% and 8% residual IFN-alpha activity 
remained in the 64 and 256 IU/ml of IFN-alpha standards 
respectively (figure 5.2 & table 5.3).
Observations obtained from the "Sucrosep" IFN-alpha 
immunoradiometric assay analysis of amniotic fluids and 
tissue homogenates.
i) Amniotic fluids
All 4 amniotic fluids analyzed by the "Sucrosep" 
IFN-alpha immunoradiometric assay had detectable levels 
of IFN-alpha, with a mean level of 10 IU/ml of IFN- 
alpha (table 5.4).
Neutralization/ blocking experiments, described in 
chapter two section E(c), showed that all detectable 
IFN-alpha activity in the 4 amniotic fluid samples 
could be removed (i.e completely neutralized) 
demonstrating physiological IFN-alpha activity as a 
natural feature of the amniotic fluids.
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ii) Tissue homogenates.
The results of IFN-alpha testing in tissue 
homogenates are given in table 5.5. It shows that 
detectable levels of IFN-alpha were observed only in 9 
placentas and 1 thyroid gland. All detectable IFN-alpha 
activity in these placental and thyroid samples was 
completely neutralized by the neutralization/ blocking 
experiment. This demonstrated that the IFN-alpha levels 
detected in the tested samples were specific.
Amendment to the homogenizations protocol, i.e 
addition of anti-protease enzymes to the homogenization 
buffer before homogenization of the tissues, had no 
effect on the detectable levels of IFN-alpha in these 
tissues.
A direct comparison between the "Sucrosep" IFN- 
alpha immunoradiometric assay and the indirect 
immunoperoxidase technique using the H51 antiserum was 
made (table 5.5). A correlation was found between the 
"Sucrosep" IFN-alpha immunoradiometric assay and the 
indirect immunoperoxidase technique using the H51 
antiserum for placenta and cerebral cortex, but not for 
choroid plexus, thyroid and adrenal glands (cerebral 
cortex, which was negative for immunoreactive IFN-alpha 
by the indirect immunoperoxidase technique described in 
chapter three, was included in this study as a negative 
control specimen for the "Sucrosep" IFN-alpha 
immunoradiometric assay). These findings suggest that
cpm
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IU/ml of IFN-alpha
Figure 5.1. VMT standard curve for IFN-alpha values (0-256IU/ml) over 
10 consecutive assays using "Sucrosep" IFN-alpha IRMA.
(A line drawn through the mean with bars indicating ± 2 standard 
deviations.)
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Figure 5 2. Neutralization/blocking of IFN-alpha activity in IFN-alpha 
standards diluted in VTM assayed by "Sucrosep" IFN-alpha 
immunoradiometric assay.
TABLE 5.1
VIRAL TRANSPORT MEDIUM (VTM) SAMPLES WITH 
NO IFN-ALPHA ASSAYED ON THE SAME DAY BY 
"SUCROSEP" IFN-ALPHA IRMA.
NUMBER OF SAMPLES VTM (cpm)
1 104
2 n o
3 121
4 125
5 120
6 124
7 113
8 119
Mean = 117
Standard deviation =7.3 
Coefficient of variation = 6.3%
IRMA = immunoradiometric assay 
cpm = counts/minute
TABLE 5.2
STATISTICAL ANALYSIS OF A SERIES OF IFN-ALPHA 
STANDARD LEVELS (0-256 IU/ml) IN VTM MEASURED 
BY "SUCROSEP" IFN-ALPHA IRMA.
IFN-alpha 
standard 
levels in 
VTM (IU/ml)
mean 
(cpm) S.D. S.E. C.V(%)
0 118.7 21.8 2 18
1 160 25.9 2 16
4 323. 8 41.6 4 13
16 822 96. 1 9 11
64 2972 362. 7 36 12
256 9417.7 1134 113 12
I.U. = International units
S.D. = Standard deviation
S.E. = Standard error
C.V(%) = Coefficient of variation
VTM. = Viral transport medium
TABLE 5.3
NEUTRALIZATION/BLOCKING OF IFN-ALPHA ACTIVITY IN
IFN-ALPHA STANDARDS IN 
IFN-ALPHA IRMA.
VTM ASSAYED BY "SUCROSEP"
IFN-ALPHA STANDARDS 
IN VTM (IU/ml)
%AGE OF REDUCTION OF IFN- 
ALPHA ACTIVITY IN IFN-ALPHA 
STANDARDS BY N/B EXPERIMENT
1 100%
4 100%
16 100%
64 98.5%
256 92%
N/B = Neutralization/blocking
TABLE 5,4
DETECTION OF IFN-ALPHA IN AMNIOTIC FLUIDS 
ASSAYED BY "SUCROSEP" IFN-ALPHA IRMA.
NUMBER OF AMNIOTIC 
FLUID SAMPLES
DETECTABLE LEVELS OF 
IFN-ALPHA (IU/ml)
I 9
2 17
3 14
4 10
Mean = 12.5 IU/ml of IFN-alpha.
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there may be a quantitative or qualitative difference 
between the tissues studied.
DISCUSSION
Many workers in the past had demonstrated the 
presence of IFN-alpha in human placenta and amniotic 
fluids, using various techniques (Chard et al.,1986; 
Bocci et al.,1985; Duc-Goiran et al.,1985; Lebon et 
al.,1982). The observations of the present study 
confirm the presence of detectable levels of IFN-alpha 
in placenta and amniotic fluids, using the "Sucrosep" 
IFN-alpha immunoradiometric assay. The same assay 
system was also used by Chard et al (1986) to 
demonstrate IFN-alpha in placenta, amniotic fluid and 
fetal tissues. In the present study approximately 50% 
of the placentas contained detectable IFN-alpha, which 
was not as high as the 96% positive result observed by 
Chard et al (1986). The range and median of the 
detectable IFN-alpha levels obtained in the present 
study was, however, somewhat similar to that observed 
by Chard et al (1986). All amniotic fluids studied had 
detectable levels of IFN-alpha, which also confirmed 
the observations of previous workers. The detectable 
IFN-alpha levels observed in 9 placentas, 1 thyroid 
gland and all 4 amniotic fluid samples in the present 
study were completely neutralized by the 
neutralization/ blocking experiment and therefore can
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be regarded specific positive observations. Chard et al
(1986) did not confirm the specificity of IFN-alpha in 
the positive samples in his study and therefore it is 
impossible to compare the apparent discrepancy between 
the two studies.
The negative observations in adult thyroid glands, 
choroid plexuses in brain and fetal adrenal glands were 
not consistent with the immunocytochemical findings 
using the H51 antiserum described earlier. There are at 
least three possible explanations for these negative 
observations. Firstly, the monoclonal antibody (Yok 
5/19) used in the "Sucrosep" IFN-alpha
immunoradiometric assay is known to recognise only 8 of 
more than 20 IFN-alpha subtypes. Therefore it is a 
possibility that those organs which did not show any 
detectable levels of IFN-alpha by the immunoradiometric 
assay, but were positive for immunoreactive IFN-alpha 
by the H51 antiserum in the indirect immunoperoxidase 
technique, contained an IFN-alpha protein not 
recognized by the monoclonal antibody Yok 5/19, used in 
the immunoradiometric assay. Secondly, all the placenta 
and amniotic fluid samples studied were obtained fresh 
within 1-2 hours of normal vaginal delivery or 
caesarean section. The adult thyroid glands, choroid 
plexuses in brain and fetal adrenal glands, on the 
other hand, were obtained from adult and fetal 
autopsies within 10-24 hours of death. It is possible
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that degradation of IFN-alpha proteins took place in 
these autopsy specimens resulting in failure to detect 
this protein by the "Sucrosep" IFN-alpha 
immunoradiometric assay. Thirdly, all tissues were 
homogenized using viral transport medium (VTM) as the 
extraction buffer. One gram of the tissue was added to 
2-4 mis of VTM. This means a dilution factor of 2-4 
times. It is suggested that these organs may contain 
such low levels of IFN-alpha proteins that the dilution 
factor makes it impossible to detect these in tissue 
homogenates using extraction buffer.
One line of future research could be to obtain 
fresh human tissues from transplant organ donors or 
from surgical operations and test them for IFN-alpha, 
instead of using tissues from autopsies.
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CHAPTER SIX
AN ATTEMPT AT DEMONSTRATING INTERFERON-ALPHA mRNA BY IN 
SITU HYBRIDIZATION. 
INTRODUCTION
As described in chapter 5, IFN-alpha was detected 
in fresh human placentas using a specific two-site 
immunoradiometric assay. Immunoreactive IFN-alpha was 
also demonstrated in macrophages, syncytiotrophoblast 
of the placenta and in parenchymal cells in various 
normal human tissues (chapter 3 & 4). However it is 
well known that many cells, and especially macrophages, 
phagocytose various proteins, foreign bodies, etc and 
thus the mere presence of IFN-alpha in cells does not 
provide conclusive evidence that these cells are 
actually producing IFN. To provide further evidence for 
IFN-alpha synthesis, it was important to demonstrate 
IFN-alpha messenger RNA (mRNA) in cells that stained 
for immunoreactive-IFN-alpha by the immunocytochemical 
methods. The presence of IFN-alpha mRNA would 
demonstrate that transcription of IFN-alpha genes and 
synthesis of IFN-alpha protein was taking place in
these cells .
Various techniques for the demonstration of 
nucleic acid sequences are available. They include in 
situ hybridization and southern, northern and dot blot
hybridization techniques. An In situ hybridization 
technique was first described by Gall & Pardue (1969) 
for the detection of ribosomal gene sequences. Since 
then a large number of workers have used the same 
principle for the demonstration of cellular mRNA. In 
situ hybridization techniques differ from the other 
three techniques in that the nucleic acid investigated 
is not extracted from the tissues. Labelled nucleic 
acid probes are hybridized with cellular DNA or RNA in 
fixed tissue sections or cytological preparations, and 
the reaction visualized by a label detection system. 
This allows precise cytological localization of the 
nucleic acid sequence in the histological sections.
In the present study two oligonucleotide 
(synthetic) probes, based on selected conserved cDNA 
sequences of IFN-alpha genes, were used in the in situ 
hybridization techniques for the demonstration of IFN- 
alpha mRNA. Probe 1 had been previously used for the 
demonstration of the IFN-alpha WA gene (Torczynski et 
al., 1984) . A poly-d-T oligonucleotide probe 
(complementary to the poly-A tail of mRNA molecules) 
used previously to detect total mRNA in formalin fixed 
tissues (Pringle et al.,1989), was used as a positive 
control for the in situ hybridization techniques used 
in this study. Oligonucleotide probes are synthetic, 
short single stranded probes which can be easily 
synthesized in abundance using automated DNA
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synthesizers. They do not require lengthy procedures of 
isolation and can be stored very conveniently at -20°C. 
They also have the advantage of better penetration of 
tissue sections than longer cDNA or RNA probes (Moench 
et al., 1985) . Most workers have used radioactive 
isotopes to label probes for in situ hybridization 
techniques. However, nonradioactive labelling methods 
using biotin, and more recently digoxigenen, have been 
described (Pringle et al., 1987; Brigati et al., 1983; 
Farquharson, Harvie & McNicol,1990). Digoxigenen is a 
derivative of the cardiac glycoside digoxin and has 
been used successfully to label oligonucleotide probes 
at the 3' end using terminal deoxynucleotidyl 
transferase (Farquharson et al.,1990). Digoxigenen can 
be identified by immunocytochemical techniques using an 
anti-digoxigenen antibody. Digoxigenen (a plant 
derivative) has not been found in human tissues, unlike 
biotin which is present in abundance in some human 
tissues. Farquharson et al (1990) suggested that 3 ’ end 
labelling of oligonucleotide probes with digoxigenen 
should be useful for use in in situ hybridization 
procedures, particularly for the detection of mRNAs in 
tissues with high endogenous biotin activity.
In this study all the three oligonucleotide probes 
were labelled at the 3 'end with digoxigenin.11.dUTP, 
using the terminal deoxynucleotidyl transferase enzyme. 
These labelled probes, hybridized to cellular mRNA i.e
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forming sequence specific, base paired duplexes with 
complementary mRNA sequences in tissue sections, can be 
identified with an alkaline phosphatase conjugated 
anti—digoxigenen antibody and appropriate chromogen.
OBSERVATIONS
i) Labelling procedure observations.
Labelling of probes 1 & 2 with digoxigenen.11.dUTP.
Both the probes were efficiently labelled with 
digoxigenen.11.dUTP by the 3 r end labelling reaction 
using the terminal deoxynucleotydal enzyme, as 
described in chapter 2, section (F). There was no 
difference between labelling reactions performed with 1 
microgram and 2 micrograms of probes 1 & 2. The 
labelled probes, separated from unincorporated material 
by the separation procedure described in chapter 2, 
were always obtained in fractions 4 & 5 (figure, 6.1).
Labelling the poly-d-T probe.
The poly-d-T probe was also labelled efficiently 
with digoxigenen.11.dUTP, and the labelled probe, 
separated from unincorporated material, was obtained in 
fractions 4 & 5.
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ii) situ hybridization procedure observations.
Probe 1.
Using probe 1 staining was observed in small round 
cells in three fetal spleens (two fixed in buffered 
formalin and one in formol saline for 24 hours) and one 
adult tonsil (fixed in buffered formalin for 24 hours) 
using the standard protocol for in situ hybridization 
described in chapter 2. In all 3 spleens, staining of 
these rounded cells was seen in tissue sections treated 
with 10-20 micrograms of proteinase-k enzyme/ml of 
proteinase-k buffer and in the tonsil in sections 
treated with 5-10 micrograms of proteinase-k enzyme/ml 
of proteinase-k buffer. These cells were small and 
round and the nuclei appeared multilobated on high 
power oil emulsion microscopy (figure, 6.2). Sections 
from the above tissues stained with the monoclonal 
antibody, LeuM 1, using an immunocytochemical technique 
described in chapter 2, showed a staining pattern 
similar to that observed in the in situ hybridization 
technique with probe 1 i.e cells identical to those 
positive with probe 1 by in situ hybridization 
technique also stained positively for LeuM 1 
(figure,6.3) . In addition to staining Reed-Sternberg 
cells in Hodgkin's disease, LeuM 1 is a recognized 
marker for polymorphonuclear neutrophils. The double 
staining technique using in situ hybridization with
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probe 1 in the part(a) and immunofluorescence with 
anti-muramidase antiserum in the part(b), as described 
in chapter 2, showed that cells fluorescing with the 
anti-muramidase antiserum were not stained with probe 1 
(figure,6.4) . There was no correlation between the 
staining patterns obtained by in situ hybridization 
with probe 1 and immunperoxidase with the monoclonal 
antibody KP1 in any tissues examined.
The positive staining observed in cells described 
above with probe 1 was not uniformly distributed 
throughout the same tissue section, being often 
confined to certain parts of the tissue section.
No staining was observed in the in situ 
hybridization technique in the other tonsils or 
placentas tested in this study.
The staining observed in the cells described above 
was seen only when 1 microgram of probe 1 was used in 
the 3' end labelling reaction. No staining was seen 
when 2 micrograms of probe 1 was used in the labelling 
reaction.
Observations of amendments in the in situ hybridization 
protocol for probe 1.
a) Varying the proteinase-k treatment.
Varying the proteinase-k treatment of the sections 
had little effect on the above staining pattern. There
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was an overall increase in the background staining with 
increased incubation times of the proteinase—k enzyme. 
Increasing the proteinase-k enzyme concentration to 40 
micrograms/ml of proteinase-k buffer showed increased 
staining of the rounded cells in splenic tissue 
sections. It did not affect the staining in tonsil.
b) Varying the incubation temperature of the 
hybridization procedure and post-hybridization 
washes.
Instead of incubating the tissue sections at room 
temperature, as in the hybridization procedure of the 
standard protocol, the tissue sections were incubated 
with the probe + hybridization buffer solution at 37°C, 
followed by post-hybridization washes, as described in 
chapter 2. It produced a similar staining pattern to 
that observed with the standard protocol. Also 
hybridization of tissue sections with the probe + 
hybridization buffer solution at 42°C, followed by 
post-hybridization washes, as described in chapter 2, 
produced a similar staining pattern to that observed 
with the standard protocol.
c) Varying the concentration of formamide.
Reducing the concentration of formamide from 50% 
in the hybridization buffer to 20%, followed by the 
hybridization procedure and post hybridization washes,
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described in chapter 2, produced negative staining in 
all tissues.
RNase treatment.
RNase treatment of spleen and tonsil sections (1-4 
milligram/ml of ribonuclease-A), as described in 
chapter 2, failed to abolish the positive staining 
observed in polymorphs, seen in certain tissues with 
probe 1.
Probe 2.
No positive staining was observed with probe 2 in 
any of the tissues studied using the standard protocol 
and applying all the amendments described in chapter 2 
for the hybridization protocol.
Poly-d-T probe.
Observations of the hybridization procedure.
The poly-d-T probe showed positive staining in the 
cytoplasm of most cells in the tissues studied 
(figure,6.5) . The staining was best, with little 
background in tissue sections treated with 2 or 5 
micrograms of proteinase-k enzyme/ml of the proteinase- 
k buffer. Increasing the proteinase-k enzyme 
concentration, although increasing the staining, caused 
very high background. The staining with the poly-d-T 
probe was consistently reproducible.
Figure 6.1
Labelling of probes 1 and 2
The labelled oligonucleotide probes 1 and 2, separated from 
unincorporated material by the separation procedure, are 
obtained in fractions 4 and 5 shown as dark spots on the 
nitrocellulose paper strip.

Figure 6.2
Probable non-specific hybridization with probe 1
Round shaped cells with multilobated nuclei are shown 
staining with probe 1 in spleen.
In situ hybridization for IFN-alpha mRNA with probe 1 
(x 880 ) .
Figure 6,3
In situ hybridisation using probe 1 in tonsil
Figure (a) and (b) are sections stained for IFN-alpha mRNA 
and LeuMlrespectively (LeuMl antibody, in addition to 
staining Reed-Sternberg cells in Hodgkin's disease, is a 
recognized marker for polymorphonuclear neutrophils). The 
distribution of staining cells is similar in both sections, 
showing that cells stained for IFN-alpha mRNA.are probably 
polymorphonuclear neutrophils.
In situ hybridization for IFN-alpha mRNA with probe 1 (a) 
and IIP for LeuMl (b) (x 350).

Figure 6.4
Cells in spleen showing, positive in situ hybridization 
with probe 1 are not macrophages.
Cells fluorescing with anti-muramidase antiserum (macrophage 
marker) in (b) are not staining with probe 1 (a) (arrow 
heads).
In situ hybridization for IFN-alpha mRNA with probe 1 (a) 
and immunofluorescence using anti-muramidase antiserum (b) 
on the same section (x 890).

Figure 6.5
In situ hybridistion for total mRNA
This shows mRNA in syncytiotrophoblast in placenta.
In situ hybridization for total mRNA with poly-d-T probe 
(x 380 ) .
This shows mRNA in various cells in lymphoid tissue in adult 
tonsil.
In situ hybridization for total mRNA with poly-d-T probe 
(x 380).
* ; H i »  i
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RNase treatment
8 milligrams of Ribonuclease—A/ml of buffer, 
applied to the sections as described earlier in chapter 
2, significantly reduced the positive staining with the 
poly-d-T probe in tissue sections.
DISCUSSION
When using probe 1 some staining was seen in cells 
in 3 spleens and 1 tonsil with the in situ 
hybridization technique for the demonstration of IFN- 
alpha mRNA in formalin' fixed paraffin embedded normal 
human tissues. The cells staining with probe 1 were 
very round and had multilobated nuclei. Tissue sections 
from these spleen and tonsil cases, stained with the 
monoclonal antibody LeuM 1, using an immunocytochemical 
technique, showed that cells with similar morphology to 
that seen in the in situ hybridization technique were 
also stained positively. (The LeuM 1 monoclonal 
antibody recognises an epitope on neutrophils and Reed- 
Sternberg cells). These cells therefore appeared 
probably to be neutrophil polymorphs. Cytological 
detail obtained with the in situ hybridization 
technique was far from excellent and thus cells could 
not always be readily identified by morphological means 
alone. Double staining of tissue sections with probe 1 
and anti-muramidase antiserum (macrophage marker) 
showed that cells fluorescing with the anti-muramrdase
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antiserum were not stained, with probe 1. These cells 
also failed to stain for KP1, the macrophage monoclonal 
antibody, demonstrating that they were probably not 
macrophages. The staining observed was inconsistent, 
not uniformly distributed in the same tissue section 
and it also failed to disappear with RNase treatment. 
Therefore this staining must be regarded as non­
specific .
No detectable staining was obtained with probe 2. 
The poly-d-T probe, on the other hand, showed specific 
positive staining in the cytoplasm of cells in all 
tissues studied. This demonstrated that mRNA was 
detectable in these formalin fixed paraffin embedded 
normal human tissues and was confirmation of previous 
work (Pringle et al.,1989).
A study using biotinylated oligonucleotide probes 
has shown calcitonin, adrenocorticotrophic hormone, 
prolactin and growth hormone mRNAs in formalin fixed 
paraffin embedded tissue sections from medullary 
thyroid carcinoma cases and pituitary glands (Hankin & 
Lloyd,1989). Using a digoxigenen labelled 
oligonucleotide probe, Farquharson et al (1990) 
demonstrated mRNA for the adrenocorticotrophin 
precursor, pro-opiomelanocortin (POMC), in rat 
pituitary gland tissues fixed in buffered formalin or 
4% paraformaldehyde. However, in all these studies mRNA 
of various hormones was detected in endocrine cells,
where the number of copies of mRNA molecules may be 
very high. In a study performed for the detection of 
human papillomavirus in various human lesions it was 
estimated that at least 800 copies of the viral 
genome/cell were required to obtain a positive result 
in an in situ hybridization technique, using a biotin 
labelled probe (Crum et al.,1986).
As described above, total cellular mRNA was 
demonstrated in this study in formalin fixed paraffin 
embedded human tissues using the poly-d-T probe by an 
in situ hybridization technique. The poly-d-T probe can 
hybridize with any mRNA molecule having a poly-A tail. 
However the study failed to show IFN-alpha mRNA in 
placenta or in macrophages in tonsil and spleen with 
the two oligonucleotide probes, 1 and 2. It is well 
known that cells of the mononuclear phagocyte system 
perform many functions, such as phagocytosis and 
antigen processing and presentation, and that they 
produce many cytokines such as interleukin 1, tumour 
necrosis factor etc. Therefore if these cells do 
produce IFN-alpha, perhaps only a very small proportion 
of the total cellular mRNA pool would be IFN-alpha 
mRNA. As already described by Crum et al (1986), a 
certain number of nucleic acid molecules are required 
to be present in cells to be detected by the biotin 
labelled in situ hybridization detection systems. It is 
suggested that the number of the IFN-alpha mRNA
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molecules may be below the threshold level for 
detection by the digoxigenen labelled probes used in 
the in situ hybridization technique. It could be argued 
that failure to detect a positive signal in the in situ 
hybridization technique may be due to the absence of 
the IFN-alpha mRNA molecules. However mRNA for IFN- 
alpha has been detected in normal human spleen and 
lymph nodes using dot blot hybridization technique 
(Tovey et al.,1987), so this explanation is unlikely.
Another possible cause of a false negative result 
in the system used here would be the fact that only 
oligonucleotide probes were used. During formalin 
fixation the target nucleic acid sequence may be broken 
and thus not detected. The use of longer probes or 
additional oligonucleotide probes may provide an 
advantage in this situation.
164
REFERENCES
Abbott, S.R., Buimovici-Klein, E., Cooper, L.Z.,
Briggs, M. & Weller, I.V.D. (1984) Rapid detection 
of immunoreactive interferon-alpha in AIDS. The 
Lancet, i, 564-566.
Adolf, G.R. (1990) Monoclonal antibodies and enzyme
immunoassays specific for human interferon-omega 
1: Evidence that IFN-omega l i s a  component of 
human leukocyte IFN. Virology, 175, 410-417.
Aguet, M. (1980) High-affinity binding of 125I-labelled 
mouse interferon to a specific cell surface 
receptor. Nature, 284, 459-61.
Anonymous, (1980) Interferon nomenclature. Nature, 286, 
110 .
Arrand, J.E. (1985) Preparation of nucleic acid probes. 
In Nucleic acid hyhridization-a practical 
approach, eds. Hames, B.D. & Higgens, S.J. pp 17- 
45. IRL Press, Oxford.
Balkwill, F.R. (1989) Interferons. The Lancet, i, 1060- 
1063.
- Belardelli, F., Gessani, S., Proietti, E., Locardi, C., 
Borghi, P., Watanabe, Y., Kawade, Y. & Gresser, I.
(1987) Studies on the expression of spontaneous 
and induced interferons in mouse peritoneal 
macrophages by means of monoclonal antibodies to
mouse interferons. Journal of General Virology,
68, 2203-2212.
Belardelli, F., Vignaux, F., Proietti, E. & Gresser, I. 
(1984) Injection of mice with antibody to 
interferon renders peritoneal macorphages 
permissive to vesicular stomatitis virus and 
encephalomyocarditis virus. Proceedings of the 
National Academy of Sciences of the U.S.A. 81, 
602-606.
Billiau, A., Van-Damme, J., Opdenakker, G., Fibbe,
W.E., Flakenburg, J.H.F. & Content, J. (1986) 
Interleukin 1 as a cytokine inducer.
Immunobiology, 172, 323-335.
Birke, C., Peter, H.H., Langenberg, U., Muller-Hermes, 
W.J.P., Peters, J.H., Heitmann, J., Leiblod, W., 
Dalluge, H., Krapf, E. Kirchner, H. (1981) 
Mycoplasma contamination in human tumour cell 
lines: Effect on interferon induction and 
susceptibility to natural killing. Journal of 
Immunology, 127, 94-98.
Blach-Olszewska, Z., Cambrzynska-Nowak, M. &
Kwasniewska, E. (1984) Age related synthesis in 
BALB/c mice. In Physiology and pathology of 
interferon systems, eds. Borecky, L. & Lackovic,
V. pp 224. Karger Basel.
Blanchard, D.K., Djeu, J.Y., Klein, T.W., Friedman, H.
& Stewart II, W.E. (1986) Interferon-gamma
induction by lipopolysaccharide: Dependence on 
interleukin 2 and macrophages. Journal of 
Immunology, 136, 963-970.
Bocci, V. (1980) Is interferon produced in
physiological conditions? Medical Hypotheses, 6, 
735-745 .
Bocci, V. (1981) Production and role of interferon in 
physiological conditions. Biological Reviews of 
the Cambridge Philosophical Society, 56, 49-85.
Bocci, V. (1988) Roles of interferon produced in
physiological conditions. A speculative review. 
Immunology, 64, 1-9.
Bocci, V., Muscettola, M., Paulesu, L. & Grasso, G.
(1984) The physiological interferon response II. 
Interferon is present in lymph but not in plasma 
of healthy rabbits. Journal of General Virology, 
65, 101-108.
Bocci, V., Paulesu, L. & Ricci, M.G (1985) The
physiological interferon response: IV. Production 
of interferon by the perfused human placenta at 
term. Proceedings of the Society for Experimental 
Biology and Medicine, 180, 137-143.
Branca, A.A. & Baglioni, C. (1981) Evidence that type I 
and II interferons have different receptors. 
Nature, 294, 768-770.
Britten, R.J. & Davidson, E.H. (1985) Hybridization 
strategy. In Nucleic acid hybridization-a
practical approach, eds. Hames B.D. & Higgens,
S.J. pp 3-15. IRL Press, Oxford.
Brigati, D.J., Myerson, D., Leary, J.J., Spalholz, B., 
Travis, S.Z., Fong, C.K.Y., Hsiung, G.D. & Ward, 
D.C. (1983) Detection of viral genomes in cultured 
cells and paraffin embedded tissue sections using 
biotin-labeled hybridization probes. Virology,
126, 32-50.
Capobianchi, M.R., Ameglio, F., Tosi, R. & Dolei, A.
(1985) Differences in the expression and release 
of DR, BR and DQ molecules in human cells treated 
with recombinant interferon-gamma: Comparison to 
other interferons. Human Immunology, 13, 1-11.
Caput, D., Beutler, B., Hartog, K., Thayer, R., Brown- 
Shimer, S. & Cerami, A. (1986) Identification of a 
common nucleotide sequence in the 3' untranslated 
region of mRNA molecules specifying inflammatory 
mediators. Proceedings of the National Academy of 
Sciences of the U.S.A. 83, 1670-1674.
Chard, T., Craig, P.H., Menabawey, M. & Lee, C. (1986) 
Alpha-interferon in human pregnancy. British 
Journal of Obstetrics and Gynaecology, 93, 1145- 
1149 .
Crum, C.C., Nagai, N., Levine, R.U. & Silverstein, S.
(1984) In situ hybridization analysis of HPV 16 
DNA sequences in early neoplasia. American Journal 
of Pathology, 123, 174-182.
168
Davis, L.G., Dibner, M.D. & Battey, J.F. (1986)
Hybridization with synthetic 32P end-labeled probe. 
In Basic methods in molecular biology, pp 75-78. 
Elsevier, New York.
Dean, R.T. & Virelizer, J.L. (1983) Interferon as a 
macrophage activating factor. I. Enhancement of 
cytoxicity by fresh and matured human monocytes in 
the absence of other soluble signals. Clinical and 
Experimental Immunology, 51, 501-510.
De-Maeyer, E. & De-Maeyer-Guignard, J. (1988a)
Production of IFN-gamma by T cells & modulation of 
T cell, B cell, and macrophage activity by 
interferons. In Interferons and other regulatory 
cytokines, pp 221-273. John Wiley & Sons, 
Chichester.
De-Maeyer, E. & De-Maeyer-Guignard, J. (1988b)
Induction of IFN-alpha and IFN-beta. In 
Interferons and other regulatory cytokines, pp 39- 
66. John Wiley & Sons, Chichester.
De-Maeyer, E. & De-Maeyer-Guignard, J. (1988c)
Production of IFN—gamma by T cells & modulation of 
T cell, B cell, and macrophage activity by 
interferons. In Interferons and other regulatory 
cytokines, pp 221-273. John Wiley & Sons, 
Chichester.
De-Maeyer, E. & D e - M a e y e r - G u i g n a r d ,  J. (1988d) The 
e f f e c t s  o f  i n t e r f e r o n s  o n  c e l l  g r o w t h  a n d
division. In Interferons and other regulatory 
cytokines, pp 134-153. John Wiley & Sons, 
Chichester.
De-Maeyer, E., Fauve R.M. & De-Maeyer-Guignard, J. 
(1971) Production d ’interferon au niveau du 
macrophage. Annales Institut Pasteur, 120, 438- 
446.
Derynck, R., Content, J., De-Clercq, E., Volckaert, G., 
Tavernier, J., Devos, R. & Fiers, W. (1980) 
Isolation and structure of a human fibroblast 
interferon gene. Nature, 285, 542-547.
Di-Bisceglie, A.M., Martin, P., Kassianides, C., 
Lisker-Melman, M., Murray, L., Waggoner, J., 
Goodman, Z., Banks, S.M. & Hoofnagle, J.H. (1989) 
Recombinant interferon-alfa therapy for chronic 
hepatitis C. New England Journal of Medicine, 321, 
1506-1510.
Douglas, R.G. Jr (1986) The common cold-relief at last? 
New England Journal of Medicine, 314, 114-115.
Duc-Goiran, P., Robert-Galliot, B., Lopez, J. & Chany, 
C. (1985) Unusual apparently constitutive 
interferons and antagonists in the human placental 
blood. Proceedings of the National Academy of 
Sciences of the U.S.A. 82, 5010-5014.
Dzvonyar, J., Ruzicska, G., Desio, G. & Csaba, B.
(1970) Distribution of p32 labelled coli endotoxin 
in the tissues of pregnant rabbit and of their
fetuses. American Journal of Obstetrics and 
Gynaecology, 106, 721-725.
Eron, L.J., Judson, F., Tucker, S., Prawer, S., Mills, 
J., Murphy, K., Hickey, K., Rogers, M., Flannigan,
S., Hien, N., Katz, H.I., Goldman, S., Gottlieb, 
A., Adams, K., Burton, P., Tanner, D., Taylor, E.
& Peets, E. (1986) Interferon therapy for 
condylomata acuminata. New England Journal of 
Medicine, 315, 1059-1064.
Exley, R., Nathan, P., Walker, L., Gordon, J. &
Clemens, M.J. (1987) Anti-proliferative effect of 
interferons on Daudi Burkitt-lymphoma cells: 
Induction of cell differentiation and loss of 
response to autocrine growth factors.
International Journal of Cancer, 40, 53-57.
Exley, T., Parti, S., Barwick, S. & Meager, A. (1984) A 
comparison of the neutralizing properties of 
monoclonal and polyclonal antibodies to human 
interferon alpha. Journal of General Virology, 65, 
2277-2280.
Falcoff, R. (1972) Some properties of virus and immune- 
induced human lymphocyte interferon. Journal of 
General Virology, 16, 251-253.
Farquharson, M., Harvie, R. & McNicol, A.M. (1990)
Detection of messenger RNA using a digoxigenen end 
labelled oligonucleotide probe. Journal of 
Clinical Pathology, 43, 424-428.
Field, A.K., Tytell, A.A., Lampson, G.P. & Hilleman, 
M.R. (1967) Inducers of interferon and host 
resistance. II. Multistranded synthetic 
polynucleotide complexes. Proceedings of the 
National Academy of Sciences of the U.S.A. 58, 
1004-1010 .
Foulis, A.K., Farquharson, M .A . & Meager, A. (1987) 
Immunoreactive alpha-interferon in insulin 
secreting beta cells in type 1 diabetes mellitus. 
The Lancet, ii, 1423-1427.
Fowler, A.K., Reed, C.D. & Giron, D.J. (1980) 
Identification of an interferon in murine 
placenta. Nature, 286, 266-267.
Freshman, M.M., Merigan, T.C., Remington, J.S. & 
Brownlee, I.E. (1966) In vitro and in vivo 
antiviral action of an interferon-like substance 
induced by toxoplasma gondii. Proceedings of the 
Society for Experimental Biology and Medicine,
123, 862-866.
Friedman, R.M. & Vogel, S.N. (1983) Advances in
Immunology, eds. Dixon, F.J. & Kunkel, H.G. Vol. 
34, pp 97-140. Academic Press, New York & London.
Galabru, T., Robert N., Buffet-Janvresse, C., Riviere, 
Y. & Hovanessian, A.G. (1985) Continuous 
production of interferon in normal mice: Effect of 
anti-interferon globulin, sex, age, strain and 
environment on the levels of 2-5A synthetase and
172
p67K kinase. Journal of General Virology, 66, 711- 
718 .
Gall, J.G. & Pardue, M.L. (1969) Formation and 
detection of RNA-DNA hybrid molecules in 
cytological preparation. Proceedings of the 
National Academy of Sciences of the U.S.A. 63, 
378-383.
Gessani, S., Belardalli, F., Borghi, D. & Gresser, I.
(1987) Correlation between the lipopolysaccharide 
response of mice and the capacity of mouse 
peritoneal cells to transfer an antiviral state. 
Role of endogenous interferon. Journal of 
Immunology, 139, 1991-1998.
Gidlund, M., Orn, A., Wigzell, H., Senik, A. & Gresser, 
I. (1978) Enhanced NK cell activity in mice 
injected with interferon and interferon inducers. 
Nature, 273, 759-761.
Gifford, G.E., Tibor, A. & Peavy, D.L. (1971)
Interferon production in mixed lymphocyte cell 
cultures. Infection and Immunity, 3, 164-166.
Giles, F.J., Singer, C.R.J., Gray, A.G., Yong, K.L., 
Brozovic, M., Davies, S.C., Grant, I.R.,
Hoffbrand, A.V., Machin, S.J., Mehta, A.B.,
Richard, J.D.M., Thomas, M.J.G., Venutas, S. & 
Goldstone, A .H . (1988) Alpha-interferon therapy
for essential thrombocythaemia. The Lancet, ii, 
70-72.
Goeddel, D.V., Leung, D.W., Dull, T.J., Gross, M.,
Lawn, R.M., McCandliss, R., Seeburg, P.H.,
Ullrich, A., Yelverton, E. & Gray, P. W. (1981)
The structure of eight distinct cloned human 
leukocyte interferon cDNAs. Nature, 290, 20-26.
Gray, P.W. & Goeddel, D.V. (1982) Structure of the
human immune interferon gene. Nature, 298, 859- 
863.
Green, J.A., Cooperband, S.R. & Kibrick, S. (1969)
Immune specific induction of interferon production 
in cultures of blood lymphocytes. Science, 164, 
1415-1417 .
Gresser, I., Vignaux, F., Belardelli, F., Tovey, M.G. & 
Maunoury, M.T. (1985) Injection of mice with 
antibody to mouse interferon-alpha/ beta decreases 
the level of 2'-5' oligoadenylate synthetase in 
peritoneal macrophages. Journal of Virology, 53, 
221-227 .
Hankin, R.C. & Lloyd, R.V. (1989) Detection of
messenger RNA in routinely processed tissue 
sections with biotinylated oligonucleotide probes. 
American Journal of Clinical Pathology, 92, 166- 
171.
Havel1, E .A. (1986) Augmented induction of interferons 
during Lesteria monocytogenes infection. Journal 
of Infectious Diseases, 153, 960-969.
Havell, E.A., Hayes, T.G. & Vilcek, J. (1978) Synthesis 
of two distinct interferons by human fibroblasts. 
Virology, 89, 330-334.
Hayes, T.S., Yip, Y.K. & Vilcek, J. (1979) Le
interferon production by human fibroblasts. 
Virology, 98, 351-363.
Hayden, F.G., Albrecht, J.K., Kaiser, D.L. & Gwaltney, 
J.M (1986) Prevention of natural colds by contact 
prophylaxis with intranasal alpha 2-interferon.
New England Journal of Medicine, 314, 71-75.
Healy, G.B., Gelber, R.D. & Trowbridge, A.L. (1988)
Treatment of recurrent respiratory papillomatosis 
with human leukocyte interferon. New England 
Journal of Medicine, 319, 401-407.
Houghton, M., Eaton, M.A.W., Stewart, A.G., Smith,
J.C., Doel, S.M., Catlin, G.H., Lewis, H.M.,
Patel, T.P., Emstage, J.S., Carey, N.H. & Porter, 
A.G. (1980) The complete amino acid sequence of 
human fibroblast interferon as deduced using 
synthetic oligodeoxyribonucleotide primers of 
reverse transcriptase. Nucleic Acids Research, 8, 
2885-2894 .
Ho-Yen, D.O. & Carrington, D. (1987) Alpha-interferon 
responses in the cerebrospinal fluid of patients 
with suspected meningitis. Journal of Clinical 
Pathology, 40, 83-86.
175
Howatson, A.G., Farquharson, M.A., Meager, A., McNicol, 
A.M. & Foulis, A.K. (1988) Localization of alpha- 
interferon in the human fetoplacental unit.
Journal of Endocrinology, 119. 531-534.
Hughes, T.K. & Baron, S. (1987) A large component of 
the antiviral activity of mouse interferon-gamma 
may be due to its induction of interferon-alpha. 
Journal of Biological Regulators and Homoeostatic 
Agents, 1, 29-32.
lies, R.K. & Chard, T. (1989) Enhancement of ectopic 
beta-human chorionic gonadotrophin expression by 
interferon-alpha. Journal of Endocrinology, 123, 
501-507 .
Imakawa, K., Anthony, R.V., Kazemi, M., Marotti, K.R., 
Polites, H.G. & Roberts, R.M. (1987) Interferon­
like sequence of ovine trophoblast protein 
secreted by embryonic trophectoderm. Nature, 330, 
377-379.
Issacs, A. & Lindenmann, J. (1957) Virus interference.
I . The interferon. Proceedings of the Royal 
Society of London. (Biological Sciences), 147, 258— 
267 .
Jaatela, M., Kiuusela, P. & Saksela, E. (1988)
Demonstration of tumour necrosis factor in human 
amniotic fluids and supernatants of placental and 
decidual tissues. Laboratory Investigation, 58,
48-52.
176
Jacob, A.I., Goldberg, P.K., Bloom, N., Degenshein,
G.A. & Kozim, P.J. (1977) Endotoxin and bacteria 
in portal blood. Gastroenterology, 72, 1268-1270.
Kasahara, T., Hooks, J.J., Dougherty, S.F. & Oppenheim, 
J.J. (1983) Interleukin-2 mediated immune 
interferon (IFN-gamma) production by human T cells 
and T cell subsets. Journal of Immunology, 130, 
1784-1789.
Kiener, P.A. & Spitalny, G.L. (1987) In Lymphokines and 
Interferons, eds. Clemens, M.J., Morris A .G . & 
Gearing, A.J.H. pp 17. IRL Press, Oxford.
Kirchner, H., Weyland, A. & Storch, C. (1986) Local 
interferon induction by bacterial
lipopolysaccharide in mice after pretreatment with 
corynebacterium parvum. Journal of Interferon 
Research, 6, 483-487.
Klavinskis, L.S., Geckeler, R. & Oldstone, M.B.A.
(1989) Cytotoxic T lymphocytes control of acute 
lymphocytic choriomeningitis virus infection: IFN- 
gamma, but not TNF-alpha displays antiviral 
activity in vivo. Journal of General Virology, 70, 
3317-3325.
Kohno, S., Kohase, M., Sakata, H., Shimizu, Y., Hikita, 
M. & Shishido, A. (1970) Production of interferon 
in primary chick embryonic cells infected with 
Rickettsia Mooseri. Journal of Immunology, 105, 
1553-1558 .
177
Lebon, P., Girard, S., Thepot, F. & Chany, C. (1982)
The presence of alpha-interferon in human amniotic 
fluid. Journal of General Virology, 59, 393-396.
Lee, C.L.Y., Lee, S.H.E., Jay, F.T. & Rozee, K.R.
(1990) Induction of Interferon-gamma synthesis by 
staphylococcal enterotoxin B (SEB) in peripheral 
blood mononuclear cells. Immunology, 70, 94-99.
Maeger, A. (1987) Antibodies against interferons.
Characterization of interferons and immunoassays. 
In lymphokines and Interferons-A Practical 
Approach, eds. Clemens, M.J., Morris A.G. & 
Gearing, A.J.H. pp 105-127. IRL Press, Oxford.
Mandelli, F., Awisati, G. & Petrucci, M.T. (1990) A
new strategy in the treatment of multiple myeloma. 
European Journal of Haematology (Supplementum),
51, 129-134.
Martinez-Maza, 0., Andersson, U., Andersson, J.,
Britton, S. & Ley, M.D. (1984) Spontaneous 
production of interferon-gamma in adult and 
newborn humans. Journal of Immunology, 132, 251- 
255 .
Moench, T.R., Gendelman, H.E., Clements, J.E., Narayan, 
0. & Griffin, D.E. (1985) Efficiency of in situ 
hybridization as a function of probe size and 
fixation technique. Journal of Virology Methods,
11, 119-130.
Moore, R.N., Larsen, H.S., Horohov, D.W. & Rouse, B.T.
(1984) Endogenous regulation of macrophage 
proliferative expansion by colony-stimulating 
factor induced interferon. Science, 223, 178-181.
Nathan, C.F., Murray, H.W., Wiebe, M.E. & Rubin, B.Y. 
(1983) Identification of interferon-gamma as the 
lymphokine that activates human macrophage 
oxidative metabolism and antimicrobial activity. 
Journal of Experimental Medcine, 158, 670-689.
Nathan, I., Groopman, J.E., Quan, S.G., Bersch, N. & 
Golde, D.W. (1981) Immune (gamma) interferon 
produced by a human T-lymphoblast cell line.
Nature, 292, 842-844.
Naylor, S.L., Sakaguchi, A.Y., Shows, T.B., Law, M.L., 
Goeddel, D.V. & Gray, P.W. (1983) Human immune 
interferon gene is located on chromosome 12. 
Journal of Experimental Medcine, 57, 1020-1027.
Noordan, S.V. (1986) Tissue preparation and
immunostaining techniques for light microscopy. In 
Immunocytochemistry. Modern methods and 
applications, eds. Polak, J.M. & Noordan, S.V. pp 
2 6-53. John Wright & Sons Ltd. Bristol.
Ojo-Amaize, E.A., Salimonu, L.S., Williams, A.I.O.,
Akinwolere, O.A.O., Shabo, R., Aim, G. & Wigzell,
H. (1981) Positive correlation between degree of 
parasitemia, interferon titres, and natural killer
179
cell activity in plasmodium falciparum-infected 
children. Journal of Immunology, 127, 2296-2300.
Pardue, M.L. (1985) In situ hybridisation. In Nucleic 
acid hybridisation-a practical approach, eds. 
Hames, B.D. & Higgens, S.J. pp 179-202. IRL Press, 
Oxford.
Paraf, A., Philips, N., Simonin, G., De Maeyer-
Guignard, J. & De Maeyer, E. (1983) Differential 
cytostatic effect of interferon on murine BALB/c B 
and T-cell tumors. Journal of Interferon Research, 
3, 253-260.
Paucker, K., Kantell, K. & Henle, W.. (1962)
Quantitative study on viral interference in 
suspended L cells. III. Effects of interfering 
viruses and interferon on the growth rate of 
cells. Virology, 11, 324-334.
Preble, O.T., Black, R.J., Friedman, R.M., Klippel,
J.H. & Vilcek, J. (1982) Systemic lupus 
erythematosus: presence in human serum of an 
unusual acid-labile leukocyte interferon. Science, 
216, 429-431.
Pringle, J.H., Primrose, L., Kind, C.N., Talbot, I.C. & 
Lander, I. (1989) In situ hybridization 
demonstration of poly-adenylated R.N.A sequences 
in formalin-fixed paraffin sections using a 
biotinylated oligoprobe. Journal of Pathology,
158, 279-286.
Prior, C. & Haslam, P.L. (1989) Interferon in lungs.
The Lancet, i, 1333.
Pulford, K.A.F., Rigney, E., Micklem, K.J., Jones, M., 
Stross, P., Gatter, K.C. & Mason, D.Y. (1989) KP1: 
a new monoclonal antibody that detects a monocyte/ 
macrophage associated antigen in routinely 
processed tissue sections. Journal of Clinical 
Pathology, 42, 414-421.
Reyes, V.E., Balias, Z.K., Singh, H. & Klimpel, G.R.
(1986) Interleukin 2 induces interferon alpha/beta 
production in mouse bone marrow cells. Cellular 
Immunology, 102, 374-385.
Rossi, G.B. (1985) Interferons and cell
differentiation. In Interferon 6, ed. Gresser, I. 
pp 31-68. Academic Press, London.
Rubinstein M. & Orchansky P. (1986) The interferon
receptors. CRC Critical Reviews in Biochemistry,
21, 249-275.
Ruiz-Moreno, M., Jimenez, J., Porres, J.C., Bartolome, 
J., Moreno, A. & Carreno, V. (1990) A controlled 
trial of recombinant IFN-alpha in Caucasian 
children with chronic hepatitis B. Digestion, 45, 
26-33.
Saksela, E., Virtanen, I., Hovi, T., Secher, D.S. &
Cantell, K. (1984) Monocytes is the main producer 
of human leucocyte alpha-interferons following
Sendai virus induction. Progress in Medical 
Virology, 30, 78-86.
Salamonsen, L.A., Stuchbery, S.J., O'Grady, C.M.,
Godkin, J.D. & Findlay, J.K. (1988) Interferon- 
alpha mimics effects of ovine trophoblast protein 
1 on prostaglandin and protein secretion by ovine 
endometrial cells in vitro. Journal of 
Endocrinology, 117, R1-R4.
Salas, M.D.P. (1987) Alpha-interferon responses in 
children with respiratory syncytial virus 
associated bronchiolitis. MSc thesis, University 
of Glasgow.
Salvin, S.B., Youngner, J.S. & Lederer, W.H. (1973)
Migration inhibitory factor and interferon in the 
circulation of mice with delayed hypersensitivity. 
Infection and Immunity, 1, 68-75.
Sehgal, P.B., Zilberstein, A., Ruggieri, R.M., May,
L.T., Ferguson-Smith, A., Slate, D.L., Revel, L. & 
Ruddle, F.H. (1986) Human chromosome 7 carries the 
beta 2 interferon gene. Proceedings of the 
National Academy of Sciences of the U.S.A. 83, 
5219-5222 .
Sergiescu, D., Gerfaux, J., Joret, A.M. & Chany, C.
(1986) Persistent expression of v-mos oncogene in 
transformed cells that revert to nonmalignancy 
after prolonged treatment with interferon.
182
Proceedings of the National Acadmey of Sciences of 
the U.S.A. 83, 5764-5768.
Shaw, G.-& Kamen, R. (1986) A conserved AU sequence 
from the 3' untranslated region of GM-CSF mRNA 
mediates selective mRNA-degradation. Cell, 46, 
659-667.
Shiozawa, S., Chihara, K., Shiozawa, K., Fujita, T., 
Ikegami, H., Koyama, S. & Kurimoto, M. (1986) A 
sensitive radioimmunoassay for alpha-interferon: 
circulating alpha-interferon like substance in the 
plasma of healthy individuals and rheumatoid 
arthritis patients. Clinical and Experimental 
Immunology, 66, 77-87.
Slate, D.L., D'Eustachio, P., Pravtcheva, D.,
Cunningham, A.C., Nagata, S., Weissmann, C. & 
Ruddle, F.H. (1982) Chromosomal location of a 
human alpha interferon gene family. Journal of 
Experimental Medcine, 155, 1019-1024.
Smith, T.J. & Wagner, R.R. (1967) Rabbit macrophage
interferons. Conditions for biosynthesis by virus- 
infected and uninfected cells. Journal of 
Experimental Medcine, 125, 559-577.
Sonnenfeld, G. & Kierszenbaum, F. (1981) Increased
serum levels of an interferon like activity during 
the acute period of experimental infection with 
different strains of Trypanosoma cruzi. American
Journal of Tropical Medicine and Hygiene, 30, 
1189-1191.
Soubiran, P., Zapitelli, J.p. & Schaffer, L. (1987) IL- 
2 like material is present in human placenta and 
amnion. Journal of Reproductive Immunology, 12, 
225-234.
Stewart, H.J., McCann, S.H.E., Barker, P.J., Lee, K.E., 
Lamming, G.E. & Flint, A.P.F. (1987) Interferon 
sequence homology and receptor binding activity of 
ovine trophoblast antiluteolytic protein. Journal 
of Endocrinology, 115, R13-R15.
Stanton, G.J., Weigent, D.A., Fleischmann, W.R. Jr.,
Dianzani, F. & Baron, S. (1987) Interferon review. 
Investigative Radiology, 22, 259-273.
Sutherland, C.G.G., Al-Badri, A.M.T., Howatson, A.G., 
Farquharson, M.A. & Foulis, A.K. (1989) 
Immunlocalisation of alpha-interferon in liver 
diseases. Journal of Clinical Pathology, 42, 1065- 
1069.
Talpaz, M., Kantarjian, H.M., McCredie, K.B., Keating, 
M.J., Trujillo, J. & Gutterman, J. (1987) Clinical 
investigation of human alpha interferon in chronic 
myelogenous leukemia. Blood, 65, 1280-1288.
Taniguchi, T., Mantei, N., Schwarzstein, M., Nagata,
S., Muramatsu, M. & Weissmann, C. (1980) Human 
leukocyte and fibroblast interferons are 
structurally related. Nature, 285, 547-549.
Torczynski, R.M., Fuke, M. & Bollon, A.P. (1984) Human 
genomic library screened with 17-base 
oligonucleotide probes yields a novel interferon 
gene. Proceedings of the National Academy of 
Sciences of the U.S.A. 81, 6451-6455.
Tovey, M.G., Streuli, M., Gresser, I., Gugenheim, J., 
Blanchard, B., Guymarho, J., Vignaux, F. & Gigou, 
M. (1987) Interferon messenger RNA is produced 
constitutively in the organs of normal 
individuals. Proceedings of the National Academy 
of Sciences of the U.S.A. 84, 5038-5042.
Trent, J.M., Olson, S. & Lawn, R.M. (1982) Chromosomal 
localization of human leukocyte, fibroblast and 
immune interferon genes by means of in situ 
hybridization. Proceedings of the National Academy 
of Sciences of the U.S.A. 79, 7809-7813.
Trinchieri, G. & Perussia, B. (1985) Immune interferon: 
a pleiotropic lymphokine with multiple effects. 
Immunology Today, 6, 131-136.
Van Damme, J., Opdenakker, G., Simpson, R.J., Rubira, 
M.R., Cayphas, S., Vink, A., Billiau, A. & Van 
Snick, J. (1987) Identification of the human 26- 
kD protein, interferon beta2 as a B cell 
hybridoma/ plasmacytoma growth factor induced by 
interleukin 1 and tumour necrosis factor. Journal 
of Experimental Medcine, 165, 914-919.
Vilcek, J., Henriksen-Destefano, D., Siege,1 D., Klion, 
A., Robb, R.J. & Le, J. (1985) Regulation of IFN- 
gamma induction in human peripheral blood cells by 
exogenous and endogenously produced interleukin 2. 
Journal of Immunology, 135, 1851-1856.
Weissmenn, C. & Weber, H. (1986) The interferon genes. 
Progress in Nucleic Acid Research and Molecular 
Biology, 33, 251-302.
Wright, J.F. & Hunter, W.M. (1983) The sucrose layering 
separation: a non-centrifugation system. In 
Immunoassays for Clinical Chemistry, eds. Hunter, 
W.M & Corrie, J.E.T. Second edition, pp 170-177. 
Churchill Livingstone, Edinburgh.
Wong, G.H.W., Clark-Lewis, I., McKimm-Breschkin, J.L., 
Harris, A.W. & Schrader, J.W. (1983) Interferon- 
gamma induces enhanced expression of la and H-2 
antigens on B lymphoid, macrophage, and myeloid 
cell lines. Journal of Immunology, 131, 788-793.
Yip, Y.K., Barrowclough, B.S., Urban, C. Vilcek, J.
(1982) Purification of two species of human gamma 
(immune) interferon. Proceedings of the National 
Academy of Sciences of the U.S.A. 79, 1820-1824.
Youngner, J.S & Stinebring, W.R. (1964) Interferon 
production in chickens injected with Brucella 
abortus. Science, 144, 1022-1023.
Zilberstein, A., Ruggieri, R., Korn, J.H. & Revel, M.
(1986) Structure and expression of cDNA and genes
for human interferon-beta 2, a distinct species 
inducible by growth-stimulatory cytokines. The 
EMBO Journal. 5, 2529-2537.
Zullo, J.N., Cochran, B.H., Huang, A.S. & Stiles, C.D.
(1985) Platlet derived growth factor and double­
stranded ribonucleic acids stimulate expression of 
the same gene in 3T3 cells. Cell, 43, 773-800.
Zoumbos, N.C., Gascon, P., Djeu, J.Y. & Young, N.S.
(1985) Interferon is a mediator of hematopoietic 
suppression in aplastic anaemia in vitro and 
possibly in vivo. Proceedings of the National 
Academy of Sciences of the U.S.A. 82, 188-192.
APPENDIX
Procedure for use of 3 ’diaminobenzidine 
tetrahydrochloride (DAB).
Reconstitute 21 mis of stock DAB (Sigma,UK) in 300 
mis of water to make a 0.03% DAB solution which is 
then aliquoted in 21 mis containers and frozen.
DAB is a potential carcinogen therefore the entire 
procedure is performed in a fume chamber.
Add 21 mis of the frozen DAB solution to 300 mis 
of tris HCL buffer, pH 7.6 and allow to thaw.
) 6 drops of 100 vols (30%) hydrogen peroxide 
(BDH,UK) are then added to the above solution.
The solution is filtered and then used to incubate 
slides. On expiry of the working life of the DAB 
solution i.e approximately 2 hours, the solution 
is poured into a waste DAB container. This 
contains 1 pellet of hypochlorite bleach that 
inactivates the DAB, which can than be poured down 
the sink. All the above procedures are performed 
in a designated covered area and gloves and 
protective clothing are worn all the time when 
using DAB.
Trypsinization
Preheat a water bath to 37°C. Place two staining 
dishes each containing 300 mis of 0.05M tris HCL 
buffer, pH 7.6. In it add 100 milligrams of
trypsin (Sigma) and 100 milligrams of calcium 
chloride to one dish. Make sure all solids are 
dissolved. Sections are first placed into the dish 
with tris HCL buffer for 5 minutes and then 
transferred to the trypsin solution.
Alkaline phosphatase substrates.
Fast Red.
Add 2 drops of dimethyl formamide to 5 milligrams 
of naphthal AS BI phosphoric acid (Sigma) in a 
tube. In a separate tube dissolve Fast Red TR salt 
in veronal acetate buffer (0.9715 gm sodium 
acetate, 1.4715 gms sodium barbitone (both from 
BDH/UK), 247.5 ml distiled water and N/10 HCL, pH 
9.2). Mix the contents of the two tubes and add 
200 micrograms of ImM levamisole (Sigma). Mix well
and filter before use.
Nitro blue tetrazolium (NBT) and 5-bromo-4-chloro- 
3-indolylphosphate (BCIP) (both from Sigma).
To 7.5 mis of buffer three add 33 microlitres of
NBT and 25 microlitres of BCIP. No levamisole was
added to the NBT/BCIP solution used in the 
labelling reaction described in chapter 2, 
section(F). In the in situ hybridization 
technique, however, 1.8 milligrams of levamisole 
was added to 7.5 mis of buffer three, to block
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endogenous alkaline phosphatase activity in the 
tissue sections.
4) Vectastain ABC reagents (Vector, UK).
Add exactly two 2 drops of reagent A (Avidin DH) 
to 10 mis of tris buffered saline (0.01M tris HCL, 
pH 7.6, 0.15M NaCl). Then add exactly 3 drops of 
reagent B (Biotinylated horseradish peroxidase H) 
to the above solution, mix and allow this solution 
to stand for about 30 minutes before use.
5) Streptavidin-biotin complex (DAKO).
One drop of reagent A (streptavidin in 0.01M
phosphate buffer, 0.15M NaCl, 15mM Na^, pH 7.2) 
and one drop of reagent B (biotinylated alkaline 
phosphatase in 0.05M tris HCL, 0.1M NaCl, ImM
MgCl2 / 15mM NaN3 , pH 7.2) are added to 5 ml of
0.01M tris HCL buffer, pH 7.6. They are mixed well 
and allowed to stand for 30 minutes before use (1 
drop is equal to approximately 45 microlitres).
6) T.E buffer.
Dissolve 0.605 gms of lOmM tris HCL and 0.186 gms
of ethylenediamine tetraacetic acid in 500 mis of
water, pH 8 .
7) Hybridization buffer.
It consisted of the following materials,
i) 0.01M tris HCL (pH 7.5).
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ii) 12.5% Denhardt's solution (0.02% Ficoll 400, 0.02% 
bovine serum albumin, 0.02% polyvinylpyrrolidone 
in DEPC water) (All were from Sigma).
iii) DEPC 2xSSC solution.
iv) 20% & 50% formamide (BDH).
0
v) 0.5% sodium dodecyl sulphate (BDH).
vi) 250 micrograms/ ml of salmon sperm DNA (denatured 
and sonicated, from Sigma).
vii) 50% dextran sulphate (Sigma).
viii) DEPC Water.
8) Coating of coverslips for use in the in situ 
hybridizatipn techniques.
Place the slides in 5% dimethyldichlorosilane in 
chloroform (Sigma) for 30 minutes. This substance 
is highly toxic and should be handled with maximum 
care in a fume chamber. Wash with plenty of water 
and spread to dry. Once dried they can be stored 
for future use.
